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SUMMARY 
Autoimmune and metabolic diseases cause numerous health and social problems 
throughout the world. The possible association of polymorphisms in Ubiquitin proteasomes 
system (UPS) subunits with human pathologies is intensively sought. We have focused our 
attention on juvenile idiopathic arthritic (JIA), bronchial asthma (BA) and obesity (OB). The 
candidate genes from proteasomes genes clusters located in the 14q11.2 - 14q23 chromosomal 
region, earlier investigated as diseases susceptible, was chosen for the current association 
study.  
Goal of the study was to investigate genetic diversity of proteasomes genes cluster 
located in 14q11.2 - 14q23 chromosomal region in Latvian (LV), Lithuanian (LT), and 
Taiwanese (TW) populations and to reveal possible associations of investigated loci with BA 
in LV and TW; with JIA, BA and OB in Latvian population.  
The significant differences were revealed in distribution of PSMA6 (rs2277460) and 
PSMC6 (rs2295826 and rs2295827) proteasomal genes variations in Latvian, Lithuanian and 
Taiwanese populations. Both LV, LT strongly differed from TW at the rs2277460, rs1048990 
and rs2348071. However, at the rs2295826 and rs2295827 Taiwanese were different only 
from LV and exhibited similarities with LT (Publication I). 
Our results suggest an association of the 14q13-23 proteasomal genes polymorphisms 
with childhood asthma in Latvians and Taiwanese and highlight risk and/or protective factors 
being the same or different between the populations (Publication III). 
Variations at the PSMA6 (rs2277460 and rs1048990), PSMC6 (rs2295826 and 
rs2295827) and PSMA3 (rs2348071) contribute to JIA susceptibility; the 
PSMA6/PSMC6/PSMA3 genetic variants and multiloci genetic modules could be suggested as 
JIA subtype- and sex-specific risk factors (Publication II). 
We demonstrate for the first time evidence of a sex-specific association of 
PSMA6/PSMC6/PSMA3 genetic variants with subtypes of JIA and plasma proteasome 
concentrations (Publication II). 
Variations at the PSMB5 (rs11543947) and PSMC6 (rs2295826 and rs2295827), 
manifested association with obesity in total diseases group and could be suggested as OB 
familial and sex-specific risk factors (Publication IV). 
In silico analysis reveals that that the nucleotide substitutions we have studied modify 
transcription factor binding sites and miRNAs, this can significantly modulate the 
transcription of related genes and gene network in response to the inflammation and other 
environmental stimuli and influence the diseases susceptibility (Publication I, II). 
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ABBREVIATIONS 
14ch Chromosome 14 
14q Long arm of Chromosome 14 
3'UTR Gene 3 'untranslated part 
5'UTR Gene 5 'untranslated part 
95% CI Confidence interval 95% 
ASA   Allele specific amplification 
BA Bronchial asthma 
BMC Latvian Biomedical Research and Study Centre 
BMI Body weight index (body mass index) 
Bp Base pairs 
CAD Coronary Artery Disease 
CAPS Cleaved amplified polymorphic site.SNP single nucleotide 
polymorphism 
cDNA Complementary deoxyribonucleic acid 
Del Deletion 
DM Diabetes mellitus  
DN    Diabetic kidney disease, or diabetic nephropathy  
DNA Deoxyribonucleic acid 
GWAS  Genome-Wide Association Studies database 
HLA Human leukocyte antigen (Human leukocyte antigen) 
ILAR   International League of Association for Rheumatology 
Ins Insertion 
IS Ischemic Stroke 
JIA Juvenile Idiopathic arthritis 
JIoA Juvenile idiopathic oligoarthritis 
JIpA Juvenile idiopathic polyarthritis 
LV   Latvian population 
LT   Lithuanian population 
MAF Rare allele frequency (minor allele frequency) 
MI Myocardial Infarction 
MicroRNA Micro ribonucleic acid 
mRNA Messenger ribonucleic acid 
MS Multiple sclerosis  
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MSs Microsatellites 
NCBI National Center of Biotechnology Information (National Center for 
Biotechnology Information, US; www.ncbi.nlm.nih.gov/) 
OB Obesity 
OR Odds ratio 
P P-value, a function of the observed sample results that is used for 
testing a statistical hypothesis 
PCR Polymerase Chain Reaction 
RA   Rheumatoid arthritis  
T1DM Type 1 diabetes mellitus  
T2DM Type 2 diabetes mellitus  
TF Transcription factor 
TFBS Transcription factor binding site  
TW Taiwanese population 
Ub Ubiquitin 
UPS Ubiquitin proteasomes system  
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INTRODUCTION 
Autoimmune and metabolic diseases cause numerous health and social problems 
throughout the world. Over the last decade increased interest of many researchers is directed 
to define the role of genetic sequence variation in the development of multifactorial diseases. 
Mutations in human genetic code can result in proteins with malformed proteins, altered 
functions, or missing proteins. Some of these changes may lead to disorders. Ubiquitin 
proteasomes system (UPS) is involved in removing of abnormal and misfolded intracellular 
proteins, and generation of antigenic peptides. The possible association of polymorphisms in 
proteasome subunits with human pathologies including metabolic and autoimmune diseases is 
intensively sought. We have focused our attention on juvenile idiopathic arthritic (JIA), 
bronchial asthma (BA) and obesity (OB). The candidate genes from proteasomes genes 
clusters located in the 14q11.2 - 14q23 chromosomal region, earlier investigated as diseases 
susceptible, was chosen for the current association study.  
The cause of JIA is complex, involving both environmental and genetic risk factors. The 
latter could include structural variations in both human leukocyte antigens and non-HLA 
genes (Prahalad et al., 2008; Thompson et al., 2010). Due to the pleiotropic effect, which is a 
frequent phenomenon in human complex traits and diseases (Sivakumaran et al., 2011) some 
loci of susceptibility may be shared among many autoimmune and other immune-mediated 
diseases (Lee et al, 2014; Thompson et al, 2010). However, interplay of multiple risk alleles 
and/or genotypes and primary driver of these diseases remains still unclear.  
Asthma is a chronic inflammatory disease caused by complex gene-gene and gene-
environment interactions with hyper-responsiveness to various nonspecific stimuli (Broide, 
2001; Galli et al., 2008) being to a large extent genetically heterogeneous in different human 
populations (Leung et al., 2014). The 14q11-24 chromosomal region was defined as one of 
well replicated asthma susceptibility loci (Hakonasron et al., 2002; Malerba et al., 2001; 
Mansur et al., 2004). The PSMA6, PSMA3 and PSMC6 proteasomal genes located in the 
region were implicated earlier in susceptibility to autoimmunity (Sjakste et al., 2004b; 2010), 
inflammation (Sjakste et al., 2007; Wang et al., 2013).  
According to the recent data the ubiquitin-proteasome system is implicated in the 
pathogenesis of obesity. It has been demonstrated that in Southern Taiwan and Japanese 
population plasma ubiquitin and proteasome levels inversely correlated with a male BMI 
(Chang et al., 2009; Sakamoto et al., 2010). The mutation in the PSMB8 gene has been 
reported to be associated with the autoinflammatory syndrome with lipodystrophy in Japanese 
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(Kitamura et al., 2011). Earlier the association of the PSMA3 gene polymorphisms with 
susceptibility to obesity in Latvian was detected (Kupca et al., 2013). 
However, these associations could significantly vary in different ethnic populations as it 
was shown for coronary artery disease (Wang et al., 2013). No systematic analysis has been 
done until now to evaluate the proteasomal gene genetic diversity in humans on population 
level. It appears that only a few studies directly addressed to that objective: 14q13.2 
microsatellite polymorphism in Latvian and Finland populations (Kalis et al., 2003; Sjakste et 
al., 2004b) and genotyping of the PSMB5 gene single nucleotide polymorphism (SNP) in four 
American ethnic groups (Wang et al., 2008), for example.  
Allele specific sequence functional motifs potentially could significantly affect particular 
gene expression, including UPS functionality in general and network of different genes and 
proteins those involved in ethnic specific adaptation to environment among the others. The 
functional consequences of the most number of mutations and polymorphisms in proteasome 
genes are not known. Several of them not associated with disease have been found in diseased 
tissues (Sjöblom, 2006). Understanding whether or not these proteasome mutations are 
important in disease development will require research to determine how these mutations 
affect proteasome function and how they affect the cell’s physiology. 
The present thesis is to investigated genetic diversity of proteasomes genes cluster 
located in 14q11.2 - 14q23 chromosomal region in population level and to reveal possible 
associations of investigated loci with autoimmune and metabolic diseases, namely juvenile 
idiopatic arthritis, bronchial asthma and obesity in Latvian population.  
Allele specific patterns of transcription factor binding sites (TFBSs) and splicing signals 
were predicted in silico to reveal a potential of nucleotide substitutions in proteasomal genes 
to be important for human genome evolution and adaptation. 
The thesis is presented in a form of publication assortment. It covers investigation of 
subtype- and sex-specific association with JIA of genetic polymorphisms of proteasome gene 
cluster located in 14q11.2 - 14q23 chromosomal region: loci PSMB5 (rs11543947), PSMA6 
(rs2277460 and rs1048990), PSMC6 (rs2295826 and rs2295827) and PSMA3 (rs2348071) 
(Publication II). Genetic diversity of above loci except the PSMB5 (rs11543947) locus was 
investigated in Latvian, Lithuanian and Taiwanese population (Publication I) and on bronchial 
asthma association in Latvian and Taiwanese population (Publication III). PSMB5 
(rs11543947) and PSMC6 (rs2295826 and rs2295827) loci in Latvians were genotyped on 
children obesity association (Publication IV). 
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Aim of the study 
 To investigate diversity of polymorphisms in proteasome gene cluster of human chromosome 
14 in population level and their association with juvenile idiopathic arthritis, bronchial asthma 
and obesity in Latvian population. 
Tasks of the study 
1. To investigate and to compare distribution of PSMA6 (rs2277460), PSMC6 (rs2295826 
and rs2295827) and PSMA3 (rs2348071) proteasomal gene variations in Latvian, 
Lithuanian and Taiwanese populations. 
2. To compare susceptibility to bronchial asthma with genetic variations in the 14q11.2 - 
14q23 proteasomal gene cluster in Latvians and Taiwanese in general and depending on 
sex. 
3. To study subtype- and sex-specific association of the PSMB5 (rs11543947), PSMA6 
(rs2277460), PSMC6 (rs2295826 and rs2295827) and PSMA3 (rs2348071)14q 
proteasomal genes with JIA in Latvians. 
4. To investigate the plasma proteasomes levels depending on JIA subtype- and sex.  
5. To evaluate a possible association between genetic variations in the PSMB5 and PSMC6 
genes and childhood obesity in the Latvian population. 
6. To evaluate the eventual functionality of nucleotide substitutions and their potential to be 
involved in human genome evolution and geographical adaptation in silico. 
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1. MATERIALS AND METHODS 
1.1. Description of the case/control groups participating in the study. 
We have analysed seven collections of DNA samples. Three of them represented the 
control groups formed by samples representing Latvian, Lithuanian and Taiwanese 
populations. The case groups were presented by Latvian juvenile idiopathic arthritis, 
childhood obesity and bronchial asthma patients, and Taiwanese patients with bronchial 
asthma diagnoses. A more detailed characterization of the collections is given below. 
Control groups: 
Latvian control group.  
LV population was represented by 191 (117 females) inhabitants who were hospitalized in 
various departments of “Bikernieki” Clinic at Riga Eastern Clinical University Hospital 
specialized in trauma medicine. Patients with only trauma diagnosis and without autoimmune 
and cardiovascular disorders, type 2 diabetes mellitus (T2DM) and obesity were included in 
this cohort.  
Lithuanian control group.  
LT population was represented by 150 individuals (97 females) who underwent 
prophylactic evaluation at Kaunas Family Medicine Centres and Hospital of Lithuanian 
University of Health Sciences and being without diagnosis or familial predisposition to 
congenital diseases, acute or chronic infections, oncological, autoimmune or any other 
chronic diseases, immunodeficiency and obesity. 
Taiwanese control group.  
TW study subjects enrolled from elementary school for allergy diseases screen were 
represented by 1097 children (558 girls) without asthma and asthma history. Written informed 
consent was obtained from all the participants. 
Patients groups (cases) 
The blood samples from juvenile idiopathic arthritis and childhood obesity patients were 
collected in cooperation with prof.  I. Rumba-Rozenfelde. These case collections were formed 
from 2003 onwards; the samples were collected in the P. Stradins Clinical University Hospital 
and Children Clinical University Hospital Clinic Gailezers in Riga, Latvia. 
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Latvian patient group with bronchial asthma. 
One hundred two children (28 girls) under five represented Latvian asthma group. LV BA 
patients were enrolled from the outpatient clinic of P. Stradins Clinical University Hospital 
and Childrens Clinical University Hospital Clinic "Gailezers" in Riga, Latvia.  
Taiwanese Bronchial asthma patient group. 
One hundred fifty nine (69 girls) under three represented Taiwanese (TW) asthma group. 
TW study subjects were enrolled from elementary school for allergy diseases screen Taoyuan 
General Hospital, Taiwan.  
All Latvian and Taiwanese patients were diagnosed with mild or moderate persistent 
asthma according to the guidelines of the Global Initiative for Asthma (GINA; 
http://www.ginasthma.org/local/uploads/files/GINA_Under5_Pocket_20091_1.pdf). Informed 
consent was obtained from all the study participants or their parents.  
Latvian Juvenile Idiopathic arthritis patients. 
Patients were 174 JIA children (108 girls) receiving consultation at the outpatient clinic of 
P. Stradins Clinical University Hospital and Children Clinical University Hospital Clinic 
Gailezers in Riga, Latvia. JIA was diagnosed and assignment of the JIA patients to subgroups 
was carried out according to the criteria of the International League of Association for 
Rheumatology (Petty et al., 2004).
 
For association analysis both persistent and extended JIoA, 
and rheumatoid factor negative and rheumatoid factor-positive JIpA subgroups were 
combined in JIoA and JIpA groups of 107 and 55 patients, respectively. Twelve other patients 
were diagnosed as having systemic (n = 9), enthesitis-related (n =2), and psoriatic (n =1) 
arthritis. 
Latvian Childhood Obesity patients group.  
Patients were 94 obese children (1–17 years of age, 44% girls) who consulted an 
endocrinologist at the “Gailezers” Clinic of Children’s Clinical University Hospital in Riga, 
Latvia After excluding a comorbid disorders – diabetes mellitus, hypertension, obstructive 
sleep apnea, or psychiatric disease - or chronic use of medications that could be implicated in 
the aetiology of obesity, a diagnosis of obesity was established in accordance with WHO 
criteria, the body mass index (BMI in kg/m2), calculated and applied to age- and height-
specific and gender-appropriate charts, was at least at the 97th percentile (de Onis M. et al., 
2007). The study consisted of initial informed consent, followed by a questionnaire-based 
interview concerning family health history, a subsequent physical examination, and blood 
withdrawal.  
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Ethics: 
LV, LT and TW studies were approved by the Central Medical Ethics Commission of the 
Latvian Ministry of Health, Kaunas Regional Biomedical Research Ethics Committee and 
Ethics Committee of Taoyuan General Hospital respectively. 
1.2. Analysed loci and genotyping methods 
DNA extraction. 
Genomic DNA was extracted from nucleated blood cells using a kit for genomic DNA 
extraction (Fermentas, Vilnius, Lithuania) or QIAamp DNA blood mini kit (Qiagen, 
Germany) and from oral swabs using QIAamp DNA Mini Kit (QIAGEN, Valencia, CA, 
USA) according to the manufacturer's protocols. Quality and quantity of DNA were 
determined using agarose gel electrophoresis (1% agarose (Chempol, Czech Republic) and 
1% gel in TAE buffer (pH = 8.5, 40 mM Tris, 20 mM acetic acid, 2 mM EDTA). Determining 
the concentration used BioPhotomter Eppendorf (Eppendorf, Germany). DNA samples were 
stored at −80 °C until use. 
Measurement of plasma proteasome concentration (Publication II) 
Plasma samples were available only for 23 JIA patients. These plasma samples were 
obtained from patients randomly chosen for plasma sampling during development of the DNA 
collection in the JIA study. Therefore, preliminary information on genotypes of these patients 
did not exist at the moment of the sampling. Blood was harvested on citrate anticoagulant, and 
plasma stored at -80°C. Plasma proteasome (p-proteasome) concentration was measured in 
triplicate per each sample using a standard 20S/26S Proteasome ELISA kit (BML-PW0575, 
ENZO Life Sciences) according to the manufacturer’s protocols. Absorbance was read at 450 
nm using a UV-Vis spectrometric plate reader. Results were expressed as concentration of 
proteasome protein in ng/ml determined by interpolation for the absorbance value using the 
generated 20S proteasome standard curve. 
Marker choice 
Due to limited data on the genetic diversity and susceptibility to diseases of proteasomal 
genes, several criteria were taken into account in choosing markers. These included the 
existence of previously reported findings on locus association with human health status, locus 
allele-specific potential to be functionally significant, locus variability in populations, Hardy-
Weinberg expectations and others concerning mainly a genotyping technology. The 
rs2277460 and rs1048990 of the PSMA6, rs2295826 and rs2295827 of the PSMC6 and 
rs23480071 of the PSMA3 were previously studied on disease susceptibility
 
 (Alsmadi et al., 
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2009; Banerjee et al., 2008; Barbieri et al., 2008; Bennett et al., 2008; Freilinger et al., 2009; 
Goncharov et al., 2009; Heckman et al., 2013; Ikeda et al., 2012; Liu et al., 2009; Ozaki et al., 
2006; Sjakste et al., 2007; Wang et al., 2013; Kupca et al., 2013). The rs11543947 of the 
PSMB5 gene was previously genotyped on genetic diversity only in HapMap populations. All 
loci fit all other mentioned criteria of marker choice. Table 1.2.1 summarizes information on 
the polymorphic loci genotyped in our study. 
Table 1.2.1. Polymorphisms’ description 
Marker ID Coordinates 
cytogenetic/g
enomic 
Gene Function MAF/MA 
count 
Association findings 
Disease Reference 
rs11543947 14q11.2/ 
14:23034812 
PSMB5 Exon1: c.70C>T; 
Intron1: c.-
112+300C>T 
T=0.0359/
180 
OB Publication IV 
rs2277460 14q13.2:/ 
14:35761573 
PSMA6 Promoter: c.-110C>A 
(c.-109-1C>A) 
A=0.0755/
378 
T2DM Sjakste et al., 2007 
JIA,  
 
BA 
Sjakste et al, 2009; 
Publication II; 
Publication III 
rs1048990 14q13.2/ 
14:35761675 
PSMA6 5’-UTR: c.-8C>G G=0.1903/
953 
T2DM Sjakste et al., 2007; 
Barbieri et al., 2008 
CVD,  Ozaki et al., 2006; 
Sjakste et al., 2007; 
Takashima et al., 2007; 
Bennet et al., 2008;  
Hinohara et al., 2009; 
Honcharov et al., 2009; 
Ikeda et al., 2012; 
Heckman et al., 2013; 
Wang et al., 2013 
JIA 
BA 
Cancer 
Publication II; 
Publication III; 
Bachman et al., 2010 
rs2295826 14q22.1/ 
14:53174923 
PSMC6 Intron 1: c.128-
104A>G 
G=0.1352/
677 
JIA, 
BA 
Publication II; 
Publication III; 
rs2295827 14q22.1/ 
14:53174981 
PSMC6 Intron 1: c.128-46C>T T=0.1078/
540 
JIA, 
BA 
Publication II; 
Publication III; 
rs2348071 14q23/14: 
58730626 
PSMA3 Intron 7: 
c.543+138G>A; 
c.522+138G>A; 
c.576+138G>A 
A=0.3482/
1744 
JIA, 
BA 
Publication II; 
Publication III; 
Obesity Kupca et al., 2013 
MA – allele minor in Caucasians; MAF – MA frequency; MAF/MA count is given 
according to the 1000genome phase 1 population project data; ancestral allele is underlined in 
the motif description; T2DM - type 2 diabetes mellitus; CVD – cardiovascular disorders; JIA 
–juvenile idiopathic arthritis.  
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1.3. DNA genotyping. 
The recommended nomenclature system 
(http://www.genomic.unimelb.edu.au/mdi/mutnomen/recs.html/) and chromosome 14 
GRCh37.p5 assembly (NCBI reference sequence: NC_000014.8) sequence information was 
used for loci description, nucleotide numbering and primer design that was done using the 
Primer 3.0 program. Genotyping methods and primer sequences used in LV and LT study are 
indicated in Table 1.3.1. 
Table 1.3.1. Primers for DNA amplification and details of the genotyping technology. 
Gene 
ID 
Marker ID Method / 
restrictase 
Primer  Product size (bp) 
amplified / restricted 
PSMB5 rs11543947 CAPS / 
AasI  
F-5’- AAATGGTCTTTCGCATCTGG-3’ 
R-5’- CTCGGCCAAGATTCATTGTT-3’ 
691 / 457 + 234 
PSMA6 rs2277460 ASA F-5’- ATGCAAGAGCGGAAGAAAC-3’ 
F-5’- ATGCAAGAGCGGAAGAAAA-3’ 
R-5’- TACCATGACAGGGCAATTCAG-3’ 
256 
 rs1048990 CAPS / 
RsaI 
256 / 161 + 94 
PSMC6 rs2295826 CAPS / 
DdeI  
F-5’- 
GCTTAAACAAGTATTGCCGATCA-3’ 
R-5’- 
AAGGAAGAAAATAAAAAGCATTACT
T-3’ 
411 / 133 + 276+ 2* 
411 / 194 + 215 + 2*  rs2295827  
PSMA3 rs2348071 CAPS / 
TscAI 
F-5’- GTCTAAGGCAGGGATGTCCA-3’ 
R-5’- ACCAGCTTTCCCATTCAGTG-3’ 
232 / 166 + 66  
 
Abbreviations of the genotyping method: ASA - allele specific amplification; CAPS - 
cleaved amplified polymorphic site. Letters “F” and “R” given in the primer sequences, 
indicate forward and reversal primers respectively. Restriction enzymes are given in italic. 
Nucleotides genotyped by ASA are boxed.  
Basic PCR was performed using the DreamTaq polymerase (Fermentas, Vilnius, Lithuania) 
with following parameters: 94°C for 5 min; then 35 - 40 cycles of 94°C for 45 sec, appropriate 
annealing temperature (55 – 61°C) for 45 sec, 72°C for 45 sec and a final extension at step at 
72°C for 7 min.  
DNA digestion by restriction enzymes was performed according to the producer protocols 
(Fermentas, Vilnius, Lithuania).  
Allele specific amplification used to identify the rs2277460 alleles was followed by the 
RsaI digestion to genotype the rs1048990. The rs2295826 and rs2295827 being in 61 bp 
distance between each other were genotyped simultaneously in one DdeI digestion reaction. 
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Each single locus genotype was represented by specific band pattern on agarose gel: the 
rs2295826 AA - 276 + 133 bp, AG - 411 + 276 + 133 bp, GG – 411; the rs2295827 CC – 215 
+ 194 bp, CT – 411 + 215 + 194 bp, TT – 411 bp giving easily distinguished specific band 
combinations for 2-locus genotypes: AA/CC – 215 + 133 + 61 bp; AA/CT – 276 + 215 + 133 
+ 61 bp;  AA/TT – 276 + 133 bp; AG/CC – 215 + 194 + 133 + 61 bp; 2 x AG/CT - 411 + 215 
+ 133 + 61 bp or 276 + 215 + 194 + 133 bp; AG/TT – 411 + 276 + 133 bp;  GG/CC – 215 + 
194 bp; GG/CT – 411 + 215 + 194 bp; GG/TT – 411 bp. Marked in bold the 276 bp band and 
underlined genotypes were not observed in the study. (*) - fragment of 2 bp was not taken into 
account in above description of genotypes discrimination. Amplified and digested products 
were analyzed by electrophoresis in 1 – 3% agarose gel. 
Taiwanese specimens were genotyped using high throughput, 384-microtiter plate, 
MassARRAY™ System, SEQUENOM according to the manufacturer's instructions. In brief, 
DNA containing the SNP site of interest was amplified, followed by the homogenous 
MassEXTEND™ assay in which label-free primer extension chemistry was used to generate 
allele-specific diagnostic products of unique molecular weight suitable to be distinguished 
through the application of matrix assisted laser desorption ionization time-of-flight mass 
spectrometry. For quality control 16 randomly chosen samples per each marker were 
genotyped in duplicate in different experiments in each LV, LT and TW population. The 
concordance of the genotyping was 100%. Genotyping data were verified by direct 
sequencing of the corresponding DNA fragments in both directions using the Applied 
Biosystems 3130xl Genetic Analyzer.  
Alleles and genotype frequencies for the rs2277460 (ss24557113), rs1048990 
(ss35076445), rs2295826 (ss3239727 and ss69157456), rs2295827 (ss23619651) and 
rs2348071 (ss3302481) were extracted from public available dbSNP (build 13) entries at 
NCBI (http://www.ncbi.nlm.nih.gov/snp) for 47, 40 and 43 unrelated participants of HapMap-
CEU (North Western European), HCB (Han Chinese) and JPT (Japanese) populations 
respectively and 5 locus genotypes were reconstructed for each individual (Publication I).  
1.4. Data processing and statistical analysis 
Documenting personalised genotyping data allowed determination of multi-locus 
genotypes, observed haplotypes, single locus genotypes (SLG) and allele frequencies were 
estimated by direct counting of genetic variants and deviations from Hardy–Weinberg 
equilibrium (HWE) were tested by ÷2 test (Rodriguez et al., 2009; 
http://www.oege.org/software/hwe-mr-calc.shtml). Inferred haplotypes prediction, haplotype 
sorting, estimation of the linkage disequilibrium and probability of recombination were 
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performed using the DnaSP software version 5.10.1 online tool at http://www.ub.es/dnasp. 
(Librado et al., 2009). Both the two-tailed Fisher’s exact test and the χ2 test were applied to 
evaluate the linkage between the rs2295826 and rs2295827 polymorphic sites at three P-value 
levels (P < 0.05; P < 0.01; P < 0.001). The Bonferroni correction included in the DnaSP 
analysis was taken into account to support the significance of the revealed disequilibrium (α´ 
= 0.05).  
Deviation from the Hardy-Weinberg equilibrium and differences between cases and 
controls in allele, genotype and haplotype frequencies were evaluated by χ2 and Cochran-
Armitage trend test using XLSTAT 2013 software for Windows.  
Genetic models for every individual locus were designed according to Lewis (Lewis et al., 
2002). Contingency tables were 2 x 3 for the AA, AB, BB genotypes in general model; 2 x 2 
for the AA, AB+BB and AA+AB, BB and AB, AA+BB genotypes in dominant, recessive and 
over dominant models respectively and A and B alleles in the multiplicative model where A is 
the major allele and B is the minor allele. Using an additive model, the AA, AB and BB 
genotype distribution was analysed using the Cochran-Armitage test for trend. An odds ratio 
(OR) more than 2 and less than 0.5 was considered to be clinically significant.  
In case of genetic variations current study in population level (Publication I) DnaSP 
software version 5.10.1 was used to evaluates the nucleotide diversity, performs Tajima's D 
(Tajima et al., 1989) and Fu and Li's F* and D* (Fu et al., 1993) tests of neutrality, and 
evaluates the pairwise linkage disequilibrium (LD) between the loci (D and r2) and pairwise 
population differentiation (Fst). Haplotype age and phylogenetic relationships were obtained 
using the Reduced Median algorithm of the Phylogenetic network software Fluxus 4.611 
(http://www.fluxus-engineering.com).  
Stratification was performed by JIoA and JIpA ILAR subtypes and by sex (Publication II); 
by sex in bronchial asthmas association study (Publication III); by sex and familial subgroups 
in childhood obesity study (Publication IV). 
Levels of p-proteasome were expressed as mean ± standard error of the mean (SE) for each 
sample to show the variability associated with the estimation, and as mean ± standard 
deviation (SD) to characterize the spread of a data set within the groups. Both SE and SD were 
calculated using the on line NCalculators (http://ncalculators.com/). Differences in p-
proteasome levels between the groups were estimated by nonparametric Mann-Whitney and/or 
Kruskal-Wellis tests using XLSTAT 2013 software. P values of less than 5x10
-2
, 2x10
-3
 and 
1x10
-4
 were considered to be of nominal, moderate and strong statistical significance, 
respectively (Manly et al., 2005). 
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1.5. SNPs functional analysis in silico (Publications I, II) 
An eventual functional significance of the SNPs showing evidence of association was 
analysed in silico on sequence similarity to transcription factors binding sites (TFBSs) using 
Genomatix software,  MatInspector, Release 7.4 online tool, at www.genomatix.de 
(Cartharius et al., 2005). Only parameters with core/matrix similarity of more than 
1.000/0.800 were taken into account. Splicing signals were predicted by Human Splicing 
Finder (HSF) Version 2.4 (http://www.umd.be/HSF; Desmet FO et al., 2011) with standard 
threshold values for branch point, donor and acceptor splice sites, enhancer, silencer, hnRNP 
and other splicing motifs. Sequence similarity to mature microRNAs and hairpin precursors 
was evaluated, and microRNA targets prediction was done using miRBase 
(http://www.mirbase.org/index.shtml; Kozomara et al., 2011) and miRNAMap 
(http://mirnamap.mbc.nctu.edu.tw/index.php; Hsu et al., 2008) online tools, respectively. 
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2. LITERATURE REVIEW 
2.1. Types of polymorphisms in human genome and their importance for 
disease research.  
Over the last decade, significant improvements have been made in genotyping efficiency, 
sequencing technology, and statistical methodology, providing researchers with better 
opportunities to define the role of sequence variation in the development of human diseases 
(Li. et al., 2013; Sonn et al., 2013; Wang et al., 2013). Many human diseases are now known 
to have a genetic component. All humans start their lives with germ-line mutations inherited 
from their parents. However, the human genetic code is constantly subjected to mutations 
which can happen during cell division or after exposure to environmental factors such as UV 
radiation, chemicals, or viruses. These mutations can result in proteins with altered functions, 
malformed proteins, or even missing proteins. Some of these changes that occur due to a 
particular mutation have no effect on biological function, some may be beneficial, and some 
may lead to disease.  
2.1.1 Single-nucleotide polymorphisms (SNPs)  
Polymorphisms occur more often (frequency of 1% or greater) in the general population 
than mutations (Wood et al., 2013; Abecasis et al., 2013).  Single-nucleotide polymorphisms 
(SNPs) are the most frequent type of variation in the human genome, account for 90% of 
human DNA polymorphisms (Gomes et al., 2013) and they provide powerful tools for a 
variety of medical genetic studies. (Wang et al., 1998) 
Most SNPs have two alleles which are named “major” or “common” and “minor” or 
“rare” based on their observed frequency in the general population. Several genotypes are 
possible at each SNP, because chromosomes are both maternal and paternal in origin: 
homozygous for the common allele, heterozygous, or homozygous for the rare allele. More 
than 10 million SNPs occur in the genome, one for every 100∼300 bases (HapMap 
Consortium, Nature, 2003). Whole genome sequencing of large sample numbers is  not 
always effective for finding SNPs, as many rare SNPs occur only once (“singletons”) or twice 
(“doubletons”) in the analysed samples The haplotype refers to an individual collection of 
short tandem repeat allele mutations at adjacent locations (loci) that are inherited together 
(Gomes et al, 2013).  
Smaller research labs are now able to analyse multiple genes belonging to the same 
pathway instead of analysing a single polymorphism on a single gene. These advances have 
led to the discovery of new polymorphisms on proteasome genes that are linked to major 
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human diseases. SNPs can be used as genetic markers for identifying susceptible with disease 
genes by linkage studies in families, linkage disequilibrium, and association analysis of 
case/control study. Most investigations use dense maps of SNPs as well as the haplotypes 
derived from these polymorphisms. Determining the causal relationship between SNP or 
haplotype and disease is currently a major researching theme. These genetic variations are 
important for genetic diversity within the population. 
Genome scan approaches to identify regions associated with diseases are now much more 
efficient (HapMap Consortium, Nature, 2003) The HapMap base contains SNPs data and 
maps of SNPs haplotype blocks, allowing users to select a group of SNPs to investigate a 
possible association between known genomic regions and the studied diseases. 
So, previously were identified four non-HLA type 1 diabetes risk loci: INS, CTLA4, 
PTPN22, and IL2RA1-4 resided in the HLA region on chromosome 6p21. (Jeffrey et al., 2009) 
Recently, the application of genome-wide SNP typing technology to large sample sets 
and comparisons with results from other immune-mediated diseases have provided 
convincing support for 19 additional type 1 diabetes loci 5
-
13, all with allelic odds ratios 
(OR’s) of less than 1.3. (Jeffrey et al., 2009) 
Genome wide association studies have identified the susceptibility locus for lung cancer 
to be present on chromosome 15. This locus 15q24-15q25.1 contains not only the genes of 
nicotinic acetylcholine receptor subunits (CHRNA3 and CHRNA5), which could be good 
candidate genes for lung cancer, but also PSMA4, the proteasome alpha type subunit isoform 
1 gene. This region was found to be strongly associated with the risk of lung cancer in the 
Caucasian and African American populations (Amos et al., 2010; Hansen et al., 2010; Liu et 
al., 2008). 
The IFIH1 (interferon induced with helicase C domain 1, also known as MDA5, or 
melanoma differentiation-associated gene 5) linkage disequilibrium block on chromosome 2q 
has also been found to be associated with T1DM in GWAS and increased gene expression is 
associated with risk of T1DM (Nokoff et al., 2013). Meta-analysis of GWAS results revealed 
an association of end-stage renal disease (ESRD) with the rs7583877 in the RNA-binding 
protein AFF3 gene and a chromosome 15q26 intergenic SNP locating between two growth 
and development-related RGMA (repulsive guidance molecule a) and MCTP2 (multiple C2-
domains with two transmembrane regions 2) genes. Functional data suggest that AFF3 
influences renal tubule fibrosis via the transforming growth factor-beta (TGF-β1) pathway. A 
whole genome linkage scan by microsatellite markers provided significant evidence of 
linkage between the T1DM and multiple sclerosis (Pitzalis et al., 2008). It should be 
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mentioned that some genetic predisposition factors apparently are not spotted in GWAS 
studies, although sufficient association is revealed in studies with individual genes. 
HapMap and PERLEGEN projects (http://www.ncbi.nlm.nih.gov/snp/) provide 
significant information on the genetic diversity of many individual loci in different ethnic 
populations; however this information is based on analysis of very small subject groups, more 
detailed studies are necessary. GWAS studies have identified alleles related to complex 
disorders; however some of these alleles seem to be associated with the disease only in certain 
populations. Some polymorphisms were found in strong association with diseases in one or a 
few ethnic groups but not confirmed by the results in other ethnic groups. So, SNP rs1048990 
(PSMA6) proteasomal genes was found in association with decreased risk of ischemic stroke 
in both Caucasians and African Americans (Heckman et al., 2013). No association between 
the PSMA6 polymorphism and CAD was found in the North Indians (Banerjee et al, 2009). 
Case/control study from Japanese and Korean populations for PSMA6 genotypes showed no 
evidence of the association with CAD (Hinohara et al., 2009).  
2.1.2 Microsatellites (MSs)  
MSs are repeating sequences of 2–6 base pairs of DNA (King et al., 2012). They are used 
as molecular markers in genetics for kinship, population, and other studies. They can also be 
used for the studies of gene duplication or deletion, marker-assisted selection, and 
fingerprinting. Microsatellites are distributed throughout the genome (King et al., 2012). 
Being variable genetic elements, microsatellites provide a potent tool for the individual 
characterization of genomes. Variability is generated due to replication slippage caused by 
mismatches between DNA strands while being replicated during meiosis (Tautz et al., 1994), 
and the event can occur once per 1000 generations (Weber et al., 1993). This slippage is much 
more common compared with point mutations (Jarne et al., 1996).  
Microsatellite repeats mutagenize human genomes and alter the human genomic 
landscape across generations (Grandi et al., 2013). The utility of microsatellites has been 
demonstrated by the study comprising 2058 germline changes discovered by analysing 85 289 
Icelanders at 2477 microsatellites. The paternal-to-maternal mutation rate ratio is 3.3, and the 
rate in fathers doubles from the age 20 to 58, whereas there is no association with age in 
mothers. Longer microsatellite alleles are more mutagenic and tend to decrease in length, 
whereas the opposite is seen for shorter alleles (Sun et al., 2012).  
Microsatellites remain highly informative and useful measures of genomic variation for 
linkage and association studies despite the fact that general preference is given to single-
nucleotide polymorphisms (SNPs). Microsatellites are much more genetically diverse 
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compared to SNPs; they generate greater haplotype diversity (Gulcher et al., 2012). Although 
mostly used as structural genetic markers, microsatellites perform several functions in the 
genome, which are still far from being completely understood.  
However, actually it has become clear that MSs and their flanking regions are involved in 
multiple gene and genome functions. MSs are known to form nuclear matrix anchorage sites 
(Boulikas et al.,  1993), tissue-specific matrix attachment sites (Lenartowski et al., 2002), and 
binding sites with vimentin and glial fibrillary acidic protein (Tolstonog et al., 2005) and give 
rise to complex DNA spatial structures of extreme functional significance (Tolstonog et al., 
2005; Li et al., 2003; Rothenburg et al., 2001). MSs appear to be important components of 
insulators (Filippova et al., 2001), silencers (Rothenburg et al., 2001), and enhancers 
(Bassuny et al., 2003). MSs are also involved in the regulation of alternative splicing (Hui et 
al., 2005), mRNA stability (Lee et al., 2004), and recombination and repair (Wang et al., 2007 
Chin et al., 2007). Expansions of microsatellite DNA repeats cause nearly 30 developmental 
and neurological inherited disorders (Kim et al., 2013). 
2.2. Ubiquitin proteasome system and UPS-related diseases 
Recent advancements in cell biology show that the function of the cells equally important 
is the proper protein biosynthesis, as well as their efficient degradation. In eukaryotes, 
processing and degradation of vast majority of regulatory proteins are mediated by ubiquitin-
proteasome system (UPS).  
2.2.1. The proteasome 
The proteasome is a multicatalytic enzyme which is highly conserved and ubiquitous. 
There are found in archaebacteria as well as the nucleus and cytoplasm, near the endoplasmic 
reticulum and even in the centrosome of all eukaryotic organisms (Fabunmi et al., 2000).  
Proteasomes, key UPS enzymatic complex possess several types of peptidase, 
endoribonuclease, protein-chaperone and DNA-helicase activities (Konstantinova et al., 2008; 
Wang et al., 2007; Yano et al., 2005) allowing to control strictly and to coordinate all steps of 
gene expression, genes’ and proteins’ networks and processes of genome-environment 
interaction. Proteasome is involved in the cellular stress response mechanisms, timely 
regulatory factors degradation provides the cell response to DNA damage, hypoxia and heat 
shock, deviations from the correct course of this process may be seen as pathological (Flick et 
al., 2012; Wang et al., 2006). Proteasomal degradation removes denatured, misfolded, 
damaged or improperly translated proteins from cells and as well as regulating the level of 
proteins such as cyclins and transcription factors (Nandi et al., 2006; Hershko et al., 1998). 
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The removal of any proteasome gene is lethal in eukaryotes (Hamazaki et al., 2007; Bedford 
et al., 2008). The importance of the proteasome in cellular functions is exemplified by 
experimental evidence which suggests that the proteolytic capacity of the proteasome in 
certain tissues declines with age and that this decline in proteasome activity is related to the 
lifespan of the organism (Carrard et al., 2002; Vernace et al., 2007; Dasuri et al., 2009; 
Chondrogianni et al., 2000; P´erez et al., 2009); Aging cells have increased levels of damaged 
proteins, possibly increasing the load on the proteasome (Hipkiss et al., 2006). 
2.2.2 Proteasomes components and structure 
Proteasome is based on a 15x10 nm cylinder with a molecular weight of approximately 
700kDa. Subunit orientation and detailed structure of the different subunits of the 20S 
catalytic particle was resolved 18 years ago (Groll et al., 1997). It consists of four rings, each 
of which consists of the seven subunits with a molecular weight of 20 to 36 kDa. The 
proteasome from the archeon Thermoplasma acidophilum is a prototype for the quaternary 
structure and topology of the enzyme (George et al., 1999). The 2 identical outer rings are 
composed of the α-type subunits and the 2 identical inner rings, of the β-type subunits. 
Therefore, the general structure of the proteasome complex is α1-7β1-7β1-7α1-7. The α-rings 
together with the 19S regulatory particles form a narrow channel through which only 
denatured proteins may pass. The β-rings, each of which contains 3 active sites, form a 
proteolytic chamber where proteins are degraded in a progressive manner.  
The proteolytic sites of the β-rings differ in their substrate specificity and proteolytic 
activity; therefore, they are named after enzymes that show similar activity or specificity: a 
“chymotryptic-like” activity with preference for tyrosine or phenylalanine at the P1 position; 
a “tryptic-like”activity with preference for arginine or lysine at the P1 position; and a 
“postglutamyl” hydrolysing activity with a preference for glutamate or other acidic residues at 
the P1 position (Orlowski, et al., 1990; Coux , et al., 1996). 
During protein degradation in the proteolytic chamber, peptides of 3-25 amino acids in 
length are generated. The above-described complex forms the 20S Core Particle (CP) - 20 S 
proteasome (S - Svedberg coefficient characterizing the particle sedimentation rate). 
(Naujokat et al., 2002; Kisselev et al., 2003; Ciechanover et al., 2012). Polyubiquitinated 
proteins cannot be degraded directly by the 20 S proteasome. After attachment of at least four 
ubiquitin molecules the target protein is recognized by specific sub-units of 19S regulatory 
particle (RP) of the proteasome. 19S RP known alternatively as PA700 (Ma et al., 1994), ball 
(Hoffman et al., 1992), 19 S cap (Glickman et al., 1998) or μ-particle (Udvardy et al., 1993) is 
a multi-protein structure that caps the two sides of the core particle (CP) of the proteasome. 
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19S is made of two sub-complexes called the lid and the base and a total of 17 peptide 
molecules. Six of them possess ATPase activity while the 11 others are non-ATPases. At 20 S 
proteasome joins 19 S ATPase complexes that recognize the substrate. These both complexes 
are formed of 26 S proteasome representing a complex of 2.5 MDa (Gomes et al., 2006; 
Tomko Jr. et al., 2013; Kish-Trier et al., 2013).  
 
Figure 2.2.2.1. Schematic diagram of the 26S proteasome (I. A. Voutsadakis, 2010) 
Intracellularly, multiple forms of the proteasome with different combinations of 
activators co-exist (Figure 2.2.2.2). 
 
Figure 2.2.2.2 Schematic diagram of different forms of the proteasome. 
(http://www.reproduction-online.org/content/142/1/1/F1.large.jpg) 
The 26S proteasome can exist with one or two 19S caps, immunoproteasomes containing 
one or two 11S caps, proteasomes containing the 20S proteasome with one or two PA200 
caps (in the nucleus only), and hybrid proteasomes which contain different combinations of 
20S and activators (Sutovsky et al, 2011; Gomes V et al, 2013). In the immunoproteasome the 
19S regulator is replaced by an alternative 11S regulator (PSME), composed of PSME1, 
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PSME2 and PSME3 subunits previously indicated as PA28 alpha, beta and gamma 
respectively. Three PSME1 and three PSME2 subunits combine to form a heterohexameric 
ring. Several others ATP-independent regulatory complexes of different functions and protein 
composition have been recently discovered and characterized (Sorokin et al., 2009). 
2.2.3 The Proteasome Proteolytic Pathway  
The proteasome becomes capable of binding the substrate after the ubiquitination 
process. The ubiquitin-proteasome proteolytic pathway starts from ubiquitin, as 
proteasomes cannot recognize a protein that is not targeted. Degradation of a protein via 
the ubiquitin-proteasome system (UPS) involves 2 successive steps (Ciechanover et al., 
2000): 
1) covalent attachment of multiple ubiquitin molecules to the substrate;  
2) degradation of the tagged protein by the 26S proteasome and recycling of ubiquitin. 
Ubiquitin is an 8 kDa protein of 76 amino-acids that has taken its name from its ubiquitous 
presence in cells. Its covalent link to a target protein is a signal for different fates for this 
target protein. Ubiquitin binds to the target protein with isopeptide site between the ubiquitin 
carboxyl terminal glycine and internal lysine of target substrate. Ubiquitin molecules, with 
additional links successively connected to one another to create a poly ubiquitin chain which 
serves as a recognition signal of the proteasome-ubiquitin in proteasome system. Modification 
of the target protein with ubiquitin or ubiquitin-like protein changes the target protein surface 
that reduces protein stability, activity and association with other proteins and its localization 
in the cell (Ciechanover et al., 2012; Bendotti et al., 2012). 
 Conjugation of ubiquitin to the protein substrate proceeds via a 3-step cascade 
mechanism carried out by enzymes E1, E2 and E3 (Fig 2.2.3.1).  
 
Figure 2.2.3.1. Enzymatic cascade of ubiquitination. (I. A. Voutsadakis, 2010) 
The process of ubiquitination begins with adenosine triphosphate ubiquitin-dependent 
activation by the enzyme E1 (ubiquitin activating enzyme). Ubiquitin is linked to cysteine 
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residue E1, forming E1 -S ~ ubiquitin and then transferred to one or more forms or E2 
ubiquitin enzymes. Third, the addition of ubiquitin to the substrate protein is catalysed by one 
of several E3 - ubiquitin ligases, which is a large group of proteins. After degradation 
deubiquitinylated enzyme separates the ubiquitin residues from substrate and ubiquitin can be 
reused (Ciechanover et al., 2012). The structure of the ubiquitin conjugating and activating 
system is hierarchical. A single E1 protein activates ubiquitin required for all modifications. It 
can transfer ubiquitin to several species of the E2 enzymes. More than 20 genes of E2 are 
discovered. Each E2 can transfer ubiquitin to one or several E3 proteins. E3 enzymes may 
belong to three different classes: proteins RING (Really Interesting New Generation proteins), 
U-box proteins and HECT-domain proteins. There are about 1000 E3-encoding genes that 
have been identified in the human genome. E3 proteins play a very important role in the 
ubiquitin-conjugating system, because they act as substrate-binding elements, which are 
responsible for specificity and selectivity of the ubiquitin-proteasome system (Glickman et al., 
2002, Schwartz et al., 2009). Conjugation of ubiquitin may also be responsible for regulation 
of protein localization, functions and their interactions. Furthermore, ubiquitination plays an 
important role in modification of histones (Anna et al., 2006). 
2.2.4. Monogenic diseases associated with UPS defects.  
„E3 diseases” 
E3 protein diversity determines their role in pathologies. Malfunction of E1 or E2 
enzymes should be fatal for organisms, on the contrary silencing of one E3 can be partially 
compensated by analogous enzymes, and however such a deficiency will not remain without 
consequences, it causes the pathology. A distinct number of pathologies are caused by 
deficiency of some E3 enzyme, we can denote then as "E3 diseases." 
Currently the role of E3 defects is better understood in neurology. About 17 different E3 
enzymes are involved in development of nervous system. The signal transfer functions are 
regulated by 11 enzymes. (Baptista et al., 2012). Angelman syndrome provides a good 
example of the case when one of the enzymes is not active. This inherited syndrome manifests 
in patients as mental retardation, speech difficulties, unsteady gait, they often clap hands, 
laugh, and look happy. Patients inherit a 4 Mb large (4 million base pairs) 15q11-13 deletion 
in Chromoosme 15 from the mother; the Ube3a gene is lost among the other genes. This gene 
encodes E6-AP ubiquitin ligase, normally expressed in the cerebellum and hippocampus. 
Similar symptoms develop when Ube3a gene mutation is formed. A number of E6-AP 
substrates has been identified, but the mechanism of pathogenesis is not well understood yet 
(Buiting et al., 2010; Mabb et al., 2011; Williams et al., 2010; Baptista et al., 2012). 
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Williams-Beuren syndrome (WBS) is caused by a Chromosome 7q11.23 deletion, 
determining a loss of 25 genes, including the E3 ligase TRIM50 (Micale et al., 2008). The 
disease is characterized by many developmental and neurological defects. E3 enzymes CUl4B 
HUWE1 and is also involved in a number of undefined mental retardation cases (Baptista et 
al., 2012). E3 enzyme UBE3A, PARK2, RFWD2, FBXO40 deficiency may be an etiological 
factor for autism (Baptista et al., 2012). Recently described mutation of the UBR1 E3 enzyme 
gene causes the typical Johnson-Blizzard syndrome or ectodermal dysplasia: abnormal 
development of the pancreas, nose and skull dysplasia, deafness and mental retardation 
(Fallahi et al., 2011). But overexpression of the TTC3 E3 ligase encoded in the "critical zone" 
for Down's syndrome can be responsible in part for neurological symptoms of this syndrome 
(Berto et al., 2007). One of the early forms of Parkinson's disease develops due to mutations 
in PARK2 E3 ligase gene (Baptista et al., 2012). Sporadic Parkinson's disease patients have a 
reduced expression of E3 ligases component in Skp1 protein complex. The increase of this 
protein expression could contribute to the increase of disease treatment efficiency (Mandel et 
al., 2012).  
Two hereditary cancer syndromes could be also classified as "E3 diseases". Von Hippel 
Lindau syndrome is characterized by E3 ligase VHL gene mutation that results in not-
degradation of hypoxia induced transcription factor in normoxia conditions, this leads to 
hyperplasia and malignization in several organs (Bader et al., 2012). ACP tumour suppressor, 
which is also a E3 enzyme is responsible for the development of familial adenomatous 
polyposis. (Benanti et al., 2012). 
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"Deubiquitination diseases"  
This group is formed by Machado-Joseph Disease, where incomplete deubiquitination of 
ATXN3 peptide accumulation causes neurotoxic effects (Costa et al., 2012). USP14 
ubiquitin-specific protease defect causes ataxia in mice (Wilson et al., 2002). Human enzyme 
with a similar function (UCH-L1 or PARK5) is absent in some patients with sporadic forms 
of the Parkinson's disease (Belin et al., 2008). 
"Immunproteasomes" and their defects. 
Induction of inflammatory cytokines such as interferon-γ or tumour necrosis factor α 
(TNF-α) stimulate the "immunoproteasome" formation. Replacements of three β-subunit 
proteins take place. Proteasome proteins PSMB1, PSMB2 and PSMB5 are replaced by 
PSMB9, PSMB8 and PSMB10 proteins. The "immunoproteasome" participates in the class I 
major histocompatibility complex protein formation and antigen presentation. Three formerly 
unknown monogenic diseases caused by mutations in the PSMB8 gene were described 
recently. These are Nakajo-Nishimura syndrome (Kanazawa et al., 2012), this syndrome is 
characterized by frostbite-like bluish erythematous patches on the skin and progressive partial 
lipodystrophy, JMP syndrome (joint contractures, muscle atrophy, microcytic anaemia, and 
panniculitis-induced lipodystrophy) - joint contractures, muscle atrophy, subcutaneous fat 
rounds of inflammation-induced lipodystrophy (Agarwal et al., 2010) and CANDLE 
syndrome (chronic neutrophil dermatosis with atypical lipodystrophy and elevated 
temperature) - a chronic atypical neutrophilic dermatosis with lipodystrophy and elevated 
temperature (Goldbach-Mansky et al., 2012). Lipodistrophy is a common feature of the three 
syndromes, other symptoms vary. However, all the three diseases are caused by c.224C> T 
mutation in exon 2 of the gene PSMB8, the mutation results in Thr75Met replacement in the 
protein. In some CANDLE syndrome patients the c.405C> A mutation identified in the same 
gene caused formation of truncated peptides.  
"Bad" proteasome substrate pathologies 
In a group of diseases inability of proteasomes to digest some substrate is a common step 
of pathogenesis. First of all these are polyglutamine tract diseases. Polyglutamine is found in 
a large number of proteins, it should have certain physiological functions. These proteins are 
degraded by ubiquitin-proteasome system, but in the course of aging, exposure to toxins, and 
in some other cases, the proteasome is no longer able to degrade aggregates formed bylong 
polyglutamine tract (Chen et al., 2005a, 2005b). Diseases can be modelled by treating the 
cells with silicon nanoparticles (Chen et al., 2005a). About ten polyglutamine tract diseases 
have been described, Huntington's disease is the most studied disease of this group; in this 
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case the neuronal protein huntingtin accumulates in neurons.  In Kennedy’s disease 
polyglutamine tract of androgen receptor provokes development of pathology (Li et al., 2011; 
Rusmini et al., 2010). Proteins with polyglutamine tract are degraded not only in the UPS 
sustem, but also in process of autophagy, stimulation of this process can have a positive 
impact on the disease symptoms (Jimenez-Sanchez et al., 2012). Liddl syndrome was 
described as a state of hypertension, hypokalaemia and metabolic alkalosis with low 
aldosterone and renin levels. It turned out that Liddl's syndrome is caused by a mutation in 
renal sodium channel (ENAC) beta subunit gene. The E3 ubiquitin ligase Nedd4 cannot 
recognize this mutated channel protein; it is not degraded in the ubiquitin-proteasome system. 
Excessive sodium reabsorption and water retention happen as result (Rotin et al., 2008). 
Some forms of Alzheimer's disease can be also included in the "bad proteasome substrate 
disease” definition. Amyotrophic lateral sclerosis, a rare disease which begins around the age 
of 60 years and manifests itself ad progressive paralysis, muscle degeneration and disability, 
also develops due to the overload of ubiquitin-proteasome system. The symptoms develop due 
degeneration of motor neurons. Patients have a mutation in superoxide dismutase (SOD1) 
gene, the enzyme eliminates free radicals. Proteasome cannot cope with the mutant protein 
processing, resulting in its aggregation, "immunproteasomes" are over expressed in the same 
time (Bendotti et al., 2012). "Poor substrate" components can modify the severity of 
lysosomal diseases. Gaucher disease is caused by mutations in the beta- glucocerebrosidases 
gene, resulting in accumulation of glycol ceramides in lysosomes. It turns out that some 
mutations of this gene slightly alter the protein structure, which makes it difficult to degrade 
(Bendikov-Bar et al., 2012), more severe symptoms develop as result.  
Autoimmune disorders 
Over the past ten years the hypothesis about the ubiquitin-proteasome system decisive 
role in antigen presentation and immune response has been confirmed many times (Kloetzel et 
al., 2001). A new special form of the proteasome - thymoproteasomes found exclusively in 
the thymus cortex, and probably involved in T cell selection was recently described (Sutoh et 
al., 2012; Tomaru et al., 2009). This indicates an even greater role of proteasomes in the 
immune response and justifies the study of proteasome system activity in patients with 
autoimmune diseases. In patients with rheumatoid arthritis (Egerer et al., 2002) and psoriatic 
arthritis (Henry et al., 2011) concentration of proteasome in blood plasma is increased. 
Antibodies against the 20S proteasome were found in patients with Sjögren's syndrome (Feist 
et al., 1999), lupus erythematosus (Arribas et al., 1991; Colmegna et al., 2008; Feist et al., 
1996), multiple sclerosis, psoriatic arthritis (Colmegna et al., 2008 ), autoimmune 
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cardiomyopathy (Voigt et al.; 2010), autoimmune myositis (Feist et al., 1996). Ubiquitin-
proteasome system is also involved in other auto-antigen and nuclear protein processing. 
Proteasome degrades many nuclear proteins, including histones (Dino Rockel, 2002). Toxic 
substances in the nucleosome core lead to accumulation of abnormal degradation of 
proteasome substrates; these proteins acquire auto-antigenic properties. (Chen et al., 2002; 
2005). Proteasome inhibitors are used for treatment of rheumatoid arthritis and other 
autoimmune diseases (Chitra et al., 2012). 
Neurodegenerative diseases 
Abnormal activity of the ubiquitin-proteasome system may be involved in the 
pathogenesis of Alzheimer's disease; however this pathway is not understood yet in detail. In 
neurons of Alzheimer's patients mainly A un  proteins resistant to proteasomal degradation 
are accumulated. Reduced proteasomal activity in neurons of patients is also reported, 
mutated ubiquitin is found sometimes. Lysosomal activity in neurons of Alzheimer diseases 
patients is increased in the initial stages of the disease; the late stages are characterized by 
increased autophagy process (Ihara et al., 2012; Dennissen et al., 2012). Mutations in 
ubiquitin gene were found in patients with amyotrophic lateral sclerosis. Huntington's disease 
is a classic "bad substrate" disease example; however diverse defects of the ubiquitin-
proteasome system are characteristic of different forms of Parkinson's disease (Dennissen et 
al., 2012). 
 
Figure 2.2.4.1. The potential proteasome malfunctions in pathology (Sjakste et al., 2013).  
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2.3. UPS system genes and their polymorphisms.  
In the human genome, there are many genes that encode the proteins of the ubiquitin-
proteasome system. In addition, the 26S proteasome is composed of proteins encoded by at 
least 34 independent genes (Nandi et. al., 2006). Distribution of the proteasomal genes 
over the human genome displays the tendency to their clustering in some chromosomes 
including the long arm of chromosome 14 where 9 related loci have been localized 
including the structural genes encoding two of beta (PSMB5 and PSMB11) and of alpha 
(PSMA3 and PSMA6) subunits of core 20S proteasome, ATPases (PSMC1 and PSMC6), 
11S non-ATPase activators (PSME1 and PSME2) and the PSMA3P pseudogene.  
Possible links between proteasomal gene polymorphism and human pathologies were 
first reported in 1994 (Van Endert et. al., 1994) and association between LMP2 (PSMB9) 
gene, which encode beta type 9 subunit of proteasome, and juvenile rheumatoid arthritis 
was reported in 1995 (Pryhuber et. al., 1996). In 2006, Ozaki et al. published evidence of a 
possible association between PSMA6 gene polymorphism and myocardial infarction 
(Ozaki et. al., 2006). After this study many other studies were performed in different 
populations, and study of the proteasomal gene polymorphisms has become popular among 
scientists. The study in a Chinese population also reported that the PSMA6 variant 
rs1048990 could be a risk factor of MI and confirmed the association between 
polymorphism of the PSMA6 gene and the development of myocardial infarction ( Liu et. 
al., 2009). However, the similar studies in other populations showed controversial results. 
Bennet et al. concluded that the risk of rs1048990 polymorphism for myocardial infarction 
was unlikely to be great in Western populations (Bennett et. al., 2008). Moreover, none of 
the single nucleotide polymorphisms of the PSMA6 gene was found to be associated with 
coronary artery disease in a study carried out in Saudi Arabia ( Alsmadi et al., 2009;). 
However, a borderline association of the rs1048990 with diastolic blood pressure was 
detected in United Kingdom population (Bennett et. al., 2008).  
"Immunproteasome" PSMB8 protein and gene PSMB9 polymorphism, were the best 
studied in relationship with autoimmune diseases. The 14q11, 14q13, and 14q22-32 regions 
harbouring the listed loci, have been previously reported as susceptible to autoimmune (Arya 
et al. 2009; Burgner et al. 2009; Chistiakov et al. 2004; Cornelis et al. 1998; Sjakste et al. 
2004b; Stuart et al. 2010; Tomer et al. 1997) and other multiple diseases (Banerjee et al. 2008; 
Barbieri et al. 2008; Bennett et al. 2008; Wang et al. 2013). Some of these proteasomes genes 
showed association with type 2 diabetes (Sjakste et al., 2007), Graves’ disease (Sjakste et al., 
2004a) as well as myocardial infarction and blood pressure (Sjakste et al., 2007). Proven 
association between PSMA6 gene microsatellite allele HSMS006 (TG)22 and type 2 diabetes 
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(Sjakste et al., 2007, 2008), multiple microsatellite alleles were found in associating with 
Graves' disease (Sjakste et al., 2004a) and juvenile idiopathic arthritis (Sjakste et al. , 2010). 
Another SNP is associated with juvenile idiopathic arthritis (Trapiņa et al. 2009). In recent 
years appeared a new investigating related to PSMA6 gene and located near a gene 
polymorphisms, which were found in association with diseases (Ozaki et al. 2006; Kim et al. 
2008; Stuart et al. 2010; Bachman et al. 2010; Barbieri et al. 2008; Liu et al. 2012; Goncharov 
et al. 2009; Liu et al. 2009; Ozaki et al. 2006; Wang et al. 2013; Burgner et al., 2009; 
Thompson et al., 2010; Arya et al. 2009). Our research shows that juvenile arthritis is 
associated with proteasomes PSMA6 gene stationed near the KIAA0391 genes genotype (AC)5 
AT(AC)17 / (AC)5 AT(AC)19 and genotypes (CA)14 / (CA)19. In addition, our data point to a 
single genotype - PSMA6 genotype (TG)18 / (TG)21  and (TG)22 / (TG)23 potential role in the 
disease in certain individuals (Sjakste et al., 2010). Promising results were obtained in studies 
in type 1 diabetes, multiple sclerosis, asthma and obesity. 
2.3.1 Proteasomal genes genetic diversity on population level  
No systematic analysis has been done until now to evaluate the proteasomal gene genetic 
diversity in humans on population level. It appears that genotyping of the PSMB5 gene single 
nucleotide polymorphism (SNP) in four American ethnic groups (Wang et al., 2008) and the 
14q13.2 microsatellite polymorphism in Latvian and Finland populations (Kalis et al., 2002; 
Sjakste et al., 2004b) are the only studies directly addressed to that objective. Case/control 
disease association studies could provide significant information on population diversity. The 
rs1048990 of the PSMA6 gene was widely genotyped during the last decade in several 
European and Asian populations for association with cardiovascular disorders, type 2 diabetes 
mellitus and other pathologies and their outcome (Table 2.3.1.1. for references).  
Multiple case/control studies conducted during the last decade to search for association 
between the rs1048990 SNP and human diseases provide significant information on locus 
variability. Firstly, different studies applied for the same ethnic groups (Latvians Sjakste et 
al., 2004b, Trapina et al., 2009), British (Bennett et al., 2008; Freilinger et al., 2009), Indians 
(Banerjee et al., 2008, 2009) and Japanese (Hinohara et al., 2009; Ikeda et al., 2012; Ozaki et 
al., 2006; Takashima et al., 2007) showed similar allele and genotype frequencies suggesting 
that control cohorts of case/control studies could successfully represent corresponding 
population. Secondly, locus variability appears to express geographical-and/or ethnos-specific 
dynamic. 
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Table 2.3.1.1. Ģenotype and allele frequencies of the rs1048990 in different ethnic groups 
over the world 
Population MAF 
(G)  
Genotype frequency No. of 
controls 
Study or 
project  
Reference 
CC  CG  GG  
YRI 0.017 0.967 0.033 - 60 HapMap NCBI resources 
Latvian 0.089 0.827 0.168 0.005 191 Population Publication I 
0.148 0.732 0.241 0.027 118 JIA Trapina et al., 2009 
0.086 0.829 0.171 0 105 DMT2 Sjakste et al., 2007 
0.107 0.796 0.193 0.014 414  Mean for Latvians 
CEU 0.117 0.783 0.200 0.017 60 HapMap NCBI resources 
Ukrainian 0.133 0.762 0.211 0.027 208 EH Honcharov et al., 2009 
South Italian 0.149 0.748 0.205↓ 0.046↑ 151# MI &DMT2 Barbieri et al., 2008 
Lithuanian 0.153 0.707 0.280 0.013 150 Population Publication I 
British 0.149 0.730 0.243 0.027 918 IS Freilinger et al., 2009 
0.156 0.708 0.271 0.021 2713 MI Bennet et al., 2008 
0.171 0.691 0.282 0.027 282 MI  Sjakste et al., 2007 
0.159 0.710 0.253 0.025 4195  Mean for British 
Germany 0.169 0.683 0.297 0.021 725 IS Freilinger et al., 2009 
Indian 0.200 0.632 0.335 0.033 212 IS Banerjee et al., 2008 
0.213 0.616 0.341 0.043 232 CAD Banerjee et al., 2009 
0.206 0.624 0.338 0.038 444  Mean for Indian 
Saudi 0.231 0.607 0.324↓ 0.069↑ 929# CAD Alsmadi et al., 2009 
Japanese 0.305 0.479 0.430 0.091 451 MI* Ozaki et al., 2006 
0.302 0.485 0.427 0.089 2851 MI^  Ozaki et al., 2006 
0.315 0.469 0.433 0.098 2186 MI Takashima et al., 2007 
0.320 0.463 0.427↓ 0.110↑ 1838 CAD Hinohara et al., 2009 
0.345 0.445 0.422 0.133 1173
#
 CAD Ikeda et al., 2012 
0.317 0.468 0.428 0.104 8499  Mean for Japanese 
Chinese 0.320 0.455 0.450 0.095 2643 MI Liu et al., 2009 
Taiwanese 0.325 0.421 0.507↑ 0.070↓ 1097# Population Publication I 
Korean 0.350 0.423 0.462 0.115 716 CAD Hinohara et al., 2009 
HCB 0.378 0.378 0.489 0.133 45 HapMap NCBI resources 
JPT 0.378 0.341 0.500 0.133 45 HapMap NCBI resources 
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HapMap population data are given in italic, average values are underlined. Symbols (*) and 
(^) indicate respectively the data of preliminary and replicative studies performed by Ozaki 
with the colleagues and given in the same publication (Ozaki et al., 2006). Symbol (
#)
 indicates 
populations having genotype distribution deviated from HWE (P < 0.05) and arrows ↓ and ↑ 
indicate genotypes under- and over-represented respectively. 
Several SNPs located within and upstream the PSMA6 gene as well as within the PSME1, 
PSME2 and PSMA3 genes were genotyped in Latvians on susceptibility to different 
pathologies (Kupca et al., 2013; Sjakste et al., 2007; Trapina et al., 2009). Similar to the 
PSMA3, Wang et al. (2008) identified several loci in the PSMB1, PSMB2 and PSMB5 
proteasomal genes being observed as minor in one ethnic group and middle/common in others 
and suggested that clinical response to proteasomal inhibitors potentially might be allele 
specific (hypothesis is discussed in Wang et al. (2008)).  
2.3.2 Association of UPS genes polymorphisms with polygenic diseases 
Disease-specific and common HLA and non-HLA genetic markers in susceptibility to 
rheumatoid arthritis, type 1 diabetes mellitus and multiple sclerosis 
The common spectrum of autoimmune diseases affect the majority of tissues within the 
body, including pancreatic beta cells in type 1 diabetes (T1DM), myelin surrounding nerve 
axons in Multiple sclerosis (MS) and synovial joint antigens in Rheumatoid Arthritis (RA). 
The diseases are likely caused by a complex interaction between multiple HLA- and non-
HLA related genes and environmental factors. The well documented co-clustering of 
autoimmune diseases within families and individuals, together with apparent sharing of 
number risk genes between the diseases suggests at least some common mechanisms of 
autoimmune development. The three diseases with possibly different manifestations were 
chosen for this review, the whole field being very vast. The fact all the three diseases with 
local rather than general symptoms (joints, pancreatic beta cells, myelin) possess common 
susceptibility factors stresses the importance of these findings.  
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases; it is chronic, 
systemic disease, manifesting as progressive, symmetrical deformation of joints, pain and 
inflammation. Around 1000 new cases of rheumatoid arthritis are diagnosed in Latvia each 
year. Both genetic and environmental factors play role in the susceptibility to this disease. 
Many genetic factors are known to increase risk for developing RA. The main genetic factor, 
involved in susceptibility and pathogenesis of RA is HLA-DRB1 gene in the Major 
Histocompatibility complex (MHC) on chromosome 6. The main players in the pathogenesis 
of RA are cytokines; therefore polymorphisms in the regions that might affect expression of 
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the cytokine genes are extensively studied in this disease. Also anti-cytokine agents are 
successfully used as drugs for this disease. Genome-wide association studies have shown 
around 200 loci, which might be interesting for rheumatoid arthritis. These loci include genes, 
mainly involved in immune pesponse and antigen presentation, importance of which for RA is 
already known and extensively studied including the PTPN22 (protein tyrosine phosphatase 
expressed by the majority of cells belonging to the innate and adaptive immune systems), 
STAT4 (signal transducer and activators of transcription, nuclear import of STAT4 is linked 
to its tyrosine phosphorylation), CTLA4 (cytotoxic T lymphocyte antigen-4, a major negative 
regulatory molecule for T-cell activation), TRAF1/C5 (tumor necrosis factor-receptor 
associated factor 1/complement component 5), PADI4 (peptidyl-arginine-deiminase type IV), 
MIF (cytokine which counteracts the immunosuppressive properties of glucocorticoids) and 
many others (Ballina et al., 2008; Robinson et al., 2010; Raychaudhuri et al., 2010; Pasha et 
al., 2012; Chang et al., 2012), as well as others genes with yet unknown function. RA patients 
can be classified in different clinically significant groups according their genomic traits 
(ACPA (anti-citrullinated-protein-autoantibody) positive versus negative, (Seielstad et al., 
2011). RA is very heterogeneous disease not only concerning the symptoms, genetic 
predisposition and antibody status, but also concerning variations in response to different 
therapeutic approaches. Several genes were found to affect the incidence of side effects and 
patients response to different drugs such as Methotrexate, these are RFC1 (reduced folate 
carrier; (Giammarco et al., 2012), ABCB1 (this gene encodes an efflux pump, ATP-binding 
cassette, sub-family B, member 1 (Takahashi et al., 2006), and MTHFR 
(methylenetetrahydrofolate dehydrogenase 1; Park et al., 2011; Lunt et al., 2011) genes. Some 
genes modify effect of  anti TNF therapy: TNFA (tumour necrosis factor alpha;  O'Rielly et 
al. 2009), interferon (IFN type 1) gene, promoter polymorphisms of interleukin IL-10 and 
other genes (Plant et al., 2011). Efficiency of Azatioprine therapy depends on TPMT gene, 
sulfasalazine - on NAT2 gene (Soejima et al., 2008). The RA susceptibility in Latvian 
population has been studied already (Mihailova et al. 2011), data on TNFA (rs1800629, 
rs361525), IL6 (rs1800795), IL18 (rs1946518, rs1946519), IL10 (rs1800894, rs1800871 
rs1800895, rs1800872), IRF5 (rs3757385, rs2004640, rs10954213 ), KLF12 (Krüppel-like 
factor 12; rs1324913) and PTPN22 (rs2476601) associations with the disease are published.  
Diabetes mellitus (DM) and its complications cause numerous health and social problems 
throughout the world. Number of DM patients constantly increases. Diabetes, characterized 
by persistent elevation of blood glucose levels (hyperglycaemia), occurs due to inadequate 
production of insulin (type 1 diabetes; T1DM), or resistance to endogenous insulin usually 
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associated with the metabolic syndrome and obesity (type 2 diabetes; T2D). Despite intensive 
glycaemic control, individuals with T1DM and T2DM are predisposed to developing vascular 
complications (reviewed in Sharma et al., 2012). DM and its complications are common n 
Latvia: in 2010 72654 DM patients were registered, 3891 with T1DM and 68217 with T2DM. 
Kidney malfunction like microalbuminuria was detected in 2737 patients, proteinuria – in 
1092, renal failure – in 228, substitution therapy was indicated to 57 patients, kidney grafts 
were transplanted to 31 patient. Etiologically T1DM is an autoimmune disease both 
environmental and hereditary factors being important for susceptibility to it. Several studies 
have demonstrated a fundamental role for the HLA in the susceptibility of, or protection to 
T1DM. While HLA remains the strongest genetic risk factor, a number of novel gene variants 
associated with T1DM have been found through genome-wide studies, some of which have 
been linked to suspected environmental risk factors. However, jointly non-HLA risk alleles 
described up till now confer only a small additional risk compared to the effect of HLADR, 
HLADQ. Variants or polymorphisms in UBASH3A (a suppressor of T cell receptor signalling 
pathway) and PTPN22 (the protein tyrosine phosphatase nonreceptor type 22) were shown as 
candidates for development of islet autoimmunity and T1DM when controlling for family 
history and in presence of the HLA-DR3/4-DQB1*0302 genotype. Polymorphisms in the 
insulin INS gene predicted development of T1DM. Although the effect of each individual 
gene is small, the combination of T1DM family history, the HLA-DR3/4-DQB1*0302 
genotype, and the susceptibility variants of PTPN22, UBASH2, and INS were reported to 
increase 16-fold the risk of islet autoimmunity and 40-fold of T1DM.  
Diabetic kidney disease, or diabetic nephropathy (DN), is a major complication of 
diabetes and the leading cause of end-stage renal disease (ESRD) that requires dialysis 
treatment or kidney transplantation. In addition to the decrease in the quality of life, DN 
accounts for a large proportion of the excess mortality associated with T1DM. The strongest 
association with DN as a primary phenotype was seen for an intronic SNP in the receptor 
tyrosine kinase ERBB4 gene (Sandholm et al., 2012). DNA damage by endogenous free 
radicals and further ineffective repair of these lesions is considered to be one of the etiological 
factors of DM (Selvaraju et al., 2012; Tatsch et al., 2012). Oxidative stress and abnormal 
production of nitric oxide are of the main causes of increased DNA breakage in DM leading 
to development of its complications. Thus polymorphism of genes responsible for the free 
radical production and scavenging appear to be of special interest. Endothelial nitric oxide 
synthase (eNOS) polymorphisms have been reported to be strongly associated with DN risk, 
there are also reports on association of some alleles of inducible NO synthase (iNOS) gene 
with DM complications (Zhou et al., 2013; Uthra et al., 2011). Increased DNA breakage due 
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to oxidative stress determines importance of DNA repair genes (base excision repair gene 
MUTYH, X-ray repair cross complementing group 1XRCC1 and 8-Oxoguanine-DNA 
glycosylase hOGG1) in resistance or susceptibility to DM (Kasznicki et al., 2009; Chen et al., 
2011).  
Multiple sclerosis (MS) is most common, clinically extremely heterogeneous, chronic 
inflammatory disease of the CNS affecting about 2.5 million people around the world (2500 
of them in the Latvia), presumably young adults, with onset usually at the second to fourth 
decade of life and, similarly to other autoimmune diseases, women being affected 3-4 times 
more frequent than men. (Compston et al., 2006). Pathologically, there are perivenular 
infiltrates of Cd4
+
 and CD8
+
 T cells in the CNS white matter and meninges with 
demyelinating lesions and loss of axons in both white and grey matter (Kornek et al., 2000). 
List of different MS subtypes includes the relapsing-remitting (RR), secondary progressive 
(SP) and primary progressive (PP), and within each subtype there is also considerable 
individual variation in disease course (Stys et al., 2012). 
The cause of MS is not clear. Disease develops in genetically susceptible individuals with 
the contributions of environmental factors, such as infection, sunlight exposure, and vitamin 
D deficiency (Miller et al., 2011). There are also marked changes in systemic immune 
function with loss of regulatory T cell (Treg) function and increases in myelin-reactive CD4
+
 
T cells (Scheneider-Hohendorf et al., 2010; Venken et al., 2010; Dominguez-Villar et al., 
2011).  
Unbiased genome-wide association scans have identified susceptibility loci in regions 
containing genes with immune, co-stimulatory, signal transduction functions and vitamin D 
related, including, for example, the CD6, CD25, CD40, CD58, HLA-A, HLA-B, HLA-DRB1, 
IL2RA, IL7R, IL12A, IRF8, the Janus kinase (JAK)/signal transducer and activator of 
transcription STAT3, gene of the receptor for tumour necrosis factor-α TNFRSF1A, CYP27B1 
(1α-hydroxylase - an enzyme, which converts vitamin D to its active form) and other genes 
(Jager et al., 2009; IMSGC 2007, 2010; IMSGC and WTCCC2 2011; ANZgene 2009; Kofler 
et al., 2011). Osteopontin OPN gene may be involved in MS development and especially, 
progression and cytokines may be suggested as therapeutic target to counteract MS 
progression (Comi et al., 2012).  
According to the ICSNPathway analysis (Identify candidate Causal SNPs and Pathway 
analysis) applied to the MS GWAS dataset (Zhang et al., 2011), 9 HLA and 7 non-HLA 
candidate SNPs and 5 and 10 candidate causal pathways respectively are mostly susceptible to 
MS including risk HLA loci: rs1802127 (MSH5), rs9277471 (HLA-DPB1), rs8084 and rs7192 
(HLA-DRA), rs2072895 and rs2735059 (HLA-F), rs915669, rs915668 and rs1063320 (HLA-
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G); and risk non-HLA loci: rs5896 (F2, prothrombin), rs8181979 (SHC1; (Src homology 2 
domain containing) transforming protein 1), rs9297605 (TAF2, RNA polymerase II), rs669 
(A2 M; M-type phospholipase A2 receptor), rs2228043 (IL6ST; interleukin 6 signal 
transducer), rs1061622 (TNFRSF1B), rs1801516 (ATM). The most strongly associated 
pathways were the rs1802127 to MSH5 to meiotic recombination and meiotic cell cycle and 
rs5896 to F2 to the transcriptional activation DNA-binding protein B from mRNA (Song et 
al., 2013).  
Evidence underlines the importance of microRNAs (miRNAs) such as miR326, miR-323, 
miR-223, miR-23a, miR-15b and others in the MS pathogenesis (Fenoglio et al., 2012; 
Ridolfi et al., 2013). It was shown (Ridolfi et al., 2013) that rs1044165 (miR-223) likely acts 
as MS protective factor, while rs3745453 (miR-23a) seems to be a risk factor for MS. 
Extracellular miRNAs appear to be taken in consideration as a new source for both biomarker 
and risk factor identification and therapeutic drug discovery. 
 
The RA, T1DM and MS common elements of genetic architecture. 
Well documented co-clustering of autoimmune diseases within families and individuals 
are in good agreement with apparent sharing of a number of risk genes and polymorphic loci 
between particular diseases. At least the IL7R-CAPSL (interleukin 7 and calcyphosine-like 
protein ) CD226, Il2RA, HLA Class I, HLA Class II, CLEC16A, RGS1 (regulator of G protein 
signaling), ZMIZ1 (zinc finger, MIZ-type containing 1), TNFSF14 (tumor necrosis factor 
(ligand) superfamily, member 14) , SOXB (SRY (sex determining region Y)-box 3), CLECL1 
and NFKB1 genes are susceptible to both the T1DM and MS. RA and MS share the 
susceptibility to variations in VCAM1 (vascular cell adhesion molecule 1), IL22RA2, PVT1, 
CLECL1 and CD37 (IMSGC and WTCCC2, 2011; Brand and Gough, 2011; Zoledziewska et 
al., 2009). Despite large number of genes reported to be associated with each given disease, 
some polymorphic loci appear to be common for several diseases. These are, for example, the 
rs2104286 of the Il2RA sharing by MS and T1DM (Maier et al., 2009) and the rs10466829 of 
the CLECL1 sharing by RA, T1DM and MS (IMSGC and WTCCC2, 2011).  
Functions of some non-HLA genes associated with autoimmune diseases are listed in 
Table 1. Several genes are involved in signaling pathways in T-lymphocytes (PTPN22, STAT 
4, CTLA-4, PADI4, MIF, PADI4), apoptosis (TRAF1/C5, TNFSF14), calcium and G-protein-
dependent signalling pathways (CLEC16A, CAPSL, RGS1) and other pathways. 
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Table 2.3.2.1. Non HLA genetic markers of autoimmune diseases 
Abbreviated  
gene  
name 
Full gene name  Function of the protein  Associated 
diseases 
Sources  
PTPN22 Protein 
tyrosine 
phosphatase 
An inhibitor of T-cell activation, 
contributes to signaling cascades 
(TLR, TCR, BCR pathways) 
initiated in immune cells, including 
B cells and cells of the innate 
immune system.  
RA, systemic 
lupus 
erythematosus 
(SLE) , T1DM, 
Hashimoto 
disease (HD), 
Graves’disease 
(GD) , vitiligo  
Fousteri et 
al., 2013  
STAT 4 Signal 
transducer and 
activators 
of transcription 
4 
Part of the JAK-STAT signalling 
pathway, expressed only 
spermatozoa, myeloid cells, and T 
lymphocytes. STAT 4 is activated 
by tyrosine phosphorylation in 
response to interleukin-12 (IL-12) 
treatment of T cells, involved in T 
helper cell function.  
RA, SLE, 
Sjögren’s 
syndrome, 
juvenile 
idiopathic 
arthritis (JIA), 
GD, 
myasthenia 
gravis  
Reich, 2013; 
Korman et 
al., 2008 
CTLA-4 Cytotoxic T-
lymphocyte an
tigen-4 
Cell surface molecule involved in 
the regulation of  signaling pathways 
affecting T-cell responses. 
Activation results in decreased T-
lymphocyte activity and regulates 
the immune response. 
RA, SLE, 
T1DM, 
Addison’s 
disease (AD), 
Vitiligo, MS, 
HD 
Fife, 
Bluestone, 
2008; 
Kristiansen et 
al., 2000 
TRAF1/C5  Tumor 
necrosis 
factor-receptor 
associated 
factor 
1/complement 
component 
5  locus 
The TNF receptor associated factor 
1 (TRAF1) is an adaptor protein, it 
is a TNF family member. TRAF1 is 
implicated in cell growth, 
proliferation, apoptosis, bone 
turnover, cytokine activation.  
RA Kurkó et al., 
2013  
PADI4 Peptidyl-
arginine-
deiminase type 
IV  
The PADI4 enzyme is expressed in  
T and B cells, neutrophils, 
eosinophils, monocytes. It mediates 
the citrullination of histones 
(conversion of arginine residues to 
citrulline). Target for autoantibodies 
in RA.  
RA Kurkó et al., 
2013; 
Anzilotti et 
al., 2010 
MIF Macrophage 
migration 
A T cell derived cytokine, inhibits 
the random migration of 
T1DM, RA Sánchez-
Zamora, 
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inhibitory 
factor 
macrophages in vitro and promotes 
macrophage accumulation during 
delayed-type hypersensitivity 
reactions.  
Rodriguez-
Sosa, 2014 
UBASH3A  Ubiquitin 
associated and 
SH3 domain 
containing A 
 
Belongs to T-cell ubiquitin ligand 
(TULA) family, facilitates growth 
factor withdrawal-induced apoptosis 
in T cells. An active phosphatase 
capable of dephosphorylating 
multiple tyrosine-phosphorylated 
proteins, suppressor of T cell 
receptor signalling pathway. 
T1DM Cerosaletti , 
Buckner, 
2012; 
Tsygankov 
2009.  
STAT3 Signal 
transducer and 
activator of 
transcription 3 
(acute-phase 
response 
factor) 
 
STAT 3 protein is activated through 
phosphorylation by the receptor 
associated kinases in response to 
various cytokines and growth factors 
including IFNs, EGF, IL5, IL6, 
HGF, LIF and BMP2. Then it forms 
homo- or heterodimers that 
translocate to the cell nucleus where 
it act as transcription activator of a 
variety of genes in response to cell 
stimuli, and thus plays a key role in 
many cellular processes such as cell 
growth and apoptosis. 
MS De Jager et 
al., 2009 
CLEC16A C-type lectin 
domain family 
16, member A 
A transmembrane calcium-
dependent (C-type) lectin-like 
receptor  
MS, RA, 
T1DM  
Zoledziewska 
et al., 2009  
CAPSL calcyphosine-
like protein 
 calcium sensor and calcium signal 
modulator. 
T1DM IMSGC and 
WTCCC2, 
2011 
RGS1 Regulator of G 
protein 
signaling  
Regulator of G protein signaling  T1DM, MS IMSGC and 
WTCCC2, 
2011 
ZMIZ1 zinc finger, 
MIZ-type 
containing 1 
 
A member of the PIAS (protein 
inhibitor of activated STAT) family 
of proteins. The encoded protein 
regulates the activity of various 
transcription factors, including the 
androgen receptor, Smad3/4, and 
p53. The encoded protein may also 
play a role in sumoylation.  
T1DM, MS IMSGC and 
WTCCC2, 
2011 
TNFSF14 tumor necrosis 
factor (ligand) 
superfamily, 
 A member of the tumor necrosis 
factor (TNF) ligand 
family.  Functions as a 
T1DM, MS IMSGC and 
WTCCC2, 
2011 
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member 14 costimulatory factor for the 
activation of lymphoid cells, 
stimulates the proliferation of T 
cells, and triggers apoptosis of 
various tumor cells.  
VCAM1  vascular cell 
adhesion 
molecule 1 
 
A cell surface sialoglycoprotein 
expressed by cytokine-activated 
endothelium, mediates leukocyte-
endothelial cell adhesion and signal 
transduction. 
T1DM, RA IMSGC and 
WTCCC2, 
2011 
SOXB SRY (sex 
determining 
region Y)-box 
3  
 
Member of SOX (SRY-related 
HMG-box) family of transcription 
factors involved in the regulation of 
embryonic development and in the 
determination of the cell fate.  
T1DM, MS IMSGC and 
WTCCC2, 
2011 
PVT1  Pvt1 oncogene 
(non-protein 
coding) 
 
Oncogene, associated with several 
types of cancer and renal diseases.  
T1DM, RA (IMSGC and 
WTCCC2, 
2011; Brand 
and Gough, 
2011; 
Zoledziewska 
et al., 2009) 
Coexistence of autoimmune diseases has been recently reviewed and statistically evaluated 
suggesting association of diseases and their common origin (Rojas-Villarraga et al., 2012). 
However the problem is only in the beginning of experimental evaluation and has to be very 
topical in genomic studies in nearest future. 
2.4. Molecular genetics of juvenile idiopathic arthritic 
Juvenile idiopathic arthritis (JIA) is the most common clinically heterogeneous chronic 
rheumatic disease in children (Ravelli et al., 2009). Onset-specific clinical features allow 
discrimination of seven JIA subtypes (Petty et al., 2004)  with oligoarthritis (JIoA) and 
polyarthritis (JIpA) being the most frequent (Ravelli et al., 2009). The cause of JIA is 
complex, involving both environmental and genetic risk factors. The latter could include 
structural variations in both human leukocyte antigens and non-human leukocyte antigen 
candidate genes. (Prahalad et al., 2008; Thompson et al., 2010; Sivakumaran et al., 2011). 
Because of the pleiotropic effect, a frequent phenomenon in complex human traits and 
diseases (Sivakumaran et al., 2011) some loci of susceptibility may be shared with other 
autoimmune diseases (Thompson et al., 2010; Sivakumaran et al., 2011). An exceptional 
biological role for the ubiquitin proteasome system (UPS) in antigen processing and immune 
response, as suggested by Kloetzel (2001) has been increasingly supported this last decade 
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experimentally. A special form of proteasomes, thymoproteasomes, expressed exclusively in 
the cortex of the thymus and probably involved in positive selection of T cells, has recently 
been described. This indicates that the role of proteasomes in the immune response might be 
even more important (Sutoh et al., 2012; Egerer et al., 2002). 
In patients with systemic autoimmune disease, the concentration of circulating 
proteasomes has been shown to be strongly increased (Egerer et al., 2002; Henry et al., 2011); 
the core 20S proteasome was identified as a target of the humeral autoreactive immune 
response.(Feist et al., 1996; 1999; Voigt et al., 2010; Arribas et al., 1991; Colmegna et al., 
2008; Fissolo et al., 2008). The proteasomal inhibitor MG132 has been reported to reduce the 
severity of arthritis and reverse pain behaviour in arthritic rat models (Ahmed et al., 2010). 
Fine 14q13.2 microsatellite scanning revealed evidence of JIA association with variability in 
the region encompassing the PSMA6 gene (Sjakste T, et al, 2010).  
2.5. Molecular genetics of bronchial asthma 
Asthma is a chronic inflammatory disease caused by complex gene-gene and gene-
environment interactions with hyper-responsiveness to various nonspecific stimuli (Broide et 
al., 2001; Galli et al., 2008; Wu et al., 2012) being to a large extent genetically heterogeneous 
between human populations (Leung et al., 2014).  
Ozaki et al. (2006) reported that the risk allele G of rs1048990 (PSMA6) might increase 
the expression of PSMA6 protein in vivo and in vitro, leading to enhanced inflammation 
through the activation of the NF-kB protein. Free NF-kB moves to the nucleus where it binds 
to target DNA elements and activate transcription of genes encoding proteins involved in 
immune responses, inflammation or cell proliferation. NF-kB could be considered as a 
coordinating element in the body’s responses to situations of stress, infection or inflammation 
(Birrell et al., 2005; Edwards et al., 2009; Gagliardo et al., 2003). Thus, this polymorphism 
might be important for the development of chronic inflammation. However, interplay of 
multiple risk alleles and/or genotypes and primary driver of the disease remains still unclear. 
Insufficient proteasome function was implicated in pathophysiology of various acute and 
chronic lung diseases and their complications (Albright et al., 2009; Majetschak et al., 2008; 
Sixt et al., 2010; Zemeckienė et al., 2013) and potentially could be a consequence of 
particular proteasomal genes structural variations. Early studies showed a possible linkage of 
chromosome 14 to asthma (Leung et al., 2014; Birrell et al., 2005).  
Multiple studies including several GWAS analyses, indicated the 14q11-24 genome 
region as susceptible to asthma (Hakonarson et al., 2002; Malerba et al., 2001; Mansur et al., 
2004; Munthe-Kaas et al., 2007; Tulah et al., 2012; Ungvári et al., 2012; Zhang et al., 2012). 
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This genomic region possess cluster of proteasomal genes including the PSMA6, PSMC6 and 
PSMA3 genes implicated previously in susceptibility to autoimmunity (Sjakste et al., 2004; 
2010), type 2 diabetes mellitus (Sjakste et al., 2007), cardio-vascular disorders (Wang et al., 
2013) and population adaptation to environment (Publication I). It appears that there is large 
potential for 14q proteasomal genes association studies to provide novel insights into 
bronchial asthma (BA) pathogenesis in particular human populations and in general. 
2.6. Molecular genetics of obesity 
The prevalence of obesity and overweight continues to raise worldwide causing serious 
health and social personal problems and substantial economic burden on societies. This 
complex multifactorial disease clearly implicated as a risk factor for many common diseases 
including diabetes, heart diseases, cancer and other health risk factors in all human 
populations (reviewed by Day & Loos 2011). Despite recent advances in the obesity genetics 
(reviewed by Day & Loos 2011; Loos 2009), further dissection of common inter-individual 
genetic backgrounds associated with and/or predisposed to obesity could bring more light on 
disease pathogenesis and assist to preventive strategies and more effective personalized 
disease treatment.  
Structural variations in the proteasomal genes potentially could affect UPS efficiency 
through modulation of a particular gene expression, realization of gene and protein networks 
and metabolic processes that finally may influence predisposition to and/or development of 
obesity or overweight. It was shown that plasma ubiquitin and proteasome levels inversely 
correlated with body mass index (BMI) and could be considered as potential biomarkers for 
human obesity (Chang et al., 2009). Proteasome dysfunction mediates obesity-induced 
endoplasmic reticulum stress and insulin resistance in the liver (Otoda et al., 2013). Novel 
BMI susceptible locus had been recently identified on the chromosome 14 in Chinese 
population (Zhang et al., 2012). Decreased proteasomal activity causes age-related 
phenotypes and promotes the development of metabolic abnormalities (Tomaru et al., 2012). 
Significant association was found between obesity-associated phenotypes in Italians and 
genetic variants of the PSMD9 gene encoding one of 26S proteasome non-ATP-ase regulatory 
subunits (Gragnoli et al., 2011). Mutation in the PSMB8 gene encoding the 
immunoproteasome specific peptidase, has been reported to be associated with Japanese 
autoinflammatory syndrome with lipodystrophy (Kitamura et al., 2011). It was shown that 
plasma ubiquitin and proteasome levels inversely correlated with male body mass index in 
Southern Taiwan and Japanese population (Chang et al., 2009; Sakamoto et al., 2010) and 
proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin 
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resistance in the liver (Otoda et al., 2013). Significant association was found between genetic 
variants of the PSMD9 gene and obesity-associated phenotypes in Italians (Gragnoli et al., 
2011). Mutation in the PSMB8 gene has been reported to be associated with autoinflammatory 
syndrome with lipodystrophy in Japanese (Kitamura et al., 2011). Earlier was detected 
association of PSMA3 gene polymorphisms with susceptibility to obesity in Latvian children 
(Kupca et al., 2013) 
2.7. Functional significance of SNPs 
The role of heredity in susceptibility to diseases manifests itself on several levels of 
genome organisation: primary structure of DNA (genetical factor per se), interacting with 
various epigenetic factors like base modifications, modifications of chromatin packaging, etc. 
Therefore impact of genomic factors on human health should be analysed in complex, taking 
into account interactions of several levels of genome organisation.  
The development of the different forms of cardiovascular, allergic, gastrointestinal and 
cancer diseases is determined by a complex interplay of environment factors with genetically 
determined features metabolism of a particular individual. Currently the traditional view that 
susceptibility to diseases is determined only by the interaction between the genes and the 
environment is being supplemented and expanded with new data about the key role of 
epigenetic reprogramming (Bird, 2002; Bruce et al., 2011; Hogg et al., 2012), heritable 
changes in gene expression that are not related to changes in the DNA sequence (Rodenhiser 
et al., 2006).  
Initial studies in the field of epigenetics stressed the importance of genetic basis in 
development of multifactorial diseases. Environmental factors also influence epigenetical 
status of the organism, and interaction of both hereditary and environmental factors maintains 
“health” of the genome (Bird, 2002; Kellermayer et al., 2012). This explains existence of 
individual variations and uniqueness of cells, tissues and organs, in spite of the identity of the 
genetic information. 
Many diseases are known to have a genetic component, but the epigenetic mechanisms 
underlying many conditions are still under study. Changes in the expression of genes within 
the body is characteristic of a significant number of disease, probably this is achieved via 
epigenetic mechanisms. These changes can be the cause of symptoms to the disease. Several 
diseases, especially cancer, have been suspected of selectively turning genes on or off in order 
to prevent the host’s immune systems from destroying the tumorous tissues (Esteller et al., 
2008). 
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The main epigenetic mediators assumed histone modifications, DNA methylation and 
non-coding RNAs (Vliet et al., 2007). It is known that the human genome contains 23,000 
genes that must be expressed in cells of different specificities in exactly fixed time. This 
process depends largely on the chromatin structure. If chromatin is condensed, the genes are 
in inactivated state, if the chromatin is in open form and activated, it determines the activation 
of gene expression. This process is determined by reversible processes such as DNA 
methylation and histone modification. It is believed that the change in the activity of these 
processes leads to deregulation of the gene expression and can induce pathological processes 
(Miltenberger-Milteny et al., 2003; Sharp et al., 2004; Yang et al., 2012). The final category 
of epigenetic mechanism is regulatory RNA (MicroRNAs), the small, noncoding sequences 
that are involved in gene expression. Thousands of them are known, and the extent of their 
involvement in epigenetic regulation is an area of ongoing research (Prasanth, 2004). 
Human single nucleotide polymorphisms (SNPs) represent the most frequent type of 
DNA variation in humans and many of them are believed to cause phenotypic differences 
between individuals. The investigation of SNP can help to understand the genetics of the 
human phenotype variations and especially the genetic basis of human complex diseases. 
Non-synonymous coding SNPs (nsSNPs) comprise a group of SNPs that, together with SNPs 
in regulatory regions, are believed to have the highest impact on phenotype (Ramensky et al., 
2002). 
The effect of SNPs involved in complex human phenotypes depends on many genetic and 
environmental components. In other words SNPs may comprise risk factors of having a 
specific phenotype in the statistical sense, and the effect of a particular SNP on phenotype 
might be seen only as a frequency difference between individuals that display the phenotype 
and unaffected controls.  
The main point of disease gene identification should be functional analysis of the disease-
associated allele for understanding of the molecular mechanism of causation of the disease 
phenotype. A possible way to overcome the problem of testing main numbers of SNPs, 
especially in the case of candidate gene studies, would be to determine SNPs according to 
their functional significance (Emahazion et al., 2001; Schork et al., 2000). This knowledge 
can be used to reduce the number of studied SNPs by focusing on specific genomic regions or 
gene sets, bioinformatics expertise may help to discriminate between neutral SNPs, which 
constitute the majority of genetic variation, and SNPs of likely functional importance.  
Various approaches have been developed to identify variants that are likely to play an 
important biological role. Most of these approaches focus on the interpretation of coding or 
other SNPs in transcribed regions (Ng and Henikoff 2003; Adzhubei et al. 2010; Saccone et 
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al. 2010). The vast majority of associated SNPs identified in GWAS, however, are in non-
transcribed regions, and it is likely that the underlying mechanism linking them to the 
phenotype is regulatory. A major challenge in the interpretation of GWAS results in a fact 
that SNPs located in close proximity in the genome tend to be in linkage disequilibrium (LD) 
with each other (The International HapMap Consortium 2005, 2007), and only a few SNPs 
per linkage disequilibrium region are measured on a given genotyping platform. Regions of 
strong linkage disequilibrium can be large, and SNPs associated with a phenotype have been 
found to be in perfect linkage disequilibrium with SNPs several hundred kilobases away.  
SNPs that influence gene expression (expression quantitative trait loci, eQTLs) (Stranger 
et al. 2007; Schadt et al. 2008) have been shown to be significantly enriched for GWAS 
associations (Nicolae et al., 2010; Zhong et al. 2010). Several recent analyses of associated 
regions use these types of functional data in order to identify functional loci in individual 
diseases (Lou et al., 2009; Carvajal-Carmona et al., 2011; Harismendy et al., 2011; Paul et al., 
2011). A recent study of chromatin marks in nine different cell lines produced a genome-wide 
map of regulatory elements and showed a twofold enrichment for predicted enhancers among 
the associated SNPs from GWAS (Ernst et al., 2011). These examples illustrate the power of 
statistical associations between a region of the genome and a phenotype.  
Chromatin accessibility has been studied using DNase-seq, which led to the identification 
of 2.89 million DNase I–hypersensitive sites that may exhibit regulatory function. (The 
ENCODE Project Consortium 2004, 2007, 2011). DNase foot printing (Hesselberth et al., 
2009; Boyle et al. 2011; Pique-Regi et al., 2011) was used to detect binding between proteins 
and the genome at a nucleotide resolution. ChIP-seq experiments were conducted for a total of 
119 transcription factors and other DNA-binding proteins. Together these data provide a rich 
source of information that can be used to associate GWAS results with functional data.  
High-throughput functional assays (chromatin immunoprecipitation assays) followed by 
sequencing (ChIP-seq) (Johnson et al., 2007; Robertson et al., 2007) and DNase I–
hypersensitive site (Gross et al., 1988) identification by sequencing (DNase-seq) (Crawford et 
al., 2006; Boyle et al., 2008) can experimentally detect functional regions such as 
transcription factor binding sites (TFBS). Approaches based on known transcription factor 
binding motifs (Xu et al., 2009; Macintyre et al., 2010) have been successfully used to 
identify specific loci that have a functional role (Jarinova et al., 2009; Landers et al., 2009). 
The presence of SNPs in these regions leads to differences in transcription factor binding 
between individuals, as shows experimental evidences (Kasowski et al., 2010). A SNP that 
overlaps an experimentally detected TFBS and is in strong linkage disequilibrium with a SNP 
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associated with a phenotype can assume more likely play a biological role than other SNPs in 
the associated region for which there is no evidence of overlap with any functional data.  
2.8. Perspectives for medical application. 
The phenotypic biomarkers integrate of both genetic and non-genetic factors and can be 
used for clinical prognosis, and genotyping for specific SNPs will be useful in clinical 
diagnosis and prognostic assessment of patients. SNP markers are already being used in the 
diagnosis of a few diseases such as Wilson disease (Schmidt et al., 2007). 
UPS components possess potential to be a therapeutic target for treatment of several 
diseases (Bedford et al., 2011). For example, the proteasome gene PSMA6 polymorphism 
rs1048990 is associated with three different diseases: myocardial infarction (Wang et al., 
2013; Heckman et al., 2013; Liu et al., 2009), type 2 diabetes (Liu et al., 2012; Barbieri et al., 
2008), and coronary artery disease (Wang et al., 2013). It has recently been shown that 
mutations and polymorphisms in the immunoproteasome catalytic subunit PSMB8 are 
associated with several inflammatory and autoinflammatory diseases including CANDLE 
syndrome (Torrelo et al., 2010), intestinal M. tuberculosis infection (Lv et al., 2011), and 
Nakajo-Nishimura syndrome (Arima et al., 2011). Polymorphisms in the insulin INS gene 
predicted development of T1DM (Wang et al., 2006.) 
The putative role of PSMA6 (8C>G) as survival factor in multiple myeloma has been 
shown for the first time: the G-allele was associated with worse 5-year survival, and it 
remained as an independent prognostic factor in multivariate analysis with a twofold higher 
risk to die compared to patients carrying the CC genotype. (Bachmann et al, 2010). 
The proteasome may contribute to disease by increasing disease related liability in 
cells, and by resulting in reduced numbers of diseased cells. A distinct class of cancer-
specific liabilities resulting from genome instability was recently reported (Nijhawan et al., 
2012). Cells containing partial PSMC2 copy number loss lack a proteasome complex 
composed of the protein product of PSMC2, Rpt1, and three other 19S subunits and 
eventually die after PSMC2 suppression (Nijhawan et al., 2012). 
In patients with rheumatoid (Egerer et al., 2002) and psoriatic (Henry et al., 2011) 
arthritis was shown to be substantially elevated the concentration of circulating proteasomes. 
Earlier, the 20S proteasome has been identified as a target of the humoral auto reactive 
immune response in patients with systemic inflammatory diseases including autoimmune 
myositis (Feist et al., 1996), primary Sjögren's syndrome (Feist et al., 1999), dilated 
cardiomyopathy (Voigt et al., 2010), systemic lupus erythematosus (Feist et al., 1996; Voigt 
et al., 2010; Colmegna et al., 2008), multiple sclerosis (Fissolo et al., 2008) and psoriatic 
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arthritis (Colmegna et al., 2008). The proteasomal inhibitor MG132 has been shown to reduce 
the severity of arthritis and reverse the pain behavior in the arthritic rat models (Ahmad et al., 
2010). The immunoproteasome PSMB9 codon 60HH variant was observed to have a reduced 
risk of developing multiple sclerosis in HLAA ∗02+ Italian females (Mishto et al., 2010). 
Results of treatment of autoimmune diseases using proteasome inhibitors have been 
successful in animal models (Paz et al., 2013; Fierabracci et al., 2013).  
An array of natural  and synthetic inhibitors of the proteolytic sites on the 20S proteasome 
have been developed both as research tools and as therapeutic agents (Nalepa et al., 2006; 
Goldberg et al., 2002; Gaczynska et al., 2005; Kisselev et al., 2001; Tsukamoto et al., 2006). 
Currently there are several inhibitors either approved or in clinical trials for the treatment of 
multiple cancers and strokes (Kisselev et al., 2001; 2006). These inhibitors have the capability 
of blocking protein degradation by the ubiquitine-proteasome pathway. They have also 
facilitated the discovery of numerous novel regulatory functions of UPS. The novel class of 
anticancer drug was represented by proteasome inhibitors (Richardson et al., 2006). 
Preclinical studies have showed that a dipeptidyl boronic acid, that is a selective inhibitor of 
the 26S proteasome, induces apoptosis and  decreases proliferation, enhances the activity of 
radiation and chemotherapy and reverses  hemoresistance in a variety of hematologic and 
solid malignancy models both in vitro and in vivo (Nawrocki et al., 2005). Dipeptidyl boronic 
acid was the first proteasome inhibitor to enter clinical trials and recently, received Food and 
Drug Administration (FDA) approval for the use of multiple myeloma and is being evaluated 
for the treatment of solid tumors (Nawrocki et al., 2005; Papandreou et al., 2004; Richardson 
et al., 2004). In preclinical animal models, selective proteasome inhibitors effectively 
suppress inflammatory arthritis and other inflammatory conditions (Palombella et al., 1998; 
Meng et al., 1999; Grisham et al., 1999; Bo Kim et al., 1999). In recent years, numerous novel 
drugs for the treatment of rheumatologic diseases have been successfully developed. The 
main approach has been to target cytokines, immune cells and their activation pathways 
(Olsen et al., 2004).  
The ability of proteasomes to control the NF-κB activity was shown in studies on 
proteasomal inhibitors. Silencing of the NF-κB pathway through proteasomal inhibition 
has shown the promising results in the studies on various cell lines and small animal 
models with asthma (Elliott et al., 2003; Moutzouris et al., 2010). The proteasomal 
inhibitors were shown as potential drugs for anticancer therapy (Kalis et al., 2003). The 
clinical studies carried out with these inhibitors in subjects with cancer have also shown 
good results (Shah et al., 2002; Millward et al., 2012). Therefore, the research on 
proteasomes and their inhibitors could provide new therapeutic agents for the treatment of 
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various diseases, such as chronic inflammatory diseases, multiple sclerosis cancer, and 
other (Elliott et al., 2001). 
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284 T. Sjakste et al. / Meta Gene 2 (2014) 283–298Population differentiation (FST statistics) was estimated from pairwise
population comparisons of loci variability, ﬁve locus haplotypes and
PSMA6 and PSMC6 two locus haplotypes. Latvians were signiﬁcantly
different from all Asians at each of 5 SNPs and from Lithuanians at the
rs1048990 and PSMC6 loci. Lithuanian and Asian populations exhib-
ited similarities at the PSMC6 loci and were different at the PSMA6 and
PSMA3 SNPs. Considering ﬁve locus haplotypes all European populations
were signiﬁcantly different from Asian; Lithuanian population was dif-
ferent from both Latvian and CEU.
Allele speciﬁc patterns of transcription factor binding sites and splicing
signals were predicted in silico and addressed to eventual functionality
of nucleotide substitutions and their potential to be involved in human
genome evolution and geographical adaptation. Current study repre-
sents a novel step toward a systematic analysis of the proteasomal gene
genetic diversity in human populations.
© 2014 The Authors. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).IntroductionThe ubiquitin-proteasome system (UPS) is the major nonlysosomal proteolytic pathway affecting
crucial intracellular processes. UPS deregulation has been implicated in the efﬁciency of the immune
response, ageing, inﬂammatory and many pathological processes (Sorokin et al., 2009; Willis et al., 2010;
Zemeckienė et al., 2013).
UPS components possess potential to be a therapeutic target for treatment of several diseases (Bedford
et al., 2011).
Importance of proteasomes in both normal and pathological processes triggers interest for search of
sequence variations in the proteasomal genes to be associated with human pathologies including cardio-
vascular disorders (Alsmadi et al., 2009; Banerjee et al., 2008; Barbieri et al., 2008; Bennett et al., 2008; Ozaki
et al., 2006; Sjakste et al., 2007b), diabetes mellitus (Sjakste et al., 2007a, 2007b), autoimmune diseases
(Sjakste et al., 2004, 2010, in press; Trapina et al., 2009), children obesity (Kupca et al., 2013), cancer and its
outcome (Bachmann et al., 2010). However, these associations could signiﬁcantly vary in different ethnic
populations as it was shown for coronary artery disease (Wang et al., 2013).
No systematic analysis has been done until now to evaluate the proteasomal gene genetic diversity in
humans on population level. It appears that genotyping of the PSMB5 gene single nucleotide
polymorphism (SNP) in four American ethnic groups (Wang et al., 2008) and the 14q13.2 microsatellite
polymorphism in Latvian and Finland populations (Kalis et al., 2002; Sjakste et al., 2007a) are the only
studies directly addressed to that objective. Case/control disease association studies could provide
signiﬁcant information on population diversity. The rs1048990 of the PSMA6 gene was widely genotyped
during the last decade in several European and Asian populations for association with cardiovascular
disorders, type 2 diabetes mellitus and other pathologies and their outcome (Table 1 and Wang et al.
(2013) for references). Several SNPs located within and upstream the PSMA6 gene as well as within the
PSME1, PSME2 and PSMA3 genes were genotyped in Latvians on susceptibility to different pathologies
(Kupca et al., 2013; Sjakste et al., 2007b, in press; Trapina et al., 2009). HapMap and PERLEGEN projects
(http://www.ncbi.nlm.nih.gov/snp/) provide signiﬁcant information on the genetic diversity of many
individual loci in different ethnic populations; however this information is based on analysis of very small
subject groups, more detailed studies are necessary.
In the current study ﬁve SNPs belonging to the PSMA6 (rs2277460 and rs1048990), PSMC6 (rs2295826
and rs2295827) and PSMA3 (rs2348071) genes, have been genotyped on genetic diversity in Latvian (LV),
Lithuanian (LT) and Taiwanese (TW) populations to evaluate extent of diversity and population differ-
entiation. Allele speciﬁc patterns of transcription factor binding sites (TFBSs) and splicing signals were
predicted in silico to reveal a potential of nucleotide substitutions in proteasomal genes to be important for
human genome evolution and adaptation.
Table 1
Polymorphism description.
Marker ID Coordinates cytogenetic/
genomic
Gene Function MAF/MA count Association ﬁndings
Disease Reference
rs2277460 14q13.2:/14:35761573 PSMA6 Promoter: c.-110CNA
(c.-109-1CNA)
A = 0.0634/138 T2DM Sjakste et al., 2007b
JIA Trapina et al., 2009, Sjakste et al., in press
rs1048990 14q13.2/14:35761675 PSMA6 5′-UTR: c.-8CNG G = 0.195/425 T2DM Sjakste et al., 2007b; Barbieri et al., 2008
CVD Ozaki et al., 2006; Sjakste et al., 2007a, 2007b;
Takashima et al., 2007; Bennett et al., 2008;
Liu et al., 2009; Banerjee et al., 2009; Alsmadi
et al., 2009; Hinohara et al., 2009; Honcharov
et al., 2009; Ikeda et al., 2012; Heckman et al.,
2013; Wang et al., 2013
Cancer Bachmann et al., 2010
rs2295826 14q22.1/14:53174923 PSMC6 Intron 1: c.128-104ANG G = 0.124/271 JIA Sjakste et al., in press
rs2295827 14q22.1/14:53174981 PSMC6 Intron 1: c.128-46CNT T = 0.102/222 JIA Sjakste et al., in press
rs2348071 14q23/14: 58730626 PSMA3 Intron 7: c.543 + 138GNA;
c.522 + 138GNA;
c.576 + 138GNA
A = 0.369/804 JIA Sjakste et al., in press
Obesity Kupca et al., 2013
Ancestral allele is underlined in the motif description. MAF/MA count is given according to the 1000 genome phase 1 population project data Abbreviations: MAF — minor allele frequency; MA —
allele minor in Caucasians; T2DM — type 2 diabetes mellitus; CVD — cardiovascular disorders; JIA — juvenile idiopathic arthritis.
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Samples
LV population was represented by 191 (117 females) patients of Riga Bikernieki Hospital, specialized
in trauma medicine. Patients with only trauma diagnosis and without autoimmune and cardiovascular
disorders, type 2 diabetes mellitus (T2DM) and obesity were included in this cohort. LT population was
represented by 150 individuals (97 females) underwent prophylactic evaluation at Kaunas Family
Medicine Centres and Hospital of Lithuanian University of Health Sciences and being without diagnosis or
familial predisposition to congenital diseases, acute or chronic infections, oncological, autoimmune or any
other chronic diseases, immunodeﬁciency and obesity. TW study subjects enrolled from elementary school
for allergy diseases screen were represented by 1097 children (558 girls) without asthma and asthma
history. Written informed consent was obtained from all the participants. LV, LT and TW studies were
approved by the Central Medical Ethics Commission of the Latvian Ministry of Health, Kaunas Regional
Biomedical Research Ethics Committee and Ethics Committee of Taoyuan General Hospital respectively.
DNA extraction and genotyping
Genomic DNA was extracted from nucleated blood cells using a kit for genomic DNA extraction
(Fermentas, Vilnius, Lithuania) or QIAamp DNA blood mini kit (Qiagen, Germany) and from oral swabs
using QIAampDNAMini Kit (QIAGEN, Valencia, CA, USA) according to themanufacturer's protocols. Quality
and quantity of DNA were determined using agarose gel electrophoresis and spectrophotometry. DNA
samples were stored at−80 °C until use.
Table 1 summarizes information on the polymorphic loci genotyped in our study.
Genotypingmethods andprimer sequences used by LV and LT teams are indicated in Supplementary Table 1.
In brief, basic PCR was performed using the DreamTaq polymerase (Fermentas, Vilnius, Lithuania) with
following parameters: 94 °C for 5 min; then 35–40 cycles of 94 °C for 45 s, appropriate annealing temperature
(55–61 °C) for 45 s, 72 °C for 45 s and a ﬁnal extension at step at 72 °C for 7 min. DNA digestion by restriction
enzymes was performed according to the producer's protocols (Fermentas, Vilnius, Lithuania). Allele speciﬁc
ampliﬁcation used to identify the rs2277460 alleles was followed by the RsaI digestion to genotype the
rs1048990. The rs2295826 and rs2295827were typed simultaneously in oneDdeI digestion reaction. Ampliﬁed
and digested products were analysed by electrophoresis in 1–3% agarose gel. TW team genotyped SNPs using
high throughput, 384-microtiter plate, MassARRAY™ System, SEQUENOM according to the manufacturer's
instructions. In brief, DNA containing the SNP site of interest was ampliﬁed, followed by the homogenous
MassEXTEND™ assay in which label-free primer extension chemistry was used to generate allele-speciﬁc
diagnostic products of unique molecular weight suitable to be distinguished through the application of matrix
assisted laser desorption ionization time-of-ﬂight mass spectrometry. For quality control 16 randomly chosen
samples per each marker were genotyped in duplicate in different experiments in each LV, LT and TW
population. The concordance of the genotypingwas 100%. Genotyping datawere veriﬁedbydirect sequencing of
the corresponding DNA fragments in both directions using the Applied Biosystems 3130xl Genetic Analyzer.
Alleles and genotype frequencies for the rs2277460 (ss24557113), rs1048990 (ss35076445), rs2295826
(ss3239727 and ss69157456), rs2295827 (ss23619651) and rs2348071 (ss3302481) were extracted from
public available dbSNP (build 13) entries at NCBI (http://www.ncbi.nlm.nih.gov/snp) for 47, 40 and 43
unrelated participants of HapMap-CEU (NorthWestern European), HCB (Han Chinese) and JPT (Japanese)
populations respectively and 5 locus genotypes were reconstructed for each individual.
Loci description and nucleotide numbering are given according to the recommended nomenclature
system (http://www.genomic.unimelb.edu.au/mdi/mutnomen/recs.html/). The chromosome 14 GRCh37.p5
assembly (NCBI reference sequence: NC_000014.8) sequence information was used for loci description,
nucleotide numbering and primer design that was done using the Primer 3.0 program.
Data analysis
Personalised genotyping data documentation resulted in knowledge of 5 locus genotype (5-LG: rs2277460/
rs1048990/rs2295826/rs2295827/rs2348071) of each individual participant of the study. The 5-LGs, observed
287T. Sjakste et al. / Meta Gene 2 (2014) 283–298haplotypes, genotypes of each individual locus (single locus genotype or SLG) and alleles' frequencies were
estimated by direct gene counting and deviations fromHardy–Weinberg equilibrium (HWE) were tested by χ2
test (Rodriguez et al., 2009; http://www.oege.org/software/hwe-mr-calc.shtml). DnaSP21 version 5 (Rozas,
2009; http://www.ub.es/dnasp/) was used to reconstruct the haplotypes from un-phased genotypes, evaluates
the nucleotide diversity, performs Tajima's D (Tajima, 1989) and Fu and Li's F* and D* (Fu and Li, 1993) tests of
neutrality, and evaluates the pairwise linkage disequilibrium (LD) between the loci (D and r2) and pairwise
population differentiation (Fst). Haplotype age and phylogenetic relationships were obtained using the Reduced
Median algorithm of the Phylogenetic network software Fluxus 4.611 (http://www.ﬂuxus-engineering.com).
SNPs functional analysis in silico
An eventual functional signiﬁcance of nucleotide substitutions was analysed in silico on the sequence
similarity to TFBSs using Genomatix software, MatInspector, release 7.4 online tool (Cartharius et al.,
2005; www.genomatix.de/) with core and matrix similarity of 1.000 and more than 0.800 respectively.
Splicing signals were predicted by Human Splicing Finder version 2.4 (Desmet et al., 2009; http://www.
umd.be/HSF/) with standard threshold values for branch point, donor and acceptor splice sites, enhancer,
silencer, hnRNP and other splicing motifs.
Results
SNPs' diversity
Data on SNPs allele and genotype presentation in LV, LT and TW populations are presented in Table 2. In
general, alleles' and genotypes' distribution was similar between LV, LT and CEU and TW, CHB and JPT
populations respectively (data for HapMap populations are not shown). However, the rs2277460 rare allele A
being previously not found in Asians, was observed in Taiwanese; and the rs2295827 rare allele TT homozygotes
found in all humanpopulations studied previously,were not detected in Taiwanese at all. The rs2348071 allele G
was major in both LV and LT populations similar to CEU and allele A was major allele in TW similar to HCB and
JPT. The rs1048990 minor allele was observed more than twice frequently in TW than in each LV and LT
(P b 0.001) and signiﬁcantlymore frequent in LT compared to LV (P b 0.05). Minor alleles at the rs2295826 and
rs2295827were signiﬁcantly (P b 0.05) less frequent in LV than in each of LT and TWand alleles' and genotypes'
presentation was found to be similar between LT and TW (P N 0.05). TW was found to deviate signiﬁcantlyTable 2
SNPs diversity in Latvian, Lithuanian and Taiwanese populations.
Marker ID Population MAF Genotype frequency HWP
(χ2)
Nucleotide
diversity (π)
Test of neutrality
11 12 22 Tajima's DT Fu and
Li's D*
Fu and
Li's F*
rs2277460 LV 0.0654 0.8691 0.1309 – 0.94 0.12265 −0.18389 0.42624 0.27631
LT 0.0933 0.8133 0.1867 – 1.59 0.16981 0.06301 0.43609 0.37690
TW 0.0073 0.9854 0.0146 – 0.06 0.01449 −0.66360 0.37096 0.03623
rs1048990 LV 0.0890 0.8272 0.1676 0.0052 0.21 0.16259 0.05540 0.42624 0.36631
LT 0.1533 0.7067 0.2800 0.0133 0.92 0.26051 0.60431 0.43609 0.57821
TW 0.3254 0.4211 0.5068 0.0702 26.15*** 0.43925 1.98494 0.37096 1.09877
rs2295826 LV 0.1047 0.8115 0.1673 0.0209 2.16 0.18799 0.20752 0.42624 0.42353
LT 0.1700 0.7000 0.2600 0.0400 0.93 0.28314 0.73936 0.43609 0.62844
TW 0.1545 0.7092 0.2726 0.0182 2.05 0.26140 0.87595 0.37096 0.65397
rs2295827 LV 0.1047 0.8115 0.1673 0.0209 2.16 0.18799 0.20752 0.42624 0.42353
LT 0.1700 0.7000 0.2600 0.0400 0.93 0.28314 0.73936 0.43609 0.62844
TW 0.1468 0.7065 0.2935 – 34.45*** 0.25056 0.80841 0.37096 0.62677
rs2348071 LV 0.2932 0.5340 0.3456 0.1204 5.28* 0,41555 1.57068 0.42624 0.93621
LT 0.2667 0.5400 0.3867 0.0733 0.02 0.39242 1.39150 0.43609 0.87098
TW 0.6541 0.1859 0.3199 0.4941 94.14*** 0.45274 2.06904nd 0.37096 1.13251
LV, LT and TW abbreviations are used to indicate Latvian, Lithuanian and Taiwanese populations respectively; MAF is given according to
allele being minor in European populations. Statistical signiﬁcance levels of probability correspond to: nd not determined (P = 0.05);
* P b 0.05; *** P b 0.001.
288 T. Sjakste et al. / Meta Gene 2 (2014) 283–298(P b 0.001) from HWE at the rs1048990 and rs2295827 where rare allele homozygotes appear to be
underrepresented and at the rs2348071 where heterozygotes appear to be underrepresented. Slight
underrepresentation of the rs2348071 heterozygotes (P b 0.05) was also detected in LV.
To assess whether the observed patterns of SNPs diversity corresponded to expectations under the
neutral model of evolution, the DT, D* and F* statistics were applied and data are presented in Table 3. For
LV and TW, DT was negative for the rs2277460; in all other cases DT was positive. At the rs2348071, DT was
slightly more than 2 in TW, however, it did not reach level of signiﬁcance (P = 0.05). For all populations
at all loci, D* and F* were positive and no DT, D* and F* values were signiﬁcant.
Linkage disequilibrium
Pairwise LD was estimated by DnaSP software and evaluated using D and r2 parameters (Table 3). The
rs2295826 and rs2295827 were found to be in complete LD (D = 1, r2 = 1) in LV and LT; linkage was
slightly disrupted in TW (D = 0.978, r2 = 0.901).
Haplotype diversity
Spectra and frequencies of ﬁve locus haplotypes are given in Table 3 for LV, LT, TW and HapMap CEU,
HCB and JPT populations and listed in order of frequency decrease in LV. From 18 haplotypes inferred by
DnaSP, the ﬁrst 10 listed showed frequency higher than 5% in one population at least. Haplotypes Hap11–
12 and Hap13–18 were inferred only for LT and TW respectively and appear to be rare (≤2%) in human
populations over the world.Table 3
Allelic composition, frequency and other characters of the 5 locus haplotypes in human populations.
Haplotype Populations (2n)
ID 1–2–3–4–5 LV (382) LT (300) CEU (94) TW (2194) HCB (80) JPT (86)
Hap 1 CCACG 0.5576 0.4967 0.6064 0.2388 0.1875 0.2558
Hap 2 CCACA 0.2068 0.1467 0.2021 0.3464 0.3000 0.2209
Hap 3 CCGTG 0.0681 0.0833 0.0638 0.0264
Hap 4 ACACA 0.0393 0.0267 0.0106 0.0027
Hap 5 CGACA 0.0340 0.0067 0.0745 0.1796 0.2625 0.2791
Hap 6 CGACG 0.0314 0.1100 0.0426 0.0706 0.0625 0.0581
Hap 7 ACACG 0.0262 0.0400 0.0046
Hap 8 CGGTG 0.0236 0.0625 0.0116
Hap 9 CCGTA 0.0131 0.0300 0.0510 0.1250 0.1163
Hap 10 CGGTA 0.0333 0.0643 0.0581
Hap 11 ACGTA 0.0233
Hap 12 AGACG 0.0033
Hap 13 CGGCA 0.0068
Hap 14 CCGCG 0.0023
Hap 15 CGGTG 0.0023
Hap 16 CGATA 0.0018
Hap 17 CCGCA 0.0014
Hap 18 CCATG 0.0009
Hd 0.638 0.710 0.586 0.779 0.792 0.797
Test of neutrality
Tajima's D, DT 0.71472 1.35443 −0.20222 2.00713nd 1.85362#* 1.91830#*
Fu and Li's D* 0.93163 0.94926 −0.01266 0.82277 0.96034 0.95389
Fu and Li's F* 1.02654 1.29964 −0.08777 1.52548#* 1.45955 1.1.48121#*
LD 3–4
DV 1.000 1.000 1.000 0.978 1.000 1.000
r2 1.000***B 1.000***B 1.000***B 0.901***B 1.000***B 1.000***B
The loci 1, 2, 3, 4, and 5 in haplotypes' conﬁgurations correspond in sequence to the rs2277460, rs1048990, rs2295826, rs2295827
and rs2348071 loci respectively; Hd — haplotype diversity; LD — linkage disequilibrium. Statistical signiﬁcance levels of probability
correspond to: #* 0.10 N P N 0.05; nd not determined: P = 0.05; *** P b 0.001; B — Bonferroni correction for multiple tests.
289T. Sjakste et al. / Meta Gene 2 (2014) 283–298Patterns of haplotypes distribution are drastically different between Europeans and Asians. Hap1 being
themost frequent haplotype in Europeans is only second in TWand JPT and third in HCB; Hap5 beingminor
in Europeans is the ﬁrst in JPT, second in HCB and third in TW.More examples could be listed (see Table 3).
Pattern of diversity being similar between LV and CEU is different to some extent from LT. The most
impressive difference concerns the Hap6 being minor (less than 5%) in both LV and CEU and presented in
11% of Lithuanians. Level of haplotype diversity is approximately the same in TW, HCB and JPT (0.779,
0.792, and 0.797 respectively); howeverminor in TWHap3, Hap4, Hap7 and Hap13–18were not suggested
for HCB and JPT; Hap8 predicted for HCB and JPT was not inferred for TW. It is of interest that Hap10 absent
in LV, CEU and HCB, was observed in LT, TW and JPT with similar frequency (3–6%).
Haplotypes' distributions were analysed on neutrality of evolution by DT, D* and F* statistics (Table 3). DT
slightly exceeded 2, was obtained only for TW, however statistical signiﬁcance was not determined (P = 0.05);
DT values for other populations as well as D* and F* values for all populations were not statistically signiﬁcant.
The PSMA6 (rs2277460/rs1048990) and PSMC6 (rs2295826/rs2295827), two locus haplotype patternswere also
tested on neutrality and no DT, D* and F* values were signiﬁcant for all populations (data not shown).
Fig. 1 illustrates proportions and phylogenetic relationships between haplotypes being most frequent
(frequency more than 1%) in particular population. Hap2 having ancestor alleles at all ﬁve loci, was
considered to be a common ancestor in all populations analysed. That haplotype being one of most
wide-spread in modern Asians appears to be an immediate ancestor of the Hap1, Hap4, Hap5 and Hap9.
Substitution A to G at the rs2348071 appears to be the most ancient among the analysed mutations. That
mutation appears to happen about 8000–15,000 years ago and generated the Hap1, the predominant
haplotype in modern Europeans. Major in Europeans and one of the most frequent in Asians, the Hap1
appears to be the immediate ancestor for Hap3, Hap6 and Hap7 having more recent time of origin.M: 1000 years
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Fig. 1.Median joining network of PSMA6/PSMC6/PSMA3 haplotypes. The networkwas generated using the ReducedMedian algorithm
of the Phylogenetic network software Fluxus 4.611 (http://www.ﬂuxus-engineering.com). Panel A: LV — Latvians, LT — Lithuanians,
CEU — NorthWestern Europeans; Panel B: TW — Taiwanese, HCB — Han Chinese, JPT — Japanese. Haplotypes are numbered as in
Table 3. Mutations at the rs2277460, rs1048990, rs2295826&rs2295827 and rs2348071 are indicated as stars of interrupted outline,
grey, black and white colours respectively. Length of the branches is equal to time of generation and dissemination of progeny
haplotype.
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Patterns of population differentiation were analysed using FST statistics for SNPs' and haplotype fre-
quencies and results are presented in Table 4. Locus-by-locus pairwise comparison between populations
revealed signiﬁcant differentiation between European populations. Both LV and LT were statistically
different from CEU at the rs2277460 (P b 0.05 and P b 0.01 respectively). LT differed from both CEU and LV
at the rs2295826 and rs2295827 (P b 0.05) and from LV at the rs1048990 (P b 0.01). No differentiation
was revealed between TW, HCB and JPT. All LV, LT and CEU strongly (P b 0.001) differed from Asians at the
rs2277460, rs1048990 and rs2348071. However, at the rs2295826 and rs2295827 Asians were different
only from LV and CEU; and exhibited similarities with LT. When ﬁve loci (1–5) haplotypes were taken into
consideration, pairwise differentiation between Europeans and Asians was of strong signiﬁcance
(P b 0.001) and LV was different from LT at nominal level of signiﬁcance (P b 0.05). Finally, we estimated
population differentiation for PSMA6 (rs2277460-rs10489990) and PSMC6 (rs2295826-rs2295827) two
locus haplotypes and obtained signiﬁcantly different patterns of differentiation. The PSMA6 haplotype
differentiated all European populations from Asians (P b 0.001 for all pairs) and LT from both LV and CEU
(P b 0.05) similar to ﬁve locus haplotype. When considering the PSMC6 haplotype, LV and CEU were
differentiated from LT (P b 0.05) and all Asian populations (P b 0.001); LT was undifferentiated from
Asians (P N 0.05).Eventual functional signiﬁcance of nucleotide substitutions
Figs. 2–4 illustrate our ﬁndings on eventual functional signiﬁcance of nucleotide substitutions evaluated
as loss/generation of TFBSs and splicing signals in the PSMA6, PSMC6 and PSMA3 genes respectively.Table 4
Pairwise estimates of Fst between human populations using individual SNP (1, 3, and 5— above ﬁrst three diagonals and 2, 4— below
ﬁrst two diagonals), 5 SNPs (1–5 haplotype— below third diagonal), PSMA6 (1–2 haplotype— above forth diagonal) and PSMC6 (3–4
haplotype — below forth diagonal) SNPs frequencies.
SNP LV LT TW CEU HCB JPT
LV 1 – 0.00228 0.04483*** 0.03655* 0.06299* 0.06299*
LT 2 0.01623** – 0.07169*** 0.06317** 0.09030** 0.09030**
TW 0.15592*** 0.07675*** – −0.00592 0.00684 0.00684
CEU −0.00291 −0.00097 0.11528*** – 0.0000 0.0000
HCB 0.21074*** 0.12179*** 0.00162 0.16684*** – 0.0000
JPT 0.23151*** 0.14021*** 0.00794 0.18688*** −0.01141 –
LV 3 – 0.01482* 0.00958* 0.00504 0.01850* 0.01822*
LT 4 0.01482* – −0.00107 0.04788* −0.00713 −0.00682
TW 0.00664* 0.00004 – 0.03787* −0.00317 −0.00299
CEU 0.00504 0.04788* 0.03220* – 0.05595* 0.05534*
HCB 0.01850* −0.0071 −0.00117 0.05595* – −0.01221
JPT 0.01822* −0.00682 −0.00106 0.05534* −0.01221 –
LV 5 – −0.00122 0.22986*** −0.00658 0.26355*** 0.24855***
LT 1–5 0.00838* – 0.26109*** −0.00607 0.29571*** 0.28040***
TW 0.13338*** 0.11657*** – 0.23385*** −0.00385 −0.00509
CEU 0.00107 0.02075** 0.14034*** – 0.26784*** 0.25274***
HCB 0.16164*** 0.13569*** −0.00145 0.17120*** – −0.011181
JPT 0.16205*** 0.13476*** 0.00023 0.17074*** −0.01184 –
D
LV 1–2 – 0.01058* 0.13730*** 0.00843 0.19030*** 0.20896***
LT 3–4 0.01482* – 0.07570*** 0.01847* 0.11609*** 0.13140***
TW 0.00813* −0.00052 – 0.10967*** 0.00170 0.0792
CEU 0.00504 0.04788* 0.03508 – 0.16266*** 0.18235***
HCB 0.01850* −0.00713 −0.00218 0.05595* – −0.01141
JPT 0.01822* −0.00682 −0.00204 0.05534* −0.01221 –
* indicates Fst values signiﬁcantly different from zero: * P b 0.05; ** P b 0.01; *** P b 0.001.
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Fig. 2. Consequences of the rs2277460 (Panel A) and rs1048990 (Panel B) nucleotide substitutions on functional potential of corresponding genomic regions of the PSMA6 gene. Promoter and exon
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293T. Sjakste et al. / Meta Gene 2 (2014) 283–298No TFBSs and splicing signals were predicted for genomic region having the rs2277460 major
and ancestral allele C. Substitution for rare allele A, potentially assists in creation of binding site to
barbiturate inducible element BARBIE.01, and similarity to number of splicing signals including the
hnRNP A1 motif.
Genomic region having the rs1048990 major and ancestral allele C, potentially possess similarity with
number of splicing signals; no TFBSs were predicted. Nucleotide substitution to minor G allele signiﬁcantly
change patterns of sequence similarity to splicing signals, assists to sequence similarity with exonic
splicing regulatory sequence and creates TFBSs of tumour suppressor p53 and DMRT families.
The rs2295826 major and ancestral allele A makes encompassing sequence to be similar to number of
splicing signals including additional branch point, potential acceptor site, the hnRNP A1 motif and number
of splicing enhancers and silencers as well as BSs to transcription factors of CREB, MYT1 and PARF families.
Substitution to G allele appears to eliminate mentioned activities and makes sequence similar mostly to
splicing silencers.
The rs2295827 major and ancestral allele C could generate additional branch point, but the sequence
afﬁnity to number of TFs of CART, BRNS, LHXF and HOXF families and similarity to number of splicing signals,
depend on the presence of minor T allele.
In contrast to the loci described above, the rs2348071 ancestral allele A is the major allele only in Asian
populations being the minor allele in Caucasians. When allele G is present, sequence manifests more
similarity to number of splicing signals than in the case of allele A; in turn the allele A assists to sequence
similarity with hnRNP A1 motif and creates BSs to TFs of CART, MEF2 and HBOX families.5' a a t a c a c c a a c a c t a t g a t a g c t g a t g a 3'
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Fig. 4. Consequences of the rs2348071 nucleotide substitutions on functional potential of corresponding genomic regions of the PSMA3
gene. Sequence features and other marks are given as described in Fig. 2. HBOX/GSH1.01–Homeobox TF Gsh-1; Cart/PHOX2.01–Phox2a
(ARIX) and Phox2b of cartilage homeoproteins family; MEF2/SL1.01–member of the RSRF related to serum response factors. Other
abbreviations are the same as in Figs. 2 and 3.
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In the current study we investigated genetic polymorphism of the PSMA6 (rs2277460 and rs1048990),
PSMC6 (rs2295826 and rs2295827) and PSMA3 (rs2348071) proteasomal genes in 1438 unrelated subjects
from LV, LT and TW populations.
The rs2277460 polymorphism locates in the promoter of the PSMA6 gene in distance of one and 110
nucleotides from the 5′-UTR and translation start respectively. Ancestral allele C, themajor allele in human
populations over the world, appears to be functionally neutral. Substitution to A generates binding sites to
the BARBIE box proteins shown to be involved in signal transduction pathways during development
(Arbouzova et al., 2006) and modulation of innate immunity (Dozmorov et al., 2009), hnRNP A1 known as
alternative splicing repressor (Clower et al., 2010) and factor facilitating processing of speciﬁc microRNAs
(Michlewski et al., 2010) as well as number of other splicing signals.
Transversion C → A appears to be rather recent mutation happed and ﬁxed in Europeans in historical
time. Alleles' and genotypes' frequencies observed in LV and LT are similar to reported previously for
Latvia (Sjakste et al., 2007b, in press; Trapina et al., 2009) and UK (Sjakste et al., 2007b). Rare allele A not
detected previously in Asian and African HapMap populations was identiﬁed in Taiwanese. In fact, our
TW group represented by approximately 50 times more subjects than each HCB and JPT populations and
potentially is more informative with respect to genetic diversity and rare allele, genotype and haplotype
identiﬁcation.
The rs1048990 SNP located in 8 nucleotides distance upstream the PSMA6 initiation codon and four
nucleotides upstream the Kozak consensus (Kozak, 1997), potentially could interfere splicing and initiation of
translation. In fact, Ozaki et al. (2006) reported that the rs1048990 G allele was associated with higher
expression of the PSMA6 gene in vitro and in vivo. Recently, Wang et al. (2013) compared levels of mRNA
expression by the rs1048990 genotypes and signiﬁcant trend byG allelewas also found.We showed here that
both C and G alleles could affect sequence functional potential. Ancestral allele C generates presumably
splicing enhancer motifs; minor allele G creates an exonic splicing regulatory motif, several splicing silencers
and binding sites for tumour suppressor p53 and double sex and mab-3 related transcription factor of DMRT
family. Gene encoding the tumour suppressor p53 was shown to express ethnic heterogeneity and may be
involved in ecological (climatic) adaptation (Själander et al., 1996). TFs of the DMRT family were shown to
play signiﬁcant roles during animal evolution contributing to the origin of novel sex-speciﬁc traits (Kopp,
2012) and potentially should be involved in human adaptation.
Ancestral allele C is a major allele in all human populations over the world being signiﬁcantly less
frequent in Asians than in Europeans (about 70% vs 90% in HCB and CEU populations respectively).
Similarly, in our study, we have observed theminor allele G approximately four and twicemore frequent in
TW compared to LV and LT respectively. Transversion C → G is one of the oldest mutations studied here
and appears to happen approximately 8000–11,000 years ago in Asians. In Europeans this mutation
appears to arise much later evolutionally or, more probably, had been introduced with human migrations
already in historical time.
Multiple case/control studies conducted during the last decade to search for association between the
rs1048990 SNP and human diseases provide signiﬁcant information on locus variability. Firstly, different
studies applied for the same ethnic groups (Latvians Sjakste et al., 2007b, in press; Trapina et al., 2009),
British (Bennett et al., 2008; Freilinger et al., 2009; Sjakste et al., 2007b), Indians (Banerjee et al., 2008,
2009) and Japanese (Hinohara et al., 2009; Ikeda et al., 2012; Ozaki et al., 2006; Takashima et al., 2007)
showed similar allele and genotype frequencies suggesting that control cohorts of case/control studies
could successfully represent corresponding population. Secondly, locus variability appears to express
geographical- and/or ethnos-speciﬁc dynamic. Minor G allele appears to be least of all presented in YRI
(MAF of 0.017). In Europe, MAF appears to increase from North East (mean for LV from current and
previous (Sjakste et al., 2007b, in press; Trapina et al., 2009) studies equal to 0.107) to SouthWest (0.133
in Ukraine (Honcharov et al., 2009), mean of 0.159 for UK (Bennett et al., 2008; Freilinger et al., 2009;
Ozaki et al., 2006) and 0.169 in Germany (Freilinger et al., 2009)) remaining signiﬁcantly rarer than in
India (mean of 0.206 Banerjee et al., 2008, 2009) and Saudi Arabia (0.231 Alsmadi et al., 2009). Allele G
showed the highest frequency in Eastern Asians where MAF varies from 0.317 in Japanese (mean from
Hinohara et al., 2009; Ikeda et al., 2012; Takashima et al., 2007) and 0.320 in Chinese (Liu et al., 2009) till
0.350 in Koreans (Hinohara et al., 2009).
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rs1048990 SNP was found to occur in frequencies consistent with HWE. However, genotype distribution
was found to deviate signiﬁcantly from HWE in our TW population, South Italian (Barbieri et al., 2008),
Saudi (Alsmadi et al., 2009) and one of Japanese control cohort (Ikeda et al., 2012). Three statistics applied
in our study did not show signiﬁcant deviation from neutral model of evolution.
The rs1048990 locus susceptibility reported for several pathologies (Table 1) appears to have ethnos-
speciﬁc character (Wang et al., 2013). We suggest that ethnos- and/or geographically-speciﬁc allele and
genotype distribution at the rs1048990 is an evolutionary natural phenomenon involved originally in the
mechanisms of ethnic adaptation to the deﬁnite environment and may inﬂuence general morbidity of
human populations.
The rs2295826 and rs2295827 both located in the ﬁrst intron of the PSMC6 gene in 61 bp from each
other, showed an r2 between 0.923 in Tuscans (Italy) and 1.0 (CEU) in different Caucasian ethnicities and a
D′ of 1.0 in all ethnicities analysed until the current study, suggesting three AC, GT and GC the rs2295826/
rs2295827 haplotypes. In both LV and LT populations, the rs2295826 and rs2295827 showed the same
alleles' and genotypes' frequencies suggesting strong linkage between the loci and only AC and GT
haplotypes' occurrence. To our surprise, we did not observed in Taiwanese the rs2295827 rare allele TT
homozygotes. This fact suggests a disruption of linkage between the rs2295826 and rs2295827 loci (D =
0.978; r2 = 0.901) and occurrence of forth rare AT haplotype in Taiwanese.
The rs2295826 A and rs2295827 C ancestral alleles were the major in all populations analysed. Alleles
and genotypes distributions were similar between LV and CEU and TW and Asian HapMap populations
respectively. To our surprise, minor alleles were signiﬁcantly more frequent in LT than in LV and CEU.
The major allele of the rs2295826 generates an additional splice site acceptor and branch point, hnRNP
A1 and several splicing enhancer and silencer motifs as well as sequence afﬁnity to TFs of CREB, MYT1
and PARF families known to be involved, in regulation of multiple physiological processes including control
of circadian clock (Male et al., 2012; Wang et al., 2010). Genetic variation occurred within coding and
non-coding regions of several genes regulating circadian rhythmwas shown to be ethnos speciﬁc (Cruciani
et al., 2008; Hawkins et al., 2008) andmight represent an evolutional history of adaptation in populations of
different geographic origin.
The rs2295826minor allele G generates splicing silencersmostly. Additional branch point is predicted
for sequence encompassing the rs2295827major allele C. Sequences having the rs2295827minor allele G
can potentially bind the CART proteins responsible for bone and cartilage development (Furukawa et al.,
2002), BRN5 and LHXF factors known to mediate transcriptional control of neuronal differentiation (Gill,
2003; Phillips and Luisi, 2000; She and Mao, 2011; Uzumcu et al., 2009) and HOXF family NANOG.01
factor shown to be generally involved in signal transduction pathways during development (Ho et al.,
2012).
The rs2348071 polymorphism located in the intron 7 of the PSMA3 gene strongly discriminates Asians
having a major ancestral allele A (about 70%) and other ethnics having a major allele G (about 70%).
Transition A → G appears to be one of the oldest among analysedmutationswhich happened in Caucasians
about 15,000 years ago andwas supported by positive selection in Caucasians over theworld. Mutation age
appears to be less in Asians and might result from both the de novo mutation event and gene ﬂow from
other ethnics.
Similar to the rs2348071, Wang et al. (2008) identiﬁed several loci in the PSMB1, PSMB2 and PSMB5
proteasomal genes being observed as minor in one ethnic group and middle/common in others and
suggested that clinical response to proteasomal inhibitors potentially might be allele speciﬁc (hypothesis
is discussed in Wang et al. (2008)).
The above mentioned and our ﬁndings indicate that loci greatly diverse between the populations in the
allele and genotype presentation could potentially be involved in processes of evolutional and/or
geographical adaptation of human populations to the environment. These should be of special interest and
perspective for medical applications.
The rs2348071 ancestral allele A generates binding sites for already mentioned CART proteins and MEF2
and HBOX factors known to mediate transcriptional control of neuronal differentiation (Gill, 2003; Phillips
and Luisi, 2000; She and Mao, 2011;Uzumcu et al., 2009) and generates splicing signals including the hnRNP
A1 and several enhancer and silencer motifs. Sequence having G allele appears to have a big potential in
respect of splicing regulation as many different splicing signals might be involved in regulation.
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UPS functionality in general and network of different genes and proteins including those involved in ethnic
speciﬁc adaptation to environment.
As it was expected, Taiwanese were signiﬁcantly different from both the LV and LT population in the
rs2277460, rs1048990 and the rs2348071 genetic diversity. However, at the rs2295826 and rs2295827,
TW was different only from LV and exhibited similarity with LT. LT and LV populations showed different
genetic diversity at the rs1048990, the PSMC6 SNPs, the PSMA6 rs2277460-rs10489990 haplotype and the
5-locus haplotype.
Finding of differentiation between the LT and LV populations appears not to be too unexpected. Living
geographically close to each other and in big extent share a common paternal Y chromosome andmaternal
mitochondrial gene pools (Kasperaviciute et al., 2004; Laitinen et al., 2002; Lessig et al., 2001; Pliss et al.,
2006), LV and LT population were shown to be different in particular markers' frequency and haplogroups'
diversity. Examples include the Y chromosome M9 rare allele C and haplogroup HG2 being twice less
frequent in LV and haplogroup HG1 observed twice more frequent in LV than in LT (Laitinen et al., 2002).
Analysis of 270,000 SNPs genotyped in samples of DNA collected all over Europe revealed that the genetic
structure of the European population correlates closely with geography and markers are grouped in a less
compact way in Latvian population compared to Lithuanian population where more similarities with
Central Europe were revealed (Nelis et al., 2009). Allele and genotype presentation of the rs1048990 was
found also to bemore similar in LT with that observed in Central Europe.We did not perform ethno genetic
study; ethnic origin of subjects was not recorded during sample collection. However evidently LV popu-
lation in our case represents very mixed inhabitants of Riga, forming some “average” genotype for
North-East Europe. On the contrary inhabitants of Kaunas are mostly Lithuanians, population is ethnically
homogenous. Admixture of non-Baltic ethnic groups in Riga is reﬂected as similarity to the European
population in general, ethnic peculiarities were revealed for Lithuania.
Similarities between LT population and Asians seem even more striking at the ﬁrst glance. It is con-
sidered that Ural mountains and Caspian sea form a border between Asian and European populations
(Kutuev et al., 2006), however numerous migrations across this border could result in genetic material
transfer, as it was shown for some Y chromosome haplogroups (Rootsi et al., 2007). Moreover similar
distribution of the D7S23 locus allelic frequencies was found among LT population, Bashkirs inhabiting
Volga region, Komi living on the North-East border of Europe, and Buryat population from East Siberia
(Khusnutdinova et al., 1994). Invasions of Asian peoples to Baltics happened several times in history, some
distinct groups of Turkic-speaking peoples still live in Lithuania. Thus, geographically close Baltic
populationsmight have differentmicroevolution of human genome acting on different traits andmetabolic
pathways including ubiquitin proteasome system.
In conclusion, we suggest that ethnic- and/or geographically-speciﬁc patterns of structural variations
in proteasomal genes may reﬂect processes of local historical and/or geographical ethnos adaptation and
reserve inﬂuence for human health and population morbidity in modern environment.
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1875-9572/Copyright ª 2014, TaiwanBackground: The ubiquitin proteasome system plays an exceptional biological role in the
antigen processing and immune response and it could potentially be involved in pathogenesis
of many immunity-related diseases, including juvenile idiopathic arthritis (JIA).
Methods: The PSMB5 (rs11543947), PSMA6 (rs2277460, rs1048990), PSMC6 (rs2295826,
rs2295827), and PSMA3 (rs2348071) proteasomal genes were genotyped on JIA subtype- and
sex-specific association; plasma proteasome levels was measured in patients having risk and
protective four-locus genotypes and eventual functional significance of allele substitutions
was evaluated in silico.
Results: Loci rs11543947 and rs1048990 were identified as disease neutral and other loci as
disease susceptible (p < 0.05). The rs2277460, rs2295826, and rs2295827 loci had the strongest
association with oligoarthritis [odds ratio (OR) Z 2.024, 95% confidence interval (CI) 1.101
e3.722; OR Z 2.371, 95% CI 1.390e4.044; OR Z 2.183, 95% CI 1.272e2.737, respectively),
but the rs2348071 locus was associated with polyarthritis in females (OR Z 3.438, 95% CI
1.626e7.265). A strong (p < 0.001) association was detected between the rs2277460/
rs2295826/rs2295827/rs2348071 four-locus genotypes and the healthy phenotype when all loci
were homozygous on common alleles (OR 0.439, 95% CI 0.283e0.681) and with the disease
phenotype when the rs2348071 and the rs2295826 and/or rs2295827 loci were represented
by risk genotypes simultaneously (OR 4.674, 95% CI 2.096e10.425). Rarely observed in controls,
the double rs2277460/rs2348071 heterozygotes were rather frequent in affected males andd Bioinformatics, Institute of Biology of the University of Latvia, Miera Str. 3, LV2169 Salaspils, Latvia.
du.lv (T. Sjakste).
014.01.007
Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
394 T. Sjakste et almore strongly associated with polyarthritis (p < 0.05). Haplotypes carrying the rare rs2295826/
rs2295827 and rs2277460 alleles showed a strong (p < 0.001) association with oligo- and poly-
arthritis, respectively. The plasma proteasome level was found to be significantly higher in fe-
males having four-locus risk genotypes compared with protective genotypes (p < 0.001).
Sequence affinity to transcription factors and similarity to splicing signals, microRNAs and/
or hairpin precursors potentially depend on allele substitutions in disease susceptible loci.
Conclusion: We demonstrate for the first time evidence of a sex-specific association of PSMA6/
PSMC6/PSMA3 genetic variants with subtypes of JIA and plasma proteasome concentrations.
Theoretical models of the functional significance of allele substitutions are discussed.
Copyright ª 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Juvenile idiopathic arthritis (JIA) is the most common
clinically heterogeneous chronic rheumatic disease in chil-
dren.1 Onset-specific clinical features allow discrimination
of seven JIA subtypes,2 with oligoarthritis (JIoA) and poly-
arthritis (JIpA) being the most frequent.1 The cause of JIA is
complex, involving both environmental and genetic risk
factors. The latter could include structural variations in
both human leukocyte antigens and non-human leukocyte
antigen candidate genes.3,4,5 Because of the pleiotropic
effect, a frequent phenomenon in complex human traits
and diseases,5 some loci of susceptibility may be shared
with other autoimmune diseases.4,5
An exceptional biological role for the ubiquitin protea-
some system (UPS) in antigen processing and immune
response, as suggested by Kloetzel,6 has been increasingly
supported this last decade experimentally. A special form
of proteasomes, thymoproteasomes, expressed exclusively
in the cortex of the thymus and probably involved in posi-
tive selection of T cells, has recently been described. This
indicates that the role of proteasomes in the immune
response might be even more important.7,8 In patients with
systemic autoimmune disease, the concentration of circu-
lating proteasomes has been shown to be strongly
increased8,9; the core 20S proteasome was identified as a
target of the humeral autoreactive immune response.10e15
The proteasomal inhibitor MG132 has been reported to
reduce the severity of arthritis and reverse pain behavior in
arthritic rat models.16
Highly conserved from an evolutionary standpoint, pro-
teasomal genes appear to be subject to multiple trait
purifying selection. Structural variations in proteasomal
genes could potentially affect UPS efficiency through
modulation of expression of a particular gene, realization
of gene and protein networks and metabolic processes that
may in the end influence predisposition to and/or devel-
opment of autoimmune disorders.
The distribution of proteasomal genes over the human
genome displays a tendency of clustering in chromosomes.
Nine of the proteasomal genes have been localized in the
long arm of chromosome 14, including two b (PSMB5 and
PSMB11) and two a (PSMA3 and PSMA6) subunits of the core
20S proteasome, ATPases (PSMC1 and PSMC6), 11S non-
ATPase activators (PSME1 and PSME2) and the PSMA3Ppseudogene. The 14q11, 14q13, and 14q22-32 regions car-
rying the mentioned genes have been reported previously
as potentially susceptible to autoimmune,17e24 and other
complex diseases in European and/or Asian pop-
ulations.Suppl 1e15 Fine 14q13.2 microsatellite scanning
revealed evidence of JIA association with variability in the
region encompassing the PSMA6 gene.24
The aim of the current study was to genotype six single
nucleotide polymorphisms (SNPs) belonging to the PSMA6
(rs2277460 and rs1048990), PSMA3 (rs2348071), PSMB5
(rs11543947) and PSMC6 (rs2295826 and rs2295827) pro-
teasomal genes for subtype- and sex-specific association
with JIA; to evaluate plasma proteasome levels in JIA pa-
tients of different multi locus genotypes, and to perform an
in silico prediction of eventual functional consequences of
nucleotide substitutions, including sequence affinity to
transcription factors (TFs) and similarity to splicing signals
and microRNAs.
2. Materials and methods
2.1. Caseecontrol study
Patients were 174 JIA children (108 girls) receiving consul-
tation at the outpatient clinic of P. Stradins Clinical Uni-
versity Hospital and Children Clinical University Hospital
Clinic Gailezers in Riga, Latvia. JIA was diagnosed and
assignment of the JIA patients to subgroups was carried out
according to the criteria of the International League of
Association for Rheumatology.2 For association analysis
both persistent and extended JIoA, and rheumatoid factor-
negative and rheumatoid factor-positive JIpA subgroups
were combined in JIoA and JIpA groups of 107 and 55 pa-
tients, respectively. Twelve other patients were diagnosed
as having systemic (nZ 9), enthesitis-related (nZ 2), and
psoriatic (n Z 1) arthritis.
The control group was represented by 191 (117 women)
patents of Riga Bikernieki Hospital admitted with a diag-
nosis of trauma and not diagnosed as having any autoim-
mune and/or cardiovascular disorders, type 2 diabetes
mellitus (T2DM), or obesity.
Informed consent was obtained from all the study par-
ticipants or their parents. The study was approved by the
Central Medical Ethics Committee of the Republic of Latvia
Ministry of Health.
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Due to limited data on the genetic diversity and suscepti-
bility to diseases of proteasomal genes, several criteria were
taken into account in choosing markers. These included the
existence of previously reported findings on locus associa-
tion with human health status, locus allele-specific potential
to be functionally significant, locus variability in Latvians,
HardyeWeinberg expectations and others concerning mainly
a genotyping technology. The rs2277460 and rs1048990 of
the PSMA6, rs2295826 and rs2295827 of the PSMC6 and
rs23480071 of the PSMA3 were previously studied on disease
susceptibilitySuppl 1e12,14e16 and/or genetic diversitySuppl 17;
rs11543947 of the PSMB5 gene was previously genotyped on
genetic diversity only in HapMap populations. All loci fit all
other mentioned criteria of marker choice.
2.3. DNA extraction and genotyping
DNA was extracted using a kit for genomic DNA extraction
from nucleated blood cells (Fermentas, Vilnius, Lithuania).
Genotyping methods and primer sequences are indicated in
Supplementary Table 1. Basic PCR was performed with
DreamTaq polymerase (Fermentas) using the following pa-
rameters: 94C for 5 minutes; then 35e40 cycles of 94C for
45 seconds, appropriate annealing temperature (55e61C)
for 45 seconds, 72C for 45 seconds and a final extension
step at 72C for 7 minutes. DNA digestion by restriction
enzymes was performed according to the manufacturer’s
protocols (Fermentas).
Amplified and digested products were analyzed by
electrophoresis in 1e3% agarose gel for all markers. For
quality control, 16 randomly chosen samples for each
marker were genotyped in duplicate in different experi-
ments. The concordance of the genotyping was 100%.
Genotyping data were verified by direct sequencing of the
corresponding DNA fragments in both directions using the
Applied Biosystems 3130xl Genetic Analyzer. Alleles and
genotype frequencies for the rs11543947 (ss69150930),
rs2277460 (ss24557113), rs1048990 (ss35076445), rs2295826
(ss3239727 and ss69157456), rs2295827 (ss23619651) and
rs2348071 (ss3302481) were obtained for HapMap-CEU
(NorthWestern European), YRI (Yoruba), JPT (Japanese),
and HCB (Han Chinese) populations from publicly available
dbSNP (build 13) entries at NCBI (http://www.ncbi.nlm.nih.
gov/snp/). Loci description and nucleotide numbering are
given according to the recommended nomenclature system
(http://www.genomic.unimelb.edu.au/mdi/mutnomen/
recs.html). Sequence information for the chromosome 14
GRCh37.p5 assembly (NCBI reference sequence:
NC_000014.8) was used for loci description, nucleotide
numbering, and primer design using the Primer 3.0
program.
2.4. Measurement of plasma proteasome
concentration
Plasma samples were available only for 23 JIA patients.
These plasma samples were obtained from patients
randomly chosen for plasma sampling during development of
the DNA collection in the JIA study. Therefore, preliminaryinformation on genotypes of these patients did not exist at
the moment of the sampling. Blood was harvested on citrate
anticoagulant, and plasma stored at e80C. Plasma protea-
some concentration was measured in triplicate for each
sample using a standard 20S/26S Proteasome ELISA kit (BML-
PW0575; ENZO Life Sciences, Farmingdale, NY, USA) accord-
ing to the manufacturer’s protocols. Absorbance was read at
450 nm using a UV-Vis spectrometric plate reader. Results
were expressed as concentration of proteasome protein in
ng/mL determined by interpolation for the absorbance value
using the generated 20S proteasome standard curve.2.5. Data analysis
Documenting personalized genotyping data allowed deter-
mination of rs11543947/rs2277460/rs1048990/rs2295826/
rs2295827/rs2348071 six-locus genotype (6-LG) of each in-
dividual participant of the study. The 6-LGs, rs2277460/
rs2295826/rs2295827/rs2348071 four-locus genotypes (4-
LGs), observed haplotypes, single locus genotypes (SLGs),
and allele frequencies were estimated by direct counting of
genetic variants. Inferred haplotypes prediction, haplotype
sorting, estimation of the linkage disequilibrium and prob-
ability of recombination were performed using the DnaSP
software version 5.10.1 online tool at http://www.ub.es/
dnasp.Suppl 18 Both the two-tailed Fisher’s exact test and
the c2 test were applied to evaluate the linkage between
the rs2295826 and rs2295827 polymorphic sites at three
p-value levels (p < 0.05; p < 0.01; p < 0.001). The Bon-
ferroni correction included in the DnaSP analysis was taken
into account to support the significance of the revealed
disequilibrium (a0 Z 0.05).
Deviation from the HardyeWeinberg equilibrium and
differences between cases and controls in allele, genotype
and haplotype frequencies were evaluated by c2 and
CochraneArmitage trend test using XLSTAT 2013 software
for Windows. Genetic models for every individual locus were
designed according to Lewis.Suppl 19 Contingency tables were
2  3 for the AA, AB, BB genotypes in the general model;
2  2 for the AA, ABþBB and AAþAB, BB, and AB, AAþBB
genotypes in the dominant, recessive, and over dominant
models, respectively and A and B alleles in the multiplica-
tive model where A is the major allele and B is the minor
allele. Using an additivemodel, the AA, AB, and BB genotype
distribution was analysed using the CochraneArmitage test
for trend. An odds ratio (OR)> 2 and<0.5 was considered to
be clinically significant. Stratification was performed by JIoA
and JIpA ILAR subtypes and by sex.
Levels of plasma proteasome were expressed as
mean  standard error of the mean for each sample to show
the variability associated with the estimation, and as
mean  standard deviation to characterize the spread of a
data set within the groups. Both standard error of the mean
and standard deviation were calculated using the online
NCalculators (http://ncalculators.com/). Differences in
plasma proteasome levels between the groups were esti-
mated by nonparametric ManneWhitney and/or Krus-
kaleWallis tests using XLSTAT 2013 software. Results were
considered to be of nominal statistical significance at
p < 0.05, moderate statistical significance at p < 0.002,
and strong statistical significance at p < 0.001.Suppl 20
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An eventual functional significance of the SNPs showing
evidence of association was analyzed in silico on sequence
similarity to transcription factors binding sites (TFBSs) using
Genomatix software, MatInspector, Release 7.4 online tool,
at www.genomatix.de.Suppl 21 Only parameters with core/
matrix similarity of > 1.000/0.800 were taken into account.
Splicing signals were predicted by Human Splicing Finder
Version 2.4 (http://www.umd.be/HSF)Suppl 22 with standard
threshold values for branch point, donor and acceptor
splice sites, enhancer, silencer, heterogeneous nuclear
ribonucleoprotein (hnRNP) and other splicing motifs.
Sequence similarity to mature microRNAs and hairpin pre-
cursors was evaluated, and microRNA targets prediction
was done using miRBase (http://www.mirbase.org/index.
shtml)Suppl 23 and miRNAMap (http://mirnamap.mbc.nctu.
edu.tw/index.php)Suppl 24 online tools, respectively.
3. Results
3.1. Genotyping results and single locus association
In both case and control cohorts, the genotyping call rate
was 100% and all six markers were found to be in Har-
dyeWeinberg equilibrium. Allele and genotype spectrumTable 1 Data on the significant associations between single loc
Groups of comparison Marker ID Genetic model Risk factor
(allele or
genotype)
Group 1 Group 2
JIA (174) C (191) rs2277460 Multiplicative a: A
Dominant g: CA
rs2295826 Multiplicative a: G
Dominant g: AG þ GG
rs2295827 Multiplicative a: T
Dominant g. CT þ TT
rs2348071 Overdominant g: AG
JIA-F (108) C-F (117) rs2295826 Multiplicative a: G
Dominant g: AG þ GG
rs2295827 Multiplicative a: T
Dominant g. CT þ TT
rs2348071 Overdominant g: AG
JIoA (107) C (191) rs2277460 Multiplicative a: A
Dominant g: CA
rs2295826 Multiplicative a: G
Dominant g: AG þ GG
rs2295827 Multiplicative a: T
Dominant g. CT þ TT
rs2348071 Overdominant g: AG
JIoA-F (63) C-F (117) rs2295826 Multiplicative a: G
Dominant g: AG þ GG
rs2295827 Multiplicative a: T
Dominant g. CT þ TT
JIpA (55) C (191) rs2348071 Overdominant g: AG
JIpA-F (39) C-F (117) rs2348071 Overdominant g: AG
p < 0.002 and odds ratio > 2 are indicated in bold.
JIA Z juvenile idiopathic arthritis; JIoA Z juvenile idiopathic oligo
F Z female; a Z risk allele; g Z risk genotype.and distributions in Latvians were found to be similar to
those of other Europeans (CEU) for all SNPs studied and to
the Yoruba population (YRI) for the rs2348071; however,
Latvians differ from YRI for resting loci and for all loci from
Japanese (JPT) and Han Chinese (HCB) populations
(Supplementary Table 2).
The rs11543947 and rs1048990 markers showed similar
levels of variation in controls and JIA patients without sig-
nificant differences between the JIoA and JIpA subtypes
and females and males. These markers were considered to
be JIA neutral, while other markers were found to be JIA
susceptible (Table 1).
The rs2277460 showed nominal association (P < 0.05)
with JIA, with highest risk effect for JIoA [ORZ 2.024, 95%
confidence interval (CI) 1.101e3.722]. Alleles and geno-
types frequencies of the rs2295826 and rs2295827 were the
same between each other in the controls and slightly
different in JIoA females with an r2Z 0.936 and D0 of 1.000
[this result is similar to data obtained for Tuscans in Italy
(HapMap TSI): r2Z 0.923], suggesting the existence of rare
GC haplotype in JIA patients. Both markers were found to
be in moderate (p < 0.002) association with JIoA
(OR Z 2.371, 95% CI 1.390e4.044; and OR Z 2.183, 95% CI
1.272e2.737 for the rs2295826 and rs2295827 risk geno-
types, respectively). Moderate association was also detec-
ted for the rs2348071 heterozygous genotype (p < 0.002)
with risk effect for JIpA in the combined cohortus variations and JIA.
Risk factor number (%) p OR CI
Group 1 Group 2
40 (11.49) 25 (6.54) <0.05 1.855 1.104e3.114
40 (22.99) 25 (13.09) <0.05 1.982 1.149e3.419
64 (18.39) 40 (10.47) <0.05 1.927 1.262e2.942
55 (31.61) 36 (18.85) <0.05 1.990 1.230e3.210
61 (17.53) 40 (10.47) <0.05 1.817 1.186e2.784
53 (30.46) 36 (18.85) <0.05 1.886 1.163e3.057
87 (50.00) 66 (34.55) <0.05 1.894 1.245e2.882
46 (21.30) 30 (12.82) <0.05 1.840 1.116e3.033
40 (37.04) 27 (23.07) <0.05 1.932 1.086e3.432
43 (19.91) 30 (12.82) <0.05 1.690 1.020e2.801
38 (35.18) 27 (23.07) <0.05 1.810 1.013e3.232
57 (52.78) 40 (34.19) <0.05 2.151 1.261e3.672
25 (11.68) 25 (6.54) <0.05 1.889 1.061e3.362
25 (23.36) 25 (13.09) <0.05 2.024 1.101e3.722
45 (21.03) 40 (10.47) <0.001 2.277 1.435e3.612
38 (35.51) 36 (18.84) <0.002 2.371 1.390e4.044
42 (19.63) 40 (10.47) <0.002 2.088 1.308e3.333
36 (33.64) 36 (18.84) <0.002 2.183 1.272e2.737
50 (46.73) 66 (34.56) <0.05 1.661 1.027e2.687
31 (24.60) 30 (12.82) <0.05 2.219 1.275e3.861
26 (41.27) 27 (23.07) <0.05 2.342 1.216e4.511
28 (22.22) 30 (12.82) <0.05 1.943 1.105e3.416
24 (38.09) 27 (23.07) <0.05 1.943 1.105e3.416
32 (58.18) 66 (34.56) <0.002 2.635 1.434e4.841
25 (64.10) 40 (34.19) <0.002 3.438 1.626e7.265
arthritis; JIpA Z juvenile idiopathic polyarthritis; C Z control;
Table 2 Four-loci genotypes (4-LGs) presentation and results of significant associations with juvenile idiopathic arthritis (JIA).
4-LG configurations 4-LGs number (%) in the groups and association results
No. Genotype of individual locus Controls JIA JIoA JIpA
PSMA6 PSMC6 PSMA3 All
n Z 191
F
n Z 117
M
n Z 74
All
n Z 174
F
n Z 108
M
n Z 66
All
n Z 107
F
n Z 63
M
n Z 44
All
n Z 55
F
n Z 39
M
n Z 16L1 L2 L3 L4
1P;Ref CC AA CC GG or
AA
86
(45.03)
52
(44.44)
34
(45.95)
46
(26.44)
24
(22.22)
22
(33.33)
32
(29.91)
17
(26.98)
15
(34.09)
11
(20.00)
6
(15.38)
5
(31.25)
Association in
the groups:
p OR 95% CI
JIA vs. C <0.001 0.439 0.283e0.681
JIA-F vs. C-F <0.001 0.357 0.200e0.637
JIoA vs. C <0.05 0.521 0.316e0.859
JIoA-F vs. C-F <0.05 0.462 0.239e0.859
JIpA vs. C <0.001 0.305 0.150e0.620
JIpA-F vs. C-F <0.002 0.227 0.091e0.568
2N CC AA CC GA 48
(25.13)
28
(23.93)
20
(27.03)
44
(25.29)
30
(27.78)
14
(21.21)
20
(18.69)
12
(19.05)
8
(18.18)
19
(34.55)
15
(38.46)
4
(25.00)
3N CC AG
GG
CT
TT
GG or
AA
22
(11.52)
18
(15.39)
4
(5.41)
19
(10.92)
14
(12.96)
5
(7.58)
11
(10.28)
7
(11.11)
4
(9.09)
7
(12.73)
6
(15.38)
1
(6.25)
4N CA AA CC GG or AA 16
(8.38)
7
(5.98)
9
(12.16)
16
(9.20)
9
(8.33)
7
(10.61)
9
(8.41)
6
(9.52)
3
(6.82)
4
(7.27)
2
(5.13)
2
(12.50)
5R CC AG
GG
GG
CT
TT
CC
GA 10
(5.24)
7
(5.98)
3
(4.05)
25
(14.37)
19
(17.59)
6
(9.09)
19
(17.76)
14
(22.22)
5
(11.36)
6
(10.91)
5
(12.82)
1
(6.25)
Association in
the groups:
p OR CI
JIA vs. C <0.001 4.674 2.096e10.425
JIA-F vs. C-F <0.001 5.881 2.231e15.500
JIoA vs. C <0.001 5.106 2.179e11.968
JIoA-F vs. C-F <0.001 6.118 2.175e17.210
JIpA vs. C <0.05 4.691 1.477e14.897
JIpA-F vs. C-F <0.05 6.190 1.574e24.343
6R CA AA CC AG 5
(2.62)
3
(2.57)
2
(2.70)
13
(7.47)
5
(4.63)
8
(12.12)
8
(7.48)
2
(3.17)
6
(13.64)
5
(9.09)
3
(7.69)
2
(12.50)
Association in
the groups:
p OR CI
JIA vs. C <0.05 4.861 1.625e13.940
JIA-M vs. C-M <0.05 6.182 1.370e27.895
(continued on next page)
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398 T. Sjakste et al(OR Z 2.635, 95% CI 1.434e4.841) and JIpA females
(OR Z 3.438, 95% CI 1.626e7.265).
In both the control and case groups, risk genotypes were
more frequent in males for the rs2277460 locus and in fe-
males for the rs2295826 and rs2295827 loci; the rs2348071
heterozygous risk genotype was more frequent in females
than in males in JIpA patients (Supplementary Table 2).
3.2. Identification of the risk/protective 4-LGs
Personalized genotyping data documentation allowed
analysis of the spectrum and frequencies in the groups of
the 4-LGs rs2277460/rs2295826/rs2295827/rs2348071
(Table 2) composed from loci individually susceptible to
disease (Table 1). Nineteen 4-LGs observed in both case and
control groups were classified by eight categories according
to presence/absence of the risk SLG listed in Table 1.
The 4-LG1, having a no risk SLG, was the most frequent
in controls (45%) with similar presentation in males and
females, but it was significantly less frequent in JIA pa-
tients of both JIoA and JIpA subtypes (about 29% and 20%
respectively) and appears to be JIA protective with a strong
level of association (p < 0.001) with healthy phenotype in
common cohort and females. The 4-LG5 unites three con-
figurations, all having the rs2348071 risk genotype in com-
bination with risk genotype at the rs2295826 and/or
rs2295827 loci. The 4-LG5 was approximately three times
more frequent in JIA than in controls and two times more
frequent in females than in males of all JIA subtypes. This
genotype showed a strong association (p < 0.001) with JIA
in common and JIoA cohorts and the female phenotype.
Rarely observed in controls and JIA females (< 5%), the
rs2277460/rs2348071 double heterozygotes (4-LG6) were
rather frequent in JIA males (> 12%) and showed an asso-
ciation (p < 0.002) with JIpA in common cohort and with
JIoA in males.
The 4-LG2, 4-LG3, and 4-LG4 genotypes were observed
with similar frequencies in cases and controls and were
considered JIA neutral. The two remaining (4-LG7 and 4-
LG8) genotypes were rare in controls and only slightly more
frequent in JIA patients.
3.3. Four loci haplotype analysis
Table 3 provides information on the four-loci haplotype (4-
LH) spectrum and frequencies in the groups. Using the
assumption of random assortment of alleles, 24 haplotype
configurations were expected for four two-allele loci;
however, only 10 variants were identified in cases and con-
trols taken together, and all of them are implicated from the
4-LGs homozygous at all four loci and/or genotypes being
heterozygous only at one locus. The 4-LH1e4-LH6 haplo-
types were observed in both controls and case groups; the 4-
LH7e4-LH10 were identified only in JIoA females. The 4-LH1
(C-C-A-G) having the common alleles at all four loci was
found to be the most frequent in all groups and used as
reference haplotype in association analysis. The 4-LH4 (C-G-
T-A) having the risk alleles at the rs2295826 and rs2295827
and the rs2348071 minor allele A was found to be in strong
association (p< 0.001) with JIA including both JIoA and JIpA
subtypes in female and male cohorts. The 4-LH5 (A-C-A-G)
Table 3 Four-loci haplotypes (4-LHs) presentation and data on significant associations with juvenile idiopathic arthritis (JIA).
Group C
n Z 191
C-F
n Z 117
C-M
n Z 74
JIA
n Z 174
JIA-F
n Z 108
JIA-M
n Z 66
JIoA
n Z 107
JIoA-F
n Z 63
JIoA-M
n Z 44
JIpA
n Z 55
JIpA-F
n Z 39
JIpA-M
n Z 16
4-LG Number (%)
Full homozygote 89
(46.60)
54
(46.15)
35
(47.30)
49
(28.16)
25
(23.15)
24
(36.36)
34
(31.78)
17
(26.98)
17
(38.64)
12
(21.82)
7
(17.95)
5
(31.25)
Single locus heterozygote 65
(34.03)
36
(30.77)
29
(39.19)
66
(37.93)
44
(40.74)
22
(33.33)
34
(31.78)
23
(36.51)
11
(25.00)
24
(43.64)
17
(43.59)
7
(43.75)
Multiple loci heterozygote 37
(19.37)
27
(23.08)
10
(13.51)
59
(33.91)
39
(36.11)
20
(30.30)
39
(36.45)
23
(36.51)
16
(36.36)
19
(34.55)
15
(38.46)
4
(25.00)
Haplotype Loci Number (%)
1e2e3e4 382 234 148 348 216 132 214 126 88 110 78 32
4-LH-1Ref C-A-C-G 231
(60.47)
147
(62.82)
84
(56.76)
178
(51.15)
109
(50.46)
69
(52.27)
117
(54.67)
68
(53.97)
49
(55.68)
53
(48.18)
38
(48.72)
15
(46.88)
4-LH-2 C-A-C-A 86
(22.51)
45
(19.23)
41
(27.70)
72
(20.69)
45
(20.83)
27
(20.45)
32
(14.95)
19
(15.08)
13
(14.77)
27
(24.55)
19
(24.36)
8
(25.00)
4-LH-3 C-G-T-G 29
(7.59)
19
(8.12)
10
(6.76)
19
(5.46)
13
(6.02)
6
(4.55)
12
(5.61)
9
(7.14)
3
(3.41)
7
(6.36)
4
(5.13)
3
(9.38)
4-LH-4R C-G-T-A 11
(2.88)
11
(4.70)
d 37
(10.63)
25
(11.57)
12
(9.09)
25
(11.68)
14
(11.11)
11
(12.50)
11
(10.00)
10
(12.82)
1
(3.13)
Association in
the groups
P OR CI
JIA vs. C <0.001 4.365 2.192e8.693
JIoA vs. C <0.001 4.487 2.161e9.318
JIpA vs. C <0.05 4.358 1.826e10.401
4-LH-5 A-A-C-A 15
(3.93)
8
(3.42)
7
(4.73)
12
(3.45)
5
(2.31)
7
(5.30)
11
(5.14)
4
(3.17)
7
(7.95)
d d d
4-LH-6R A-A-C-G 10
(2.62)
4
(1.71)
6
(4.05)
22
(6.32)
11
(5.09)
11
(8.33)
9
(4.21)
4
(3.17)
5
(5.68)
12
(10.91)
7
(8.97)
5
(15.63)
Association in
the groups
P OR CI
JIA vs. C <0.05 2.855 1.338e6.093
JIpA vs. C <0.001 5.230 2.185e12.517
4-LH-7 A-G-T-G d d d 3 3 d 3 3 d d d d
4-LH-8 A-G-T-A d d d 2 2 d 2 2 d d d d
4-LH-9 C-G-C-G d d d 1 1 d 1 1 d d d d
4-LH-10 C-G-C-A d d d 2 2 d 2 2 d d d d
Superscripts “Ref” and “R” indicate the reference and risk haplotypes respectively. Single nucleotide polymorphism loci in the 1e2e3e4 haplotypes are given in the
rs2277460ers2295826ers2295827ers2348071 sequence. Risk alleles are indicated in bold and underlined. Probability of association < 0.002 is indicated in bold. Frequencies of the 4-LH7,
4-LH8, 4-LH9 and 4-LH10 haplotypes rare/absent in all groups (<3%) are not indicated in the table. In statistical analysis the 4-LH1 haplotype was considered as reference.
4-LG Z four-loci genotype; JIA Z juvenile idiopathic arthritis; JIoA Z juvenile idiopathic oligoarthritis; JIpA Z juvenile idiopathic polyarthritis; C Z control; F Z female; M Z male.
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Figure 1 Plasma proteasome level in juvenile idiopathic
oligoarthritis patients. Carriers of different four-locus geno-
types (4-LGs), 4-LG1, 4-LG2, 4-LG3, 4-LG4, and 4-LG5, were
represented by four, six, three, three, and seven patients
respectively. * p < 0.05, ** p < 0.001, # p > 0.05.
400 T. Sjakste et alhaving the only risk allele at the rs2277460 locus showed
strong (p < 0.001) association with JIpA.
3.4. Genotype dependent plasma proteasome
levels in JIoA patients
Plasma samples were available for 23 JIoA females, carriers
of five different 4-LGs (Figure 1). Females of 4-LG1
exhibited a plasma proteasome concentration of approxi-
mately 2000 ng/mL, which is similar to previously reported
plasma proteasome levels for healthy donors.25e27 Careers
of the 4-LG2 and 4-LG5 genotypes exhibited significantly
(p < 0.05 and p < 0.001) higher plasma proteasome levels.Figure 2 Consequences of the nucleotide substitutions on functi
arthritis associated single nucleotide polymorphisms of the PSMA6,
transcription factors. Upward and downward arrows indicate splic
SSA Z splicing site acceptor. Details are given in Supplementary THigh plasma proteasome levels were also detected in fe-
males of 4-LG3; however, the small number of patients in
this group did not allow the results to reach statistical
significance.
3.5. Eventual functional significance of the SNPs
allelic variants
Figure 2 summarizes results of the in silico analysis of the
functional significance of allele substitutions (only loci
detected as JIA susceptible were taken into account)
evaluated on the eventual sequence affinity to TFs and
splicing signals similarity, and on the homology to known
microRNAs and their precursors.
The major allele of only the rs2295826 locus potentially
assists in sequence affinity to TFs. These are proteins of the
CREB, MYT1 and PARF families. The rs2295826 minor allele
appears to abolish any sequence affinity to TFs. Minor al-
leles at the rs2277460, rs2295827, and rs2348071 loci
potentially assist in the binding of proteins belonging to the
BARBIE box, CART, BRN5, LHXF, HOXF, HBOX, and MEF2
families.
Major alleles of both the rs2295826 and rs2295827 loci
potentially assist in the generation of additional branch
points; the rs2295826 major allele creates a splice site
acceptor and targets for the hnRNP A1; the hnRNP A1 target
motif is also generated in presence of both the rs2277460
and rs2348071 minor alleles. Major alleles of the rs2295826
and rs2348071 and minor alleles of all loci besides the
rs2295826 could potentially change the sequence similarity
to a number of splicing enhancers and/or silencers (Figure 2
and Suppl Table 3).
The rs2295827 major and rs2295826 minor allele in-
crease sequence similarity to hsa-miR-603 and hsa-miR-
5584-3p, respectively (Figure 2).onal potential of the genome site harboring juvenile idiopathic
PSMC6, and PSMA3 genes. Only family names are indicated for
ing enhancers and silencers, respectively. BP Z branch point;
able 3.
PSMA6/PSMC6/PSMA3 & juvenile idiopathic arthritis 4014. Discussion
The aim of the current study was to evaluate six SNPs
belonging to the PSMA6 (rs2277460 and rs1048990), PSMA3
(rs2348071), PSMB5 (rs11543947), and PSMC6 (rs2295826
and rs2295827) proteasomal genes for association with JIA
with adjustment by JIA subtype and sex.
From all SNPs analyzed, the rs1048990 (PSMA6 c.-8C>G)
located in the 50- untranslated region of the gene is the
most studied SNP of proteasomal genes, which has been
widely genotyped for association with cardiovascular
diseases,Suppl 1e12,14,15 T2DM,Suppl 3,14 and children obesi-
ty.Suppl 16 Summarizing the results obtained by different
teams, we suggested a potential of the rs1048990 to influ-
ence JIA susceptibility. However, we did not find any as-
sociation between the rs1048990 polymorphism and JIA in
Latvians. Similarly, locus did not show any association with
obesity in Latvian children.Suppl 16 In turn, the rs2277460 of
the promoter region of the same gene (PSMA6 c.-110C>A)
has been detected as JIA susceptible locus. This conclusion
is based on the results of the subtype- and sex-specific
disease association with rare allele A, heterozygous SLG,
4-LG6 heterozygous at the rs2277460, and 4-LH6 haplotype
both having the rs2277460 rare allele in its structure (Tables
1e3).
It had been reported that the rs2230087 polymorphism
of the PSMB5 gene (30-untranslated region) is associated
with T2DM.Suppl 9 In our study we were interested in the
rs11543947 of the same gene locating in exon 1 or intron 1
(PSMB5 c.70C>T or PSMB5 c.-112þ300C>T, respectively)
depending of transcript variant. This SNP did not show any
association with JIA in our study.
The rs2295826 and rs2295827 loci locate in close vicinity
to each other in intron 1 of the PSMC6 gene (PSMC6 c.86-
104A>G and PSMC6 c.86-46C>T respectively). Linkage be-
tween loci is not complete, and rare GC haplotypes were
observed in our study similar to data obtained for Tuscans in
Italy. Rare alleles of these loci and their risk SLGs showed
(dominant model) JIoA subtype-specific association by
themselves and as component of risk 4-LG5 genotype and
risk 4-LH4 haplotype.
The rs2348071 locus belongs to intron 7 of the PSMA3
gene (PSMA3 c.543þ138G>A or c.522þ138G>A depending
of transcript variant). Heterozygous genotype GA was found
to be associated mostly with JIpA. In 4-LG structures, the
rs2348071 heterozygotes were involved in both risk 4-LG5
and 4-LG6. Interestingly, the rs2348071 heterozygotes were
implicated previously as an obesity risk factor in Latvian
children with a family history of obesity.Suppl 16
It is important to note that strength of association with
the disease was much stronger for combination of several
risk SLGs than for any individual risk SLG. Therefore, we
have reported here for the first time evidence of an asso-
ciation between JIA and genetic variants in the PSMA6/
PSMC6/PSMA3 gene cluster represented by combinations of
at least two risk SLGs in a particular 4-LG, namely 4-LG5
(risk rs2295826/rs2295827/rs2348071) and 4-LG6 (risk
rs2277460/rs2348071). The 4-LG1 having no risk SLGs in its
composition showed strong association with healthy
phenotype (p < 0.001).
The JIA-associated SNPs discovered in our study poten-
tially could be themselves primarily susceptible to disease orlinked with other primary genetic variations linked to dis-
ease. It appears that both scenarios are possible. Concerning
chromosome 14, several loci potentially susceptible to
autoimmunediseases have been reported in different human
populations.17e24 The functional significance of the discov-
ered allele substitutions is to be clarified. We attempted to
shed more light on the problem using two approaches.
First, we evaluated plasma proteasome level in JIoA fe-
males of different 4-LGs and found significantly increased
levels of plasma proteasomes in JIoA female carriers of the 4-
LG5 risk genotype in comparison to carriers of protective 4-
LG1 (p < 0.001) genotype. Earlier, circulating proteasomes
were suggested as markers in autoimmune diseases.8 Con-
centration of circulating proteasomes was shown to be sub-
stantially elevated in patients with rheumatoid8 and
psoriatic9 arthritis. The 20S proteasome has been identified
as a target of the humoral autoreactive immune response in
patients with systemic inflammatory diseases including
autoimmune myositis,10 primary Sjo¨gren’s syndrome,11
dilated cardiomyopathy,12 systemic lupus erythemato-
sus,10,13,14 multiple sclerosis,15 and psoriatic arthritis.14 The
proteasomal inhibitor MG132 has been reported to reduce
the severity of arthritis and reverse the pain behavior in the
arthritic rat models.16 To our knowledge, plasma levels of
factors within the UPS have not been yet evaluated in JIA,
and here we report data on that for the first time.
Second, we have evaluated eventual functional signifi-
cance of allele substitutions on sequence affinity to TFs,
splicing signals similarity and on the homology to known
microRNAs and their precursors.
The major allele of the rs2295826 potentially assists to
sequence affinity for TFs of CREB, MYT1, and PARF families
known to be involved in regulation of multiple physiological
processes and control of the circadian clock.28e30 CREB-
related TFs are especially interesting with respect of JIA
pathogenesis, as they are known to be essential for osteo-
blast differentiation and function,28 and they have been
implicated in immune response.29 It is of interest that
expression of CREB, MYT1, and PARF proteins potentially
could share the same epigenetic mechanism of regulation
by hsa-miR-1264 originated from the X chromosome and
potentially be differently expressed and differently
involved in epigenetic network in females and males (data
not shown).
The presence of a minor allele at the rs2277460 locus
creates a binding site to the BARBIE box proteins reported to
be involved in signal transduction pathways during devel-
opment31 and modulation of innate immunity.32 Sequences
having minor alleles at the rs2295827 and rs2348071 sites
can potentially bind CART proteins responsible for bone and
cartilage development.33 Moreover, the rs2295827 and
rs2348071 minor alleles could assist in sequence affinity to
BRN5, LHXF, MEF2, and HBOX factors known to mediate
transcriptional control of neuronal differentiation34e37 and
HOXF family NANOG.01 factor generally involved in signal
transduction pathways during development.38
Similar to TFBSs, patterns of predicted splicing signals
are allele specific. The rs2295826 and rs2348071 loci create
a number of allele-specific targets for splicing enhancers
and silencers. Only minor allele of the rs2277460 and only
major allele of the rs2295827 is functional in this respect.
Nucleotide substitutions at the rs2277460, rs2295826, and
402 T. Sjakste et alrs2348071 define affinity of corresponding sequences to the
hnRNP A1 known as alternative splicing repressor39 and
factor facilitating processing of specific microRNAs.40 The
above mentioned allele-specific differences in spectra of
splicing signals could potentially significantly affect genes
splicing activity and affect UPS efficiency.
Therefore, all of the above types of associations
revealed and data on functional significance of allele sub-
stitutions are in good agreement between themselves and
provide evidence that: (1) variations at the rs2277460,
rs2295826, rs2295827, and rs2348071 loci could assist JIA
susceptibility; (2) combination of the rs2348071 and
rs2295826 and/or rs2295827 risk genotypes (4-LG5) repre-
sents the genetic module highly associated with both JIoA
and JIpA and JIA female phenotype and plasma proteasome
level in JIoA females; (3) combination of the rs2348071 and
rs2277460 risk genotypes (4-LG6) represents the genetic
module presumably associated with JIpA and male pheno-
type; (4) nucleotide substitutions affect the potential of
encompassing sequences to create splicing signals, TFBSs
and microRNAs; and (5) the PSMA6/PSMC6/PSMA3 genetic
variants and multiloci genetic modules could be suggested
as JIA subtype- and sex-specific risk factors.
In conclusion it should be mentioned that, despite the
rather small number (174/191 of cases/controls), this study
can be considered as representative for the small Latvian
population (< 2 million). Keeping in mind that JIA unites
several clinically different subtypes, and that this disease
tends to affect females more than males, we have applied
stratification by JIA-subtype and sex. Due to the small
subgroups, we sometimes could not reach significance.
However, when significance was achieved, we obtained
interesting results to be investigated with reference to
other populations.
Conflicts of interest
All contributing authors declare no conflicts of interest.
Acknowledgments
Support for this work was partly provided by the Latvian
National Research Program 2014 and European Social
Foundation Project No 2013/0043/1DP/1.1.1.2.0/13/APIA/
VIAA/002.
Appendix A. Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.pedneo.2014.01.007.
References
1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;
369:767e78.
2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN,
Goldenberg J, et al. International League of Associations for
Rheumatology classification of juvenile idiopathic arthritis:
second revision, Edmonton, 2001. J Rheumatol 2004;31:
390e2.3. Prahalad S, Glass DN. A comprehensive review of the genetics
of juvenile idiopathic arthritis. Pediatr Rheumatol Online J
2008;6:11.
4. Thompson SD, Barnes MG, Griffin TA, Grom AA, Glass DN.
Heterogeneity in juvenile idiopathic arthritis: impact of mo-
lecular profiling based on DNA polymorphism and gene
expression patterns. Arthritis Rheum 2010;62:2611e5.
5. Sivakumaran S, Agakov F, Theodoratou E, Prendergast JG,
Zgaga L, Manolio T, et al. Abundant pleiotropy in human
complex diseases and traits. Am J Hum Genet 2011;89:607e18.
6. Kloetzel PM. Antigen processing by the proteasome. Nat Rev
Mol Cell Biol 2001;2:179e87.
7. Sutoh Y, Kondo M, Ohta Y, Ota T, Tomaru U, Flajnik MF, et al.
Comparative genomic analysis of the proteasome b5t subunit
gene: implications for the origin and evolution of thymopro-
teasomes. Immunogenetics 2012;64:49e58.
8. Egerer K, Kuckelkorn U, Rudolph PE, Ru¨ckert JC, Do¨rner T,
Burmester GR, et al. Circulating proteasomes are markers of
cell damage and immunologic activity in autoimmune diseases.
J Rheumatol 2002;29:2045e52.
9. Henry L, Le Gallic L, Garcin G, Coux O, Jumez N, Roger P, et al.
Proteolytic activity and expression of the 20S proteasome are
increased in psoriasis lesional skin. Br J Dermatol 2011;165:
311e20.
10. Feist E, Do¨rner T, Kuckelkorn U, Schmidtke G, Micheel B,
Hiepe F, et al. Proteasome alpha-type subunit C9 is a primary
target of autoantibodies in sera of patients with myositis and
systemic lupus erythematosus. J Exp Med 1996;184:1313e8.
11. Feist E, Kuckelkorn U, Do¨rner T, Do¨nitz H, Scheffler S, Hiepe F,
et al. Autoantibodies in primary Sjo¨gren’s syndrome are
directed against proteasomal subunits of the alpha and beta
type. Arthritis Rheum 1999;42:697e702.
12. Voigt A, Bartel K, Egerer K, Trimpert C, Feist E, Gericke C,
et al. Humoral anti-proteasomal autoimmunity in dilated car-
diomyopathy. Basic Res Cardiol 2010;105:9e18.
13. Arribas J, Luz Rodrı´guez M, Alvarez-Do Forno R, Castan˜o JG.
Autoantibodies against themulticatalytic proteinase in patients
with systemic lupus erythematosus. J ExpMed 1991;173:423e7.
14. Colmegna I, Sainz Jr B, Citera G, Maldonado-Cocco JA,
Garry RF, Espinoza LR. Anti-20S proteasome antibodies in
psoriatic arthritis. J Rheumatol 2008;35:674e6.
15. Fissolo N, Kraus M, Reich M, Ayturan M, Overkleeft H,
Driessen C, et al. Dual inhibition of proteasomal and lysosomal
proteolysis ameliorates autoimmune central nervous system
inflammation. Eur J Immunol 2008;38:2401e11.
16. Ahmed AS, Li J, Ahmed M, Hua L, Yakovleva T, Ossipov MH,
et al. Attenuation of pain and inflammation in adjuvant-
induced arthritis by the proteasome inhibitor MG132.
Arthritis Rheum 2010;62:2160e9.
17. Arya R, Hare E, Del Rincon I, Jenkinson CP, Duggirala R,
Almasy L, et al. Effects of covariates and interactions on a
genome-wide association analysis of rheumatoid arthritis. BMC
Proc 2009;3:S84.
18. Burgner D, Davila S, Breunis WB, Ng SB, Li Y, Bonnard C, et al. A
genome-wide association study identifies novel and function-
ally related susceptibility loci for Kawasaki disease. PLoS
Genet 2009;5:e1000319.
19. Chistyakov DA, Savost’anov KV, Turakulov RI, Nosikov VV. Ge-
netic determinants of Graves disease. Mol Genet Metab 2000;
71:66e9.
20. Corne´lis F, Faure´ S, Martinez M, Prud’homme JF, Fritz P, Dib C,
et al. New susceptibility locus for rheumatoid arthritis sug-
gested by a genome-wide linkage study. Proc Natl Acad Sci U S
A 1998;95:10746e50.
21. Stuart PE, Nair RP, Ellinghaus E, Ding J, Tejasvi T,
Gudjonsson JE, et al. Genome-wide association analysis iden-
tifies three psoriasis susceptibility loci. Nat Genet 2010;42:
1000e4.
PSMA6/PSMC6/PSMA3 & juvenile idiopathic arthritis 40322. Tomer Y, Davies TF. The genetic susceptibility to Graves’ dis-
ease. Baillieres Clin Endocrinol Metab 1997;11:431e50.
23. Sjakste T, Eglite J, Sochnevs A, Marga M, Pirags V, Collan Y,
et al. Microsatellite genotyping of chromosome 14q13.2-14q13
in the vicinity of proteasomal gene PSMA6 and association with
Graves’ disease in the Latvian population. Immunogenetics
2004;56:238e43.
24. Sjakste T, Trapina I, Rumba-Rozenfelde I, Lunin R, Sugoka
O,Sjakste N. Identification of a novel candidate locus for ju-
venile idiopathic arthritis at 14q13.2 in the Latvian population
by association analysis with microsatellite markers. DNA Cell
Biol 2010;29:543e51.
25. Lavabre-Bertrand T, Henry L, Carillo S, Guiraud I, Ouali A,
Dutaud D, et al. Plasma proteasome level is a potential marker
in patients with solid tumors and hemopoietic malignancies.
Cancer 2001;92:2493e500.
26. Stoebner PE, Lavabre-Bertrand T, Henry L, Guiraud I, Carillo S,
Dandurand M, et al. High plasma proteasome levels are
detected in patients with metastatic malignant melanoma. Br
J Dermatol 2005;152:948e53.
27. Minagar A, Ma W, Zhang X, Wang X, Zhang K, Alexander JS,
et al. Plasma ubiquitin-proteasome system profile in patients
with multiple sclerosis: correlation with clinical features,
neuroimaging, and treatment with interferon-beta-1b. Neurol
Res 2012;34:611e8.
28. Wang Q, Maillard M, Schibler U, Burnier M, Gachon F. Cardiac
hypertrophy, low blood pressure, and low aldosterone levels in
mice devoid of the three circadian PAR bZip transcription
factors DBP, HLF, and TEF. Am J Physiol Regul Integr Comp
Physiol 2010;299:R1013e9.
29. Male V, Nisoli I, Gascoyne DM, Brady HJ. E4BP4: an unexpected
player in the immuneresponse.Trends Immunol2012;33:98e102.
30. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, et al.
Leptin regulation of bone resorption by the sympathetic ner-
vous system and CART. Nature 2005;434:514e20.31. Dozmorov M, Wu W, Chakrabarty K, Booth JL, Hurst RE,
Coggeshall KM, et al. Gene expression profiling of human
alveolar macrophages infected by B. anthracis spores demon-
strates TNF-alpha and NF-kappab are key components of the
innate immune response to the pathogen. BMC Infect Dis 2009;
9:152.
32. Arbouzova NI, Bach EA, Zeidler MP. Ken & barbie selectively
regulates the expression of a subset of Jak/STAT pathway
target genes. Curr Biol 2006;16:80e8.
33. Furukawa K, Iioka T, Morishita M, Yamaguchi A, Shindo H,
Namba H, et al. Functional domains of paired-like homeo-
protein Cart1 and the relationship between dimerization and
transcription activity. Genes Cells 2002;7:1135e47.
34. Gill GN. Decoding the LIM development code. Trans Am Clin
Climatol Assoc 2003;114:179e89.
35. Phillips K, Luisi B. The virtuoso of versatility: POU proteins that
flex to fit. J Mol Biol 2000;302:1023e39.
36. She H, Mao Z. Regulation of myocyte enhancer factor-2 tran-
scription factors by neurotoxins. Neurotoxicology 2011;32:
563e6.
37. Uzumcu A, Karaman B, Toksoy G, Uyguner ZO, Candan S, Eris H,
et al. Molecular genetic screening of MBS1 locus on chromo-
some 13 for microdeletions and exclusion of FGF9, GSH1 and
CDX2 as causative genes in patients with Moebius syndrome.
Eur J Med Genet 2009;52:315e20.
38. Ho B, Olson G, Figel S, Gelman I, Cance WG, Golubovskaya VM.
Nanog increases focal adhesion kinase (FAK) promoter activity
and expression and directly binds to FAK protein to be phos-
phorylated. J Biol Chem 2012;287:18656e73.
39. ClowerCV, ChatterjeeD,WangZ,Cantley LC,VanderHeidenMG,
Krainer AR. The alternative splicing repressors hnRNPA1/A2 and
PTB influence pyruvate kinase isoform expression and cell
metabolism. Proc Natl Acad Sci U S A 2010;107:1894e9.
40. Michlewski G, Guil S, Ca´ceres JF. Stimulation of pri-miR-18a
processing by hnRNP A1. Adv Exp Med Biol 2010;700:28e35.
 56 
 
 
 
 
 
 
 
 
PUBLICATION III 
3.3. Genetic variants in the PSMA6, PSMC6 and PSMA3 genes associated 
with childhood asthma in Latvian and Taiwanese populations 
 
 
 
 
 
 
 
 
 
  
BIOMEDICINE
UDC 577.21 + 616.248
Genetic variants in the PSMA6, PSMC6 and PSMA3
genes associated with childhood asthma in Latvian and
Taiwanese populations
N. Paramonova1, L. Shi-Shin Wu2, I. Rumba-Rozenfelde3, 4, J.-Y. Wang5,
N. Sjakste1, 6, T. Sjakste1
1Genomics and Bioinformatics, Institute of Biology,
University of Latvia
3, Miera Str., Salaspils, Latvia, LV-2169
2Institute of Biomedicine, Tzu-Chi University
701, Zhongyang Rd., Sec 3., Hualien 97004, Taiwan
3Faculty of Medicine,
University of Latvia
1a, Sharlotes Str., Riga, Latvia, LV-1001
4University Children Hospital
20, Juglas Str., Riga, Latvia, LV-1079
5Division of Allergy and Clinical Immunology, College of Medicine,
National Cheng Kung University
1, University Road, Tainan City 701, Tainan, Taiwan
6Latvian Institute of Organic Synthesis
21, Aizkraukles Str., Riga, Latvia, LV-1006
Equal contribution
tanja@email.lubi.edu.lv
Proteasomes mediate functional realization of signaling proteins implicated in asthma pathogenesis. Aim. To
evaluate main and sex-specific association between the PSMA6, PSMC6 and PSMA3 proteasomal genes varia-
tions and childhood asthma in Latvians and Taiwanese. Methods. SNPs rs2277460, rs1048990, rs2295826,
rs2295827 and rs2348071 were genotyped in 102 Latvian and 159 Taiwanese cases for comparison with ge-
netic diversity in populations (191 and 1097 subjects respectively). Results. Haplotype CGACG showed strong
(P < 0.0001) association with asthma risk in both populations. All loci heterozygous genotypes and haplotype
CCGTA were identified as asthma risk factors in Latvians; rs1048990 and rs2348071 GG homozygotes and
rs2295826 and rs2295827 heterozygotes showed asthma risk and protective effect in Taiwanese females respec-
tively. The multi locus genotypes homozygous for alleles being common in Latvian population were identified as
protective in Latvians and disease susceptible in Taiwanese. Conclusions. Our results suggest an association of
the 14q13-23 proteasomal genes polymorphisms with the childhood asthma in Latvians and Taiwanese and high-
light risk and/or protective factors being the same or different between the populations.
Keywords: chromosome 14q13-23, SNPs, PSMA6, PSMC6, PSMA3, childhood asthma.
Introduction. Asthma is a chronic inflammatory disea-
se caused by complex gene–gene and gene–environ-
ment interactions with hyper-responsiveness to various
nonspecific stimuli [1–3] being to a large extent geneti-
cally heterogeneous between human populations [4]. A
number of genes implicated in asthma encode various
signaling proteins and transcription factors including
those driven by NF-B signaling pathways [5–7].
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However, interplay of multiple risk alleles and/or
genotypes and primary driver of the disease remains still
unclear.
In eukaryotes, processing and degradation of vast
majority of regulatory proteins are mediated by ubiqui-
tin-proteasome system (UPS). Proteasomes, key UPS
enzymatic complex possess several types of peptidase,
endoribonuclease, protein-chaperone and DNA-helica-
se activities [8–10] allowing strict control and coordina-
tion of all steps of gene expression, genes and proteins
networks and processes of genome–environment inter-
action. Insufficient proteasome function was implica-
ted in pathophysiology of various acute and chronic
lung diseases and their complications [11–14] and po-
tentially could be a consequence of particular proteaso-
mal genes structural variations.
Multiple studies including several GWAS analy-
ses, indicated the 14q11-24 genome region as suscep-
tible to asthma [15–21]. This genomic region possesses
a cluster of proteasomal genes including the PSMA6,
PSMC6 and PSMA3 genes implicated previously in sus-
ceptibility to autoimmunity [22–24], type 2 diabetes mel-
litus [25, 26], cardio-vascular disorders [27] and popu-
lation adaptation to environment [28]. It appears that
there is a large potential for the 14q proteasomal genes
association studies to provide novel insights into the
bronchial asthma (BA) pathogenesis in particular human
populations and in general.
Aim of the current study was to genotype five sin-
gle nucleotide polymorphisms (SNPs) belonging to
the PSMA6 (rs2277460 and rs1048990), PSMA3
(rs2348071), and PSMC6 (rs2295826 and rs2295827)
proteasomal genes and evaluate main and sex-specific
association between variations of these genes and asth-
ma in Latvians and Taiwanese.
Materials and methods. One hundred two child-
ren (28 girls) aged under five and 159 (69 girls) aged un-
der three represented Latvian (LV) and Taiwanese (TW)
asthma groups respectively. LV BA patients were en-
rolled from the outpatient clinic of P. Stradins Clinical
University Hospital and Children Clinical University
Hospital «Gailezers» in Riga, Latvia.
TW study subjects were enrolled from elementary
school for allergy diseases screen Taoyuan General
Hospital, Taiwan. All patients were diagnosed with
mild or moderate persistent asthma according to the
guidelines of the Global Initiative for Asthma (GINA;
http://www.ginasthma.org/local/uploads/files/GINA_
Under5_Pocket_20091_1.pdf). The studies were ap-
proved by the Central Medical Ethics Commission of
the Republic of Latvia Ministry of Health and Ethics
Committee of Taoyuan General Hospital, Taiwan. In-
formed consent was obtained from parents of study
participants.
Latvian and Taiwanese control groups of 191 (age =
= 54.8 ± 18.6; 117 women) and 1097 (aged under five;
558 girls) participants respectively, were described and
genetic diversity of SNPs of interest was studied pre-
viously [28] providing primary genotyping data to be
used in current study to evaluate asthma main effects
for each particular SNP, construct multi locus genoty-
pes and stratify controls by sex to reveal asthma sex spe-
cific associations in single- and multi-locus models.
DNA extraction and genotyping technologies were
the same as in [28].
For quality control, of the 16 randomly chosen sam-
ples per each marker were genotyped in duplicate in
different experiments for asthma samples from both
Latvian and Taiwanese collections. The concordance
of the genotyping was 100 %. The chromosome 14
GRCh37.p5 assembly (NCBI reference sequence: NC_
000014.8) sequence information was used for loci
description.
Personalised genotyping data documentation resul-
ted in knowledge of 5 locus genotype (5-LG: rs2277460/
rs1048990/rs2295826/rs2295827/rs2348071) of each in-
dividual participant of the study. The 5-LGs, single locus
genotypes (SLGs) and alleles frequencies were estima-
ted by direct gene counting. DnaSP version 5 (http://
www.ub.es/dnasp/ [29] was used to reconstruct the hap-
lotypes from un-phased genotypes, evaluate the nucleo-
tide and haplotype genetic diversity and pairwise linka-
ge disequilibrium (LD) between the loci (D' and r
2). Both
the two-tailed Fisher's exact test and the
2 test were ap-
plied to evaluate the linkage between the rs2295826 and
rs2295827 polymorphic sites at three p-value levels (p <
0.05; p < 0.01; p < 0.001). The Bonferroni correction in-
cluded in DnaSP analysis was taken into account to sup-
port the significance of the revealed disequilibrium (' =
= 0.05).
Deviation from the Hardy-Weinberg equilibrium
and differences between case and control groups in al-
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lele, genotype and haplotype frequencies as well as per-
mutation test (Monte Carlo method/number of simula-
tions = 10000) were evaluated by 
2 using XLSTAT
2013 software forWindows. Dominant, recessive, over
dominant and multiplicative genetic models for every
individual locus were designed according to Lewis [30]
and analysed by using 2  2 contingency tables. Odds
ratio (OR)more than 2 and less than 0.5 was considered
to be clinically significant. Stratification was perfor-
med by sex.
Results and discussion. In both Latvian and Taiwa-
nese sample collections the genotyping call rate was
100 % for all markers; alleles and genotypes fre-
quencies are given in Tables 1 and 2. The rs2348071
being in Latvian patients in HWE, significantly (P <
0.001) deviated from equilibrium in Taiwanese. Other
markers were found to be in HWE in both LV and TW
patients. The rs2295826 and rs2295827 were observed
in complete (D' = 1, r2 = 1) and slightly disrupted (D' = 1,
r2 = 0.896) LD in Latvians and Taiwanese respectively.
The distributions of alleles and genotypes in case
groups were compared with those previously identified
in the populations [28] and the data on single-locus as-
sociation are summarized in Table 1 and Table 2. In Lat-
vians all five loci showed the asthma main effect for ra-
re alleles and heterozygous genotypes. The rs1048990
was associated with the disease in both females and ma-
les. The asthma susceptibility of resting loci was charac-
terized by nonadditivity; that was, the rs2277460 and
rs2348071 were associated with asthma in females, and
the rs2295826 and rs2295827 were associated with as-
thma in males. In Taiwanese, the rs2277460 appears to
be asthma neutral and resting loci showed the disease
susceptibility only in females. The asthma risk effect
was observed for the rs1048990 and rs2348071 GG ge-
notypes and rs2348071 allele G. Rare alleles and hete-
rozygous genotypes of the rs2295826 and rs2295827
showed female-specific asthma protective effect.
The multi-locus genotypes showing asthma risk or
protective effect in any of our populations are listed in
Table 3 (see suppl.). In Latvians a statistically signifi-
cant protective effect was observed for all variants of
multi locus genotypes being homozygous for the alleles
common in the population. The 5LG of CC/CC/AA/CC/
GG configuration being protective in Latvians (OR =
= 0.322 [0.196 – 0.651]), showed the asthma risk effect
in Taiwanese females (OR = 2.911 [1.327–6.387]). Si-
milarly, being protective in Latvians the AA/CC/GG
(rs2295826/rs2295827/rs2348071) genotype appears to
be the disease susceptible in Taiwanese. In Latvians, the
risk effect was observed for the rs2277460/rs2348071,
rs1048990/rs2348071, rs1048990/rs2295826/rs2295827
and rs2295826/rs2295827/rs2348071 genotypes being
simultaneously heterozygous at all loci involved. All
mentioned genotypes were neutral in Taiwanese. In
contrast, the rs2295826/rs2295827/rs2348071 genoty-
pe of AG/CT/AA configuration being neutral in Latvi-
ans, showed the protective effect in Taiwanese females.
The data of haplotype analysis are given in Table 4
(see suppl.). Haplotype diversity was higher in Latvian
patients than in the population and did not differ bet-
ween the cases and population in Taiwanese. The most
frequent in Latvians the Hap1 (CCACG) showed male
specific asthma protective (OR = 0.633 [0.416–0.963])
effect in this population. The Hap6 (CGACG) showed
strong (P < 0.0001) association with the asthma risk in
both Latvians (OR = 4.525 [2.286–8.958]) and Taiwa-
nese (OR = 2.448 [1.763–3.399]) for both females and
males. Minor in both populations and Taiwanese cases
the Hap9 (CCGTA) was strongly (P < 0.0001) associa-
ted with the asthma phenotype in Latvians.
Identification of the genetic risk factors for asthma
is complicated by potential interaction of genes and me-
tabolic pathways, genotype with sex and environment;
most of the reported asthma genes were not replicated
across populations [4, 31]. The 14q11-24 chromosomal
region is one of well replicated asthma susceptibility lo-
ci [15–21]; the PSMA6, PSMA3 and PSMC6 proteaso-
mal genes located in the region were implicated earlier
in susceptibility to autoimmunity [22–24], inflamma-
tion [25–27] and historical and geographical adaptation
[28].
In this paper we provide for the first time the evi-
dence that polymorphism in the PSMA6, PSMC6, and
PSMA3 proteasomal genes may contribute to the risk of
childhood asthma in both Latvian and Taiwanese popu-
lations. The most remarkable finding of our study is
that haplotype CGACGwas revealed to be a strong (P <
0.0001) asthma risk factor in both Latvians and Taiwa-
nese. Other identified asthma risk and protective sing-
le- and multi-locus genetic variants are different bet-
ween two populations. The difference between human
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Marker
Allele or
genotype
Distribution of alleles and genotypes, n (%)
BA patients Controls*
Total (n = 102) Females (n = 28) Males (n = 74) Total (n = 191) Females (n = 117) Males (n = 74)
rs2277460
C 176 (86.27) 47 (83.93) 129 (87.16) 357 (93.46) 232 (94.87) 135 (91.22)
A 28 (13.73) 9 (16.07) 19 (12.84) 25 (6.54) 12 (5.13) 13 (8.78)
CC 74 (72.55) 19 (67.86) 55 (74.32) 166 (86.91) 105 (89.74) 61 (82.43)
CA 28 (27.45) 9 (32.14) 19 (25.68) 25 (13.09) 12 (10.26) 13 (17.57)
rs1048990
C 165 (80.88) 44 (78.57) 121 (81.76) 348 (91.10) 211 (90.17) 137 (92.57)
G 39 (19.12) 12 (21.43) 27 (18.24) 34 (8.90) 23 (9.83) 11 (7.43)
– – – – – –
CC 65 (63.73) 16 (57.14) 49 (66.22) 158 (82.72) 95 (81.20) 63 (85.14)
CG 35 (34.31) 12 (42.86) 23 (31.08) 32 (16.75) 21 (17.95) 11 (14.86)
GG 2 (1.96) – 2 (2.70) 1 (0.52) 1 (0.85) –
rs2295826
A 166 (81.37) 47 (83.93) 119 (80.41) 342 (89.53) 204 (87.18) 138 (93.24)
G 38 (18.63) 9 (16.07) 29 (19.59) 40 (10.47) 30 (12.82) 10 (6.76)
AA 66 (64.71) 19 (67.86) 47 (63.51) 155 (81.15) 90 (76.93) 65 (87.84)
AG 34 (33.33) 9 (32.14) 25 (33.78) 32 (16.75) 24 (20.51) 8 (10.81)
GG 2 (1.96) – 2 (2.70) 4 (2.09) 3 (2.56) 1 (1.35)
rs2295827
C 166 (81.37) 47 (83.93) 119 (80.41) 342 (89.53) 204 (87.18) 138 (93.24)
T 38 (18.63) 9 (16.07) 29 (19.59) 40 (10.47) 30 (12.82) 10 (6.76)
CC 66 (64.71) 19 (67.86) 47 (63.51) 155 (81.15) 90 (76.93) 65 (87.84)
CT 34 (33.33) 9 (32.14) 25 (33.78) 32 (16.75) 24 (20.51) 8 (10.81)
TT 2 (1.96) – 2 (2.70) 4 (2.09) 3 (2.56) 1 (1.35)
rs2348071
G 119 (58.33) 34 (60.71) 85 (57.43) 270 (70.68) 170 (72.65) 100 (67.57)
A 85 (41.67) 22 (39.29) 63 (42.57) 112 (29.32) 64 (27.35) 48 (32.43)
GG 35 (34.31) 8 (28.57) 27 (36.49) 102 (53.40) 65 (55.55) 37 (50.00)
GA 49 (48.04) 18 (64.29) 31 (41.89) 66 (34.56) 40 (34.19) 26 (35.14)
AA 18 (17.65) 2 (7.14) 16 (21.62) 23 (12.04) 12 (10.26) 11 (14.86)
*Data on an allele and genotype presentation in control group are given according to Sjakste et al. [24, 28]; P - probability calculated by 
2
test;
Table 1
SNP allele and genotype distribution and data on association with paediatric asthma in Latvian population
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Marker ID
Allele or
genotype
Statistics
Genetic model Group P (Pc) OR [95 % CI]
rs2277460
C A vs C Total 0.0038 (0.0045) 2.272 [1.293–3.933]
A – Females 0.0032 (0.0059) 3.702 [1.506–9.101]
CC CA vs CC Total 0.0023 (0.0029) 2.512 [1.379–4.578]
CA – Females 0.0031 (0.0066) 4.145 [1.568–10.957]
rs1048990
C G vs C Total 0.0004 (0.0006) 2.419 [1.478–3.960]
G – Females 0.0167 (0.0238) 2.502 [1.157–5.342]
– Male 0.0054 (0.0085) 2.779 [1.339–5.768]
CC CG vs Total 0.0007 (0.0011) 2.596 [1.491–4.519]
CG CC + GG Females 0.0047 (0.0077) 3.429 [1.435–8.192]
GG – Male 0.0190 (0.0308) 2.583 [1.166–5.722]
rs2295826
A G vs A Total 0.0056 (0.0064) 1.957 [1.213–3.158]
G – Male 0.0011 (0.0022) 3.363 [1.596–7.088]
AA AG vs Total 0.0012 (0.0016) 2.484 [1.424–4.334]
AG AA + GG Male 0.0008 (0.0008) 4.209 [1.783–9.937]
GG – – – –
rs2295827
C G vs A Total 0.0056 (0.0064) 1.957 [1.213–3.158]
T – Male 0.0011 (0.0022) 3.363 [1.596–7.088]
CC AG vs Total 0.0012 (0.0016) 2.484 [1.424–4.334]
CT AA + GG Male 0.0008 (0.0008) 4.209 [1.783–9.937]
TT – – – –
rs2348071
G A vs G Total 0.0026 (0.0039) 1.722 [1.208–2.454]
A – – – –
GG GA vs Total 0.0244 (0.0343) 1.751 [1.075–2.851]
GA GG + AA Females 0.0035 (0.0059) 3.465 [1.485–8.085]
AA – – – –
P
c
– corrected probability calculated by Monte Carlo method with 10000 simulations.
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Marker
Allele or
genotype
Distribution of alleles and genotypes, n (%)
BA patients Controls*
Total (n = 159) Females (n = 69) Males (n = 90) Total (n = 1097) Females (n = 558) Males (n = 539)
rs2277460
C 315 (99.06) 137 (99.28) 179 (99.44) 1081 (99.27) 547 (99.01) 534 (99.54)
A 2 (0.63) 1 (0.72) 1 (0.56) 16 (0.73) 11 (0.99) 5 (0.46)
CC 157 (98.74) 68 (98.55) 89 (98.89) 1081 (98.54) 547 (98.03) 534 (99.07)
CA 2 (1.26) 1 (1.45) 1 (1.11) 16 (1.46) 11 (1.97) 5 (0.93)
rs1048990
C 209 (65.72) 85 (61.59) 124 (68.89) 1480 (67.46) 738 (66.13) 742 (68.83)
G 109 (34.28) 53 (38.41) 56 (31.11) 714 (32.54) 378 (33.87) 336 (31.17)
CC 66 (41.51) 28 (40.58) 38 (42.22) 462 (42.12) 228 (40.86) 234 (43.42)
CG 77 (48.43) 29 (42.03) 48 (53.33) 556 (50.68) 282 (50.54) 274 (50.83)
GG 16 (10.06) 12 (17.39) 4 (4.44) 79 (7.20) 48 (8.60) 31 (5.75)
rs2295826
A 286 (89.94) 129 (93.48) 157 (87.22) 1855 (84.55) 948 (84.95) 907 (84.14)
G 32 (10.06) 9 (6.52) 23 (12.78) 339 (15.45) 168 (15.05) 171 (15.86)
AA 129 (81.13) 60 (86.96) 69 (76.67) 778 (70.92) 404 (72.40) 374 (69.39)
AG 28 (17.61) 9 (13.04) 19 (21.11) 299 (27.26) 140 (25.08) 159 (29.05)
GG 2 (1.26) – 2 (2.22) 20 (1.82) 14 (2.51) 6 (1.11)
rs2295827
C 289 (90.88) 129 (93.48) 160 (88.89) 1872 (85.32) 962 (86.20) 910 (84.42)
T 29 (9.12) 9 (6.52) 20 (11.11) 322 (14.68) 154 (13.80) 168 (15.58)
CC 130 (81.76) 60 (86.96) 70 (77.78) 775 (70.64) 404 (72.40) 371 (68.83)
CT 29 (18.24) 9 (13.04) 20 (22.22) 322 (29.35) 154 (27.60) 168 (31.17)
TT – – – – – –
rs2348071
G 126 (39.62) 61 (44.20) 65 (36.11) 759 (34.59) 380 (34.05) 379 (35.16)
A 192 (60.38) 77 (55.80) 115 (63.89) 1435 (65.41) 736 (65.95) 699 (64.84)
GG 40 (25.16) 19 (27.54) 21 (23.33) 204 (18.60) 97 (17.39) 107 (19.85)
GA 46 (28.93) 23 (33.33) 23 (25.56) 351 (31.99) 186 (33.33) 165 (30.61)
AA 73 (45.91) 27 (39.13) 46 (51.11) 542 (49.41) 275 (49.28) 267 (49.54)
*Data on an allele and genotype presentation in control group are given according to Sjakste et al. [28]; P – probability calculated by 
2
test;
Table 2
SNP allele and genotype distribution and data on association with paediatric asthma in Taiwanese population
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Marker ID
Allele or
genotype
Statistics
Genetic model Group P (Pc) OR [95 % CI]
rs2277460
C – – –
–
A – – – –
CC – – – –
CA – – – –
rs1048990
C – – – –
G – – – –
CC GG vs Females 0.0192 (0.0311) 2.237 [1.135–4.410]
CG CC + CG – – –
GG – – – –
rs2295826
A G vs A Total 0.0114 (0.0117) 0.612 [0.418–0.896]
G – Females 0.0066 (0.0094) 0.394 [0.200–0.776]
AA AG vs Total 0.0094 (0.0091) 0.570 [0.372–0.873]
AG AA + GG Females 0.0266 (0.0346) 0.488 [0.220–0.911]
GG – – – –
rs2295827
C T vs C Total 0.0076 (0.0099) 0.583 [0.392–0.868]
T – Females 0.0165 (0.0215) 0.436 [0.221-0.861]
CC CT vs CC Total 0.0023 (0.0024) 0.523 [0.344–0.796]
CT – Females 0.0093 (0.0117) 0.394 [0.194–0.799]
TT – – – –
rs2348071
G C vs A Females 0.0185 (0.0228) 1.534 [1.74–2.192]
A – – – –
GG GG vs Females 0.0404 (0.0315) 1.806 [1.025–3.182]
GA GA + AA – – –
AA – – – –
P
c
– corrected probability calculated by Monte Carlo method with 10000 simulation.
populations in asthma genetics is a well-known pheno-
menon described for a number of asthma susceptible
loci having mainly ethnos specific differences in gene-
tic diversity [4]. The Latvian and Taiwanese popula-
tions significantly differ in genetic diversity of loci stu-
died here [28]. This suggests involvement of these loci
in the processes of evolutional and/or geographical
adaptation to environment and a potential for allele
substitutions to have different ethnic specific influence
on the human health and population morbidity [28].
Several associations revealed in our study showed
non-additivity between sexes. In Latvians the rs2277460
and rs2348071 were associated with asthma in females,
and the rs2295826 and rs2295827 were disease suscep-
tible in males; in Taiwanese all asthma susceptible loci
were limited to females. Sex specific differences in inci-
dence, prevalence, and severity are also well known fea-
tures of asthma epidemiology. Sex-specific associations
with the disease have been recently reported for SNPs
of several genes-candidates including the IFNG [31],
IL17F [32], TSLP [33], VDR [34], and KCNB1 [35]
genes. Our analysis of the BA main effect in Latvian
population is a subject to some limitation as sexes were
not equally presented in both BA and control groups.
Although a significant asthmamain effect was detected
for all five loci studied, only the rs1048990 showed an
additive effect that was an association in both females
and males. The replication study in additional larger co-
horts represented by sexes equally is required to valida-
te the results found in the current study for Latvian po-
pulation.
Due to the pleiotropic effect, a frequent phenome-
non in human complex traits and diseases [36], some lo-
ci of susceptibility may be shared among many autoim-
mune and other immune-mediated diseases [37, 38].
Earlier the genetic pleiotropic effect has been reported
for asthma and obesity [39, 40] and for asthma and ju-
venile rheumatoid arthritis [41, 42]. Similarly, SNPs as-
sociated with asthma in our current study, previously
have been found to be susceptible in Latvians to other
immune-mediated pathologies including juvenile idio-
pathic arthritis [24, 43], children obesity [44] and mul-
tiple sclerosis [45]. The rs1048990 was widely genoty-
ped in many human populations and reported as an eth-
nic specific risk factor for inflammation within the car-
dio-vascular system [27, 28].
All loci we have studied here belong to the non-co-
ding regions of corresponding genes and nucleotide
substitutions potentially may influence the gene expres-
sion through allele specific targeting of different regu-
latory elements. Among the allele-specific targets de-
scribed by Sjakste with co-authors earlier [24, 28], se-
veral sites showed affinity to transcription factors and
splicing signals implicated previously in immunity, lung
function and lung pathology. The targeting of these re-
gulatory proteins may influence asthma pathogenesis
and needs to be mentioned in respect of current study.
The rs2277460 ancestral allele C, the major allele in hu-
man populations over the world, appears to be functional-
ly neutral. Substitution to A generates a target to hnRNP
A1, a multifunctional protein implicated in the associa-
tion with multiple promoter sequences and modulation
of a number of transcriptional events [46]. The hnRNP
A1 has been shown to play a key role in many human
pathologies including lung cancer and response to viral
pathogens [46, 47]. It may influence protein-protein in-
teractions including those with participation of NF-B
[46] playing in turn a significant role in the asthma de-
velopment and progression [5–7]. Additionally, it is in-
volved in crosstalk with ubiquitin proteasome system
at different levels of NF-B and other regulatory pro-
teins signaling pathways [48]. Allele A also assists to
sequence affinity to the BARBIE box proteins found to
be involved in inflammatory response of alveolar mac-
rophages [49]. Substitution C  G at the rs1048990
was shown to influence the gene expression in vivo and
in vitro [27, 50] and significantly change the sequence
capacity to bind a number of splicing signals and
transcription factors [28]. Rare allele G generates bind-
ing sites for the multifunctional proteins of p53 and
DMRT families implicated in the processes of climatic
[51] and evolutional [52] adaptation. The targeting of
these proteins potentially could be involved in the
mechanisms of natural selection and ethnos specific
susceptibility to inflammation [27, 28].
Common allele A of the rs2295826 (first intron of
the PSMC6 gene) generates the targets for the mentio-
ned above hnRNP A1 regulatory protein and for the
transcription factor of CREB family involved in trans-
criptional control of many pro-inflammatory genes [53,
54] and implicated in asthma pathogenesis [55], asthma
phenotypes and response to therapy [56].
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The rs2348071 SNP strongly discriminates Latvi-
ans having a major allele G (about 70 %) and Taiwane-
se having a major ancestral allele A (about 70 %). Pre-
viously we have suggested [28] that transition A  G
happened in Caucasians about 15,000 years ago was
supported by positive selection. This mutation elimina-
tes potential targets for hnRNPA1 and the transcription
factors of CART family shown to be an essential parti-
cipant of signaling respiratory network [57] and the
MEF2 family implicated in transcriptional switch bet-
ween metabolism and immunity [58].
Summarizing mentioned results we suggest that the
nucleotide substitutions we have studied may signifi-
cantly modulate the transcription of related genes and
gene network in response to the inflammation and other
environmental stimuli and influence the asthma sus-
ceptibility.
Conclusions. Our findings provide an evidence that
single- andmulti locus variations in the 14q13-23PSMA6/
PSMC6/PSMA3 proteasomal genes cluster are associa-
ted with childhood asthma in Latvian and Taiwanese
populations and could play an important role in asthma
and other immune-mediated pathologies in both Cauca-
sians and Asians, as either the risk or protective ethnic-
and sex-specific genetic factors.
Identification of genetic variants susceptible to asth-
ma and other immune-mediated pathologies, both com-
mon and different across populations, is important in
understanding pathogenesis and phenotype variability
of these multifactorial diseases. It might be a subject of
thorough investigation in the nearest future.
Funding. This work was suported by the Latvia-
Lithuania-Taiwan Cooperation Project No V3 20100512
and Latvian National Research Programme 2010.10.-
4/VPP4.
Ãåíåòè÷í³ âàð³àíòè ãåí³â PSMA6, PSMC6 ³ PSMA3, àñîö³éîâàí³
ç áðîíõ³àëüíîþ àñòìîþ ó ä³òåé ëàòâ³éñüêî¿ ³ òàéâàíüñüêî¿
ïîïóëÿö³é
Í. Ïàðàìîíîâà, Ë. Ñ.-Ñ. Âó, ². Ðóìáà-Ðîçåíôåëäå, Äæ.-ß. Âàíã,
Í. Ñüÿêñòå, T. Ñüÿêñòå
Ðåçþìå
Ïðîòåàñîìè îïîñåðåäêîâóþòü ðåàë³çàö³þ ôóíêö³é ñèãíàëüíèõ
á³ëê³â, çàëó÷åíèõ äî ïàòîãåíåçó áðîíõ³àëüíî¿ àñòìè. Ìåòà. Îö³-
íèòè çàãàëüíó ³ çàëåæíó â³ä ñòàò³ àñîö³àö³þ âàð³àö³é ïðîòåàñîì-
íèõ ãåí³â PSMA6, PSMC6 ³ PSMA3 ç áðîíõ³àëüíîþ àñòìîþ ó ä³-
òåé ³ç Ëàòâ³¿ ³ Òàéâàíÿ. Måòîäè. Îäíîíóêëåîòèäí³ ïîë³ìîðô³ç-
ìè rs2277460, rs1048990, rs2295826, rs2295827 ³ rs2348071 ãåíî-
òèïîâàíî ó 102 õâîðèõ ç Ëàòâ³¿ ³ 159 – ç Òàéâàíÿ. Äëÿ ïîð³âíÿííÿ
âçÿòî êîíòðîëüí³ ãðóïè, ÿê³ ïðåäñòàâëÿþòü ãåíåòè÷íå ð³çíîìà-
í³òòÿ â ïîïóëÿö³ÿõ: 191 ëàòâ³éñüêèõ ³ 1097 òàéâàíüñüêèõ çðàçê³â.
Ðåçóëüòàòè. Ãàïëîòèï CGACG âèÿâèâñÿ ò³ñíî (P < 0.0001) àñî-
ö³éîâàíèì ç ðèçèêîì ðîçâèòêó àñòìè â îáîõ ïîïóëÿö³ÿõ. Ãåòåðî-
çèãîòí³ ãåíîòèïè çà âñ³ìà ëîêóñàìè ³ ãàïëîòèï CCGTA ³äåíòèô³-
êîâàíî ÿê ôàêòîð ðèçèêó äëÿ ðîçâèòêó àñòìè ó æèòåë³â Ëàòâ³¿.
Ãîìîçèãîòè GG ïî rs1048990 ³ rs2348071 ïîâ’ÿçàí³ ç ðèçèêîì, à ãå-
òåðîçèãîòè ïî rs2295826 ³ rs2295827 ïðîÿâëÿþòü çàõèñíèé
åôåêò ç-ïîì³æ òàéâàíüñüêèõ æ³íîê. Áàãàòîëîêóñí³ ãåíîòèïè, ãî-
ìîçèãîòí³ çà ðîçïîâñþäæåíèìè â Ëàòâ³¿ àëåëÿìè, âèÿâèëèñÿ çà-
õèñíèìè äëÿ æèòåë³â Ëàòâ³¿, àëå ïîâ’ÿçàíèìè ç ðèçèêîì çàõâîðþ-
âàííÿ ñåðåä òàéâàíüö³â. Âèñíîâêè. Íàø³ ðåçóëüòàòè âêàçóþòü
íà àñîö³àö³þ ïîë³ìîðô³çì³â ïðîòåàñîìíèõ ãåí³â ëîêóñó 14q13-23 ç
áðîíõ³àëüíîþ àñòìîþ ñåðåä ä³òåé ó ëàòâ³éñüê³é ³ òàéâàíüñüê³é
ïîïóëÿö³ÿõ, àñîö³àö³ÿ ìîæå áóòè ïîâ’ÿçàíà ÿê ç ðèçèêîì çàõâîðþ-
âàííÿ, òàê ³ ç çàõèñíèì åôåêòîì. Çà äàíîþ îçíàêîþ ïîïóëÿö³¿ ìî-
æóòü ð³çíèòèñÿ àáî íå ð³çíèòèñÿ.
Këþ÷îâ³ ñëîâà: õðîìîñîìà 14q13-23, îäíîíóêëåîòèäí³ ïîë³ìîð-
ô³çìè, PSMA6, PSMC6, PSMA3, áðîíõ³àëüíà àñòìà ó ä³òåé.
Ãåíåòè÷åñêèå âàðèàíòû ãåíîâ PSMA6, PSMC6 è PSMA3,
àññîöèèðîâàííûå ñ áðîíõèàëüíîé àñòìîé ó äåòåé â ëàòâèéñêîé
è òàéâàíüñêîé ïîïóëÿöèÿõ
Í. Ïàðàìîíîâà, Ë. Ñ.-Ñ. Âó, È. Ðóìáà-Ðîçåíôåëäå, Äæ.-ß. Âàíã,
Í. Ñüÿêñòå, T. Ñüÿêñòå
Ðåçþìå
Ïðîòåàñîìû îïîñðåäóþò ðåàëèçàöèþ ôóíêöèé ñèãíàëüíûõ áåë-
êîâ, âîâëå÷åííûõ â ïàòîãåíåç áðîíõèàëüíîé àñòìû. Öåëü. Îöåíèòü
îáùóþ è çàâèñèìóþ îò ïîëà àññîöèàöèþ âàðèàöèé ïðîòåàñîìíûõ
ãåíîâ PSMA6, PSMC6 è PSMA3 ñ áðîíõèàëüíîé àñòìîé ó äåòåé èç
Ëàòâèè è Òàéâàíÿ. Måòîäû. Îäíîíóêëåîòèäíûå ïîëèìîðôèçìû
rs2277460, rs1048990, rs2295826, rs2295827 è rs2348071 ãåíîòè-
ïèðîâàíû ó 102 áîëüíûõ èç Ëàòâèè è 159 – èç Òàéâàíÿ. Äëÿ ñðàâíå-
íèÿ âçÿòû êîíòðîëüíûå ãðóïïû, ïðåäñòàâëÿþùèå ãåíåòè÷åñêîå
ðàçíîîáðàçèå â ïîïóëÿöèÿõ: 191 ëàòâèéñêèõ è 1097 òàéâàíüñêèõ
îáðàçöîâ. Ðåçóëüòàòû. Ãàïëîòèï CGACG îêàçàëñÿ òåñíî (P <
0.0001) àññîöèèðîâàííûì ñ ðèñêîì ðàçâèòèÿ àñòìû â îáåèõ ïîïó-
ëÿöèÿõ. Ãåòåðîçèãîòíûå ãåíîòèïû ïî âñåì ëîêóñàì è ãàïëîòèï
CCGTA èäåíòèôèöèðîâàíû êàê ôàêòîð ðèñêà äëÿ ðàçâèòèÿ àñò-
ìû óæèòåëåé Ëàòâèè. ÃîìîçèãîòûGG ïî rs1048990 è rs2348071
ñâÿçàíû ñ ðèñêîì, à ãåòåðîçèãîòû ïî rs2295826 è rs2295827 ïðî-
ÿâëÿþò çàùèòíûé ýôôåêò ñðåäè òàéâàíüñêèõ æåíùèí. Ìíîãî-
ëîêóñíûå ãåíîòèïû, ãîìîçèãîòíûå ïî ðàñïðîñòðàíåííûì â Ëàò-
âèè àëëåëÿì, îêàçàëèñü çàùèòíûìè äëÿ æèòåëåé Ëàòâèè, íî ñâÿ-
çàííûìè ñ ðèñêîì çàáîëåâàíèÿ ñðåäè òàéâàíüöåâ. Âûâîäû. Íàøè
ðåçóëüòàòû óêàçûâàþò íà àññîöèàöèþ ïîëèìîðôèçìîâ ïðîòåà-
ñîìíûõ ãåíîâ ëîêóñà 14q13-23 ñ áðîíõèàëüíîé àñòìîé ñðåäè äå-
òåé â ëàòâèéñêîé è òàéâàíüñêîé ïîïóëÿöèÿõ, àññîöèàöèÿ ìîæåò
áûòü ñâÿçàíà êàê ñ ðèñêîì çàáîëåâàíèÿ, òàê è ñ çàùèòíûì ýô-
ôåêòîì. Ïî äàííîìó ïðèçíàêó ïîïóëÿöèè ìîãóò îòëè÷àòüñÿ èëè
íå îòëè÷àòüñÿ.
Këþ÷åâûå ñëîâà: õðîìîñîìà 14q13-23, îäíîíóêëåîòèäíûå ïîëè-
ìîðôèçìû, PSMA6, PSMC6, PSMA3, áðîíõèàëüíàÿ àñòìà ó äåòåé.
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According to the recent data the ubiquitin-proteasome system (UPS) is implicated in the pathogenesis of obesity.
Aim of our study was to evaluate a  possible association between genetic variations in the PSMB5 and PSMC6
genes and childhood obesity in the Latvian population. Methods. The rs11543947 (PSMB5), rs2295826 and
rs2295827 (PSMC6) were genotyped in 94 overweight children versus 191 controls. Stratification was made by
family history and sex. Results. Heterozygous genotype at rs11543947 (PSMB5) manifested association with the
disease (P < 0.01) in total group and in patients with family history (OR = 2.445 [95 % CI 1.378–4.339] and OR =
= 2.746 [95 % CI 1.427–5.283], respectively). This genotype was observed more frequently (P < 0.05) in males
with family obesity and in females without family history (P < 0.01).The heterozygotes at rs2295826 and
rs2295827 showed association (P < 0.01) in obesity (OB), in patients with family history (OR = 2.119 [95 % CI
1.207–3.718] and OR = 2.379 [95 % CI 1.249–4.533], respectively) and in males group. The rs11543947/
rs2295826-rs2295827 multi locus genotype heterozygous at all the studied loci and the haplotype represented by 
the rare alleles were more frequent in obese children when compared to controls (P < 0.001 and P = 0.0001 res-
pectively). Conclusions. Genetic variations of the PSMB5 (rs11543947) and PSMC6 (rs2295826 and rs2295827)
genes can influence childhood obesity in Latvians.
Keywords: PSMB5, PSMC6, SNPs, obesity, familial obesity, genotype–sex interaction.
Introduction. The ubiquitin-proteasome system (UPS)
has been recently shown to be implicated in the patho-
genesis of obesity (OB). It has been demonstrated that
plasma ubiquitin and proteasome levels inversely corre-
lated with a male body mass index in Southern Taiwan
and Japanese population [1, 2] and that the proteasome
dysfunction mediated the obesity-induced endoplas-
mic reticulum stress and insulin resistance in the liver
[3]. A significant association was found between gene-
tic variants of the PSMD9 gene and obesity-associated
phenotypes in Italians [4]. The mutation in the PSMB8
gene has been reported to be associated with the autoin- 
flammatory syndrome with lipodystrophy in Japanese
[5]. Earlier we have detected the association of  the 
PSMA3 gene polymorphisms with susceptibility to obe-
sity in Latvian children [6]. 
The   current study was aimed to elucidate whether 
the single nucleotide polymorphisms (SNPs) of the
PSMB5 (rs11543947) and PSMC6 (rs2295826 and
rs2295827) genes are associated with the children obe-
sity in the Latvian population.
Materials and methods. Case/control groups (94
obese children and 191 controls, respectively) were des-
cribed previously [6, 7]. The rs2295826 and rs2295827 
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genotyping data for controls were extracted from
Sjakste et al. [7] and used in current study for the as-
sociation analysis. The study was approved by the Cent-
ral Medical Ethics Commission of the Latvian Ministry 
of Health.
The PSMB5 (rs11543947) and PSMC6 (rs2295826,
rs2295827) genotyping procedures and analysis of amp- 
lified and digested products were the same as published 
previously [7, 8].
Single loci (SLGs) and multi locus rs11543947/
rs2295826-rs2295827 genotypes and alleles’ frequen-
cies were estimated by direct gene counting.  The  devia- 
tions from the Hardy-Weinberg equilibrium and asso-
ciation/correlation analyses were tested by the c2 test
(allele, multi-loci genotype frequencies, recessive and
dominant, over dominant and multiplicative models)
using PAST (version 3.03) software for Windows [9].
Only 2 < OR < 0.5 was considered to be clinically signi-
ficant. DnaSP version 5 (http://www.ub.es/dnasp, [10]) 
was used to reconstruct the haplotypes from un-phased
genotypes, and to evaluate the nucleotide and haploty-
pe genetic diversity and pairwise linkage disequilib-
rium (LD) between the loci (D' and r2). Stratification
was performed by the sex and obesity family history. 
Results and discussion. In both cases and controls
genotyping call rate was 100 %. Homozygotes on com- 
mon alleles for all loci were observed more frequently
in controls than obese patients (more than 80 % and less 
than 70 %, respectively) and  the tendencies were similar 
in children with and without family history (Table). The
dominant and multiplicative models [11] were the most
informative to reveal OB susceptible genotypes and alle- 
les, respectively. 
The rs11543947 heterozygous genotype showed a
modest (P < 0.01) association with OB risk in total group
and in children with familial OB. A rare T allele was ob-
served more frequently (P < 0.05) in both these groups
than in controls. The rs2295826 and rs2295827 loci al-
leles in OB patients were found to be in full linkage (D' = 
= 1; r2 = 1), as it was previously reported for Latvian
controls [7]. These loci heterozygous genotypes were
found to be in association (P < 0.01) with OB and fami-
lial OB groups. Rare alleles manifested nominal asso-
ciation with the disease (P < 0.05).
The family background was found to be an obesity
risk factor (OR = 1.86 for mother; OR = 2.98 for sib-
lings) among Chinese male youths [12]. A significant
difference (p < 0.01) was observed between the sub-
jects having the obesity family history and non-obese
controls in rs2348071 heterozygous genotype frequen-
cies at the PSMA3 locus [6]. Bennet et al. have shown
[13] that a greater predisposition to diabetes in Middle
Eastern immigrants may be explained by a more exten-
sive family history of the disorder. 
In the current association study an interaction bet-
ween sexes and familial obesity was revealed. The
rs11543947 risk CT genotype and rare T allele were
found more frequently in males with family obesity (P <
0.05) and in females without family history (P < 0.01).
The rs2295826 and rs2295827 heterozygous genotypes 
and minor alleles were associated (P < 0.01 and P <
0.05, respectively) with all OB subgroups in males. 
Sex specific differences in incidence and severity
are also well known features for epidemiology of obe-
sity. The sex-influenced association of obesity with ge- 
netic variations at the LYPLAL1 locus, which encodes a 
lipase/esterase expressed in adipose tissue was sug-
gested [14]. Seven new loci exhibited marked sexual di-
morphism with a stronger effect on weight-hip ratio in
women than men (P for sex difference < 0.05 to P <
0.0001) [15].
Thus, our data on the importance of interactions bet-
ween the family history and sex for susceptibility for
childhood obesity confirm the previous reports. Ob-
viously having in our disposition a collection of a relati-
vely small number of samples  we can't reach high statis- 
tical reliability of results. The small number of subjects
and the wide range of values (reflected by large stan-
dard deviation) precluded reliable statistical confirma-
tion of this admission. However, even a study with small
subject number reveals the trend on the association of
the disease and can predict the common trends of as-
sociation also for larger sample groups collected in lar-
ger populations.
The rs11543947/rs2295826-rs2295827 three locus
genotype heterozygous at all the loci involved was found
about four times more frequently in OB patients than in
controls (about 3 and 13 %, respectively) and showed to
be OB susceptible (P < 0.001). The multi locus T/G-T
haplotype represented by rare alleles of the studied loci
was more frequent (P = 0.0001) in obese children when
compared to controls (0.5 and 6 %, respectively). 
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Susceptibility of genes encoding proteasome subu-
nits to the immunity related disorders was studied pre-
viously in Latvians. The rs1048990 (PSMA6), rs2295826 
and rs2295827 (PSMC6), rs2348071 (PSMA3) were
found to be associated with susceptibility to bronchial
asthma [16]. The rs2277460 (PSMA6), rs2295826 and
rs2295827 (PSMC6) and rs2348071 (PSMA3) manifes-
ted association with juvenile idiopathic arthritis [8].
The rs2348071 (PSMA3) was found to be associated with
multiple sclerosis [17] and childhood obesity [6]. 
Obesity in the young characterized by visceral fat
accumulation has been shown to be a major risk factor
for adult-onset type 2 diabetes mellitus [18, 19], there-
fore, we cannot exclude  in our cases a possibility of the 
development of  diabetes in adult age.
Conclusions. The genetic variation of PSMB5
(rs11543947) and PSMC6 (rs2295826 and rs2295827)
14q proteasomes subunits can influence OB in Latvians.
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Асоціація між ге не тич ни ми варіан та ми PSMB5 і PSMC6 
та ди тя чим ожирінням з-поміж жи телів Латвії
Н. Па ра мо но ва, С. Купча, И. Рум ба-Ро зен фел де, 
Н. Сьяк сте, Т. Сьяк сте
Ре зю ме 
Згідно з останніми да ни ми, убіквітин-за леж на про те а сом на сис-
тема бере участь у па то ге незі ожиріння. Мета. Оцінити мож ли-
вий зв’я зок між ге не тич ни ми варіан та ми про те а сом них генів
PSMB5 і PSMC6 та схильністю до за хво рю ван ня ди тя чим ожирін- 
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Gene/SNP ID MA/Genotype
Number (frequency %) Statistically significant association
Control,  n =191 OB,  n = 94 FH, n = 59 NFH, n = 32 P OR [95 % CI]
PSMB5/rs11543947 T 34 (8.90) 31 (16.49) 21 (17.80) 10 (15.63) < 0.05OB  2.021 [1.247–3.391]
– – – – < 0.05FH  2.216 [1.236–3.971]
– – – – > 0.05NFH – –
CC 159 (83.25) 63 (67.02) 38 (64.41) 22 (68.75) – – –
CT 30 (15.71) 31 (32.98) 21 (35.59) 10 (31.25) < 0.01OB 2.445 [1.378–4.339]
– – – – < 0.01FH 2.746 [1.427–5.283]
TT 2 (1.04) No No No – – –
PSMC6/rs2295826-
rs2295827 (D' = 1;
 r2 = 1)*
G 40 (10.47) 33 (17.55) 22 (18.64) 10 (15.63) < 0.05OB 1.820 [1.109–2.987]
– – – – < 0.05FH 1.959 [1.116–3.439]
– – – – > 0.05NFH – –
AA 155 (81.15) 63 (67.02) 38 (64.41) 23 (71.88) – – –
AG 32 (16.75) 29 (30.85) 20 (33.90) 8 (25.00) < 0.01OB 2.119 [1.207–3.718]
– – – – < 0.01FH 2.379 [1.249–4.533]
– – – – > 0.05NFH – –
GG 4 (2.10) 2 (2.13) 1 (1.69) 1 (3.13) – – –
Loci L1/L2-L3 – – – – – – –
Heterozygous
genotypes CT/AG-CT 5 (2.62) 12 (12.77) 7 (11.86) 5 (15.63) < 0.001
OB 9.018 [2.967–27.410]
Rare alleles haplotype T/G-T 2 (0.52) 11 (5.85) 7 (5.93) 4 (6.25) 0.0001OB 13.660 [2.895–62.524]
 N o t e. OB patients were represented by 59 children with obesity family history, 32 children without family history and there were no data on
familial history of obesity in 3 cases. Abbreviations: OB – Obesity; FH – obesity with family history; NFH – obesity without family history.
*Alleles and genotypes frequencies of the rs2295826 and rs2295827 were found in full linkage. L1/L2-L3 corresponds to the rs11543947 and
rs2295826-rs2295827 loci respectively.  
SNPs association with childhood obesity in common cohort, with and without family history groups
ням у Латвійській по пу ля ции. Ме то ди. Ло ку си rs11543947 (PSMB5), 
rs2295826 і rs2295827 (PSMC6) ге но ти пу ва ли у 94 дітей з над лиш -
ко вою ва гою і у 191 здо ро во го індивіда. Оцінку про во ди ли за асоці- 
ацією з ожирінням як та ким, за сімей ною історією та за стат -
тю. Ре зуль та ти. Ге те ро зи гот ний ге но тип, який на ле жить до
ло ку су rs11543947 (PSMB5), ви я вив ся помірно асоційо ва ним ( Р <
0,01) із за хво рю ван ням як та ким і з ожирінням з сімей ною істо-
рією (співвідно шен ня шансів СШ = 2,445 [95 % ДІ 1.378–4.339] і
СШ = 2,746 [95 % ДІ 1.427–5.283] відповідно). Цей ге но тип на й -
частіше спос терігав ся у чо ловіків із сімей ною історією ожиріння 
(P < 0,05) та у жінок без сімей ної історії  (P < 0,01). Ге те ро зи гот-
ні ге но ти пи по ло ку сах rs2295826 і rs2295827 знай де но в помірній
асоціації (P < 0,01) в основній групі за хво рю ван ня і у пацієнтів з
сімей ною історією (СШ = 2,119 [95 % ДІ 1.207–3.718] і СШ =
= 2,379 [95 % ДІ 1.249–4.533] відповідно), а та кож у чо ловіків.
Ба га то ло кус ний ге но тип rs11543947/rs2295826-rs2295827, пред-
став ле ний ге те ро зи го та ми по всіх ло ку сах, і гап ло тип, пред став ле-
ний рідкісни ми але ля ми, були на й частішими у групі хво рих на ожи-
ріння порівня но з кон троль ною гру пою (Р < 0,001 і Р = 0,0001 відпо-
відно). Вис нов ки. Ге не тичні варіації ло кусів PSMB5 (rs11543947)
і PSMC6 (rs2295826 і rs2295827) мо жуть впли ва ти на схильність
до за хво рю ван ня ожирінням у де тей Латвійської по пу ляції.
Клю чові сло ва: PSMB5, PSMC6, SNPs, ожиріння, сімей не ожи- 
ріння, взаємодія ге но тип–стать.
Ассоциация меж ду ге не ти чес ки ми ва ри ан та ми PSMB5 и PSMC6 и 
дет ским ожи ре ни ем сре ди жи те лей Лат вии
Н. Па ра мо но ва, С. Купча, И. Рум ба-Ро зен фел де, 
Н. Сьяк сте, Т. Сьяк сте
Ре зю ме 
Сог лас но по след ним дан ным, убик ви тин-за ви си мая про те а сом -
ная сис те ма учас тву ет в па то ге не зе ожи ре ния. Цель. Оце нить
возмож ную связь меж ду ге не ти чес ки ми ва ри ан та ми про те а сом-
ных ге нов PSMB5 и PSMC6 и под вер жен нос тью за бо ле ва нию дет-
ским ожи ре ни ем в Лат вий ской по пу ля ции. Ме то ды. Ло ку сы
rs11543947 (PSMB5), rs2295826 и rs2295827 (PSMC6) ге но ти пи -
ро ва ли у 94 де тей с из бы точ ным ве сом и у 191 здо ро во го ин ди ви -
да. Оцен ку про во ди ли по ас со ци а ции с ожи ре ни ем как та ко вым, с
се мей ной ис то ри ей и с по лом. Ре зуль та ты. Ге те ро зи гот ный ге -
но тип, от но ся щий ся к ло ку су rs11543947 (PSMB5), ока зал ся уме -
рен но ас со ци и ро ван ным ( Р < 0,01) с за бо ле ва ни ем как та ко вым и
с ожи ре ни ем с се мей ной ис то ри ей (от но ше ние шан сов ОШ =
= 2,445 [95 % ДИ 1.378–4.339] и ОШ = 2,746 [95 % ДИ 1.427–
5.283] со от ве тствен но). Этот ге но тип на и бо лее час то на блю -
дался у муж чин с се мей ной ис то ри ей ожи ре ния (p < 0,05) и у жен-
щин без се мей ной ис то рии (P < 0,01). Ге те ро зи гот ные ге но ти пы
по ло ку сам rs2295826 и rs2295827 на й де ны в уме рен ной ас со ци а -
ции (P < 0,01) в основ ной груп пе за бо ле ва ния и у па ци ен тов с се -
мей ной ис то ри ей (ОШ = 2,119 [95 % ДИ 1.207–3.718] и ОШ =
= 2,379 [95 % ДИ 1.249–4.533] со от ве тствен но) и у муж чин. Мно-
го ло кус ный ге но тип rs11543947/rs2295826-rs2295827, пред став -
лен ный ге те ро зи го та ми по всем ло ку сам, и гап ло тип, пред став -
лен ный ред ки ми ал ле ля ми, были на и бо лее час ты ми в груп пе боль-
ных ожи ре ни ем по срав не нию с кон троль ной груп пой (Р < 0,001 и
Р = 0,0001 со от ве тствен но). Вы во ды. Ге не ти чес кие ва ри а ции ло-
ку сов PSMB5 (rs11543947) и PSMC6 (rs2295826 и rs2295827) мо -
гут вли ять на под вер жен ность за бо ле ва е мос ти ожи ре ни ем у де -
тей в Лат вий ской по пу ля ции.
Клю че вые сло ва: PSMB5, PSMC6, SNPs, ожи ре ние, се мей ное
ожи ре ние, вза и мо де йствие ге но тип–пол.
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summary. The review summarizes literature data on the positive results of association studies 
between the length of microsatellite repeats and predisposition to pathologies. Actually, the data can 
be classified according to the localization of the microsatellite: in the gene promoter, in the part of 
exon 1 coding the signal sequence, in gene introns, in the coding areas of genes, and in 3'-untrans-
lated regions. The functional significance of microsatellite length changes can be evaluated in many 
cases. The authors came up to the conclusion that further studies on microsatellite associations with 
diseases remain prospective as they reflect changes in the gene functional activity. 
Introduction 
Microsatellites (MSs) are repeating sequences of 
2–6 base pairs of DNA (1). They are used as mo-
lecular markers in genetics for kinship, population, 
and other studies. They can also be used for the 
studies of gene duplication or deletion, marker-as-
sisted selection, and fingerprinting. Microsatellites 
are distributed throughout the genome (1). Being 
variable genetic elements, microsatellites provide 
a potent tool for the individual characterization of 
genomes. Variability is generated due to replica-
tion slippage caused by mismatches between DNA 
strands while being replicated during meiosis (2), 
and the event can occur once per 1000 generations 
(3). This slippage is much more common compared 
with point mutations (4). Microsatellite repeats mu-
tagenize human genomes and alter the human ge-
nomic landscape across generations (5). The util-
ity of microsatellites has been demonstrated by the 
study comprising 2058 germline changes discovered 
by analyzing 85 289 Icelanders at 2477 microsatel-
lites. The paternal-to-maternal mutation rate ratio 
is 3.3, and the rate in fathers doubles from the age 
20 to 58, whereas there is no association with age 
in mothers. Longer microsatellite alleles are more 
mutagenic and tend to decrease in length, whereas 
the opposite is seen for shorter alleles (6).
Microsatellites remain highly informative and 
useful measures of genomic variation for linkage 
and association studies despite the fact that general 
preference is given to single-nucleotide polymor-
phisms (SNPs). Microsatellites are much more ge-
netically diverse compared to SNPs; they generate a 
greater haplotype diversity (7).
Although mostly used as structural genetic mar-
kers, microsatellites perform several functions in 
the genome, which are still far from being com-
pletely understood. However, actually it has be-
come clear that MSs and their flanking regions are 
involved in multiple gene and genome functions. 
MSs are known to form nuclear matrix anchorage 
sites (8), tissue-specific matrix attachment sites (9), 
and binding sites with vimentin and glial fibrillary 
acidic protein (10) and give rise to complex DNA 
spatial structures of extreme functional significance 
(10–12). MSs appear to be important components 
of insulators (13), silencers (12), and enhancers 
(14). MSs are also involved in the regulation of al-
ternative splicing (15), mRNA stability (16), and re-
combination and repair (17, 18). 
Expansions of microsatellite DNA repeats cause 
nearly 30 developmental and neurological inherited 
disorders (19). Further, we shall try to summarize 
and classify the data about the association between 
MSs and human diseases in connection to the lo-
calization of repeats in the genes and their possible 
functional role. Triplet expansion diseases will be 
excluded from our analysis, as the problem has been 
extensively reviewed (20, 21). 
Promoter Microsatellites. MSs can determine the 
activity of the upstream gene regulation elements 
like the locus control region of the beta-globin gene 
domain. The (AT)(8)N(12)GT(AT)(7) configura-
tion of a microsatellite found in the hypersensi-
tive site of the structure is associated with a spe-
cial form of sickle cells, Tunisian βs chromosomes 
(22). The most common allele of the MS marker 
in STAT4, the STAT4-MS1-254 allele, located in 
the 5' flanking region of the gene, is significantly 
associated with sarcoidosis (23). Changes in the 
length of microsatellites within promoters and other 
cis-regulatory regions can also change the level of 
gene expression, and they are linked to abundant 
variations in cis-regulatory control regions in the 
human genome (24). For example, a CA-repeat mi-
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crosatellite in the insulin-like growth factor 1 pro-
moter is associated with the level of this growth fac-
tor. It has turned out that the intensity of the gene 
transcription is regulated by the interaction of sev-
eral SNPs and microsatellite-generating haplotypes 
with lower or higher levels of the gene transcription 
(25). Promoter microsatellites tend to be guanine-
cytosine rich; they are often found at the start of 
genes and are probably associated with the regula-
tory elements such as CpG islands, G-quadruplexes 
(G4), and untranslated regulatory regions. Numer-
ous promoter microsatellites possess the potential to 
influence human phenotypes by generating muta-
tions in regulatory elements, which may ultimately 
lead to a disease (26). A CpG-CA repeat within the 
human endothelin-converting enzyme 1 promoter 
is highly polymorphic, harbors transcriptional start 
sites, is able to recruit the transcription factors and 
poly(ADP-ribose) polymerase-1 and splicing fac-
tors, and is functional regarding haplotype-specific 
promoter activity. The overall CpG-CA repeat com-
position of patients with Alzheimer’s disease and 
nondemented control individuals has been found 
to be distinct (27). A length polymorphism of GT 
repeats in the promoter region of the human heme 
oxygenase-1 (HO-1) gene modulates the transcrip-
tion of this gene (28). Numerous studies have linked 
human HO-1 gene promoter polymorphisms to a 
risk of vascular diseases (29). Persons carrying lon-
ger (GT)(n) repeats in the HMOX1 gene (L allele) 
promoter may be at a higher risk of type 2 diabe-
tes mellitus (30). Functional analyses have shown 
that the persons with impaired glucose regulation 
and type 2 diabetes mellitus, carrying the L/L (GT)
(n) genotype, have significantly lower HO-1 protein 
expression levels than those with the S/S genotype 
(31). The same microsatellite is associated with sus-
ceptibility to cardiovascular complications of the 
disease. Patients with longer lengths of GT repeats 
in the heme oxygenase-1 gene promoter exhibit 
higher inflammation and oxidative stress. These pa-
tients have a higher risk of long-term cardiovascu-
lar events and mortality (32). A short allele of the 
same microsatellite might be associated with an ab-
dominal aortic aneurysm (33). Long (GT)n repeats 
in the microsatellite polymorphism region of the 
HMOX1 gene have been reported to be associated 
with symptomatic malaria (34).
The aldose reductase (AKR1B1) gene promoter 
harbors a (CA)n microsatellite significantly associ-
ated with diabetic retinopathy. The z-2 microsat-
ellite has been found to confer risk in type 1 and 
type 2 diabetes mellitus and the z+2 microsatellite 
to confer protection against diabetic retinopathy in 
type 2 diabetes mellitus regardless of ethnicity (35, 
36). The S allele of a ((CCTTT)(n) repeat in the 
promoter of the NOS2 gene is associated with both 
hypertension and responsiveness to antihyperten-
sive drug therapy (37). The same microsatellite is 
also associated with diabetic retinopathy, as well as 
the (GT)n promoter repeat in the tumor necrosis 
factor β gene (36). 
Promoter MSs might also be associated with 
mental problems; the promoter TA microsatellite 
repeat in the estrogen receptor alpha gene is sig-
nificantly associated with postpartum depression 
(38). The arginine vasopressin receptor 1A gene 
(AVPR1A) is widely expressed in the brain and is 
considered to be a key receptor in the regulation of 
social behavior. 5'-Flanking region polymorphisms 
in the human AVPR1A, RS3, and RS1 show differ-
ences in relative promoter activity by length. Shorter 
repeat alleles of RS1 and RS3 have decreased rela-
tive promoter activity in the human neuroblastoma 
cell line SH-SY5Y. The short alleles of RS1 are as-
sociated with autism (39).
A recent meta-analysis by Shen et al. has report-
ed that CYP11A1 promoter microsatellite [TTTA]
n repeat polymorphisms may contribute to increas-
ing susceptibility to the risk of polycystic ovary syn-
drome (40).
Signal Sequence Microsatellites. Some micro-
satellites are localized in translated areas of the 
genes. For example, the carnosinase gene contains 
a D18S880 microsatellite formed of a leucine trip-
let repeat in its signal sequence. Homozygotes for 5 
trinucleotide repeats in this microsatellite are sus-
ceptible to diabetic nephropathy (41). The human 
signal transducer and activator of transcription 6 
(STAT6) gene represents one of the most promising 
candidate genes for asthma and other inflammatory 
diseases on the chromosomal region 12q13-q24. 
The gene exon 1 contains a GT repeat upstream the 
first methionine codon. Allele A4 of the GT repeat 
polymorphism is associated with an increase in the 
eosinophil cell count (42). The genotype of 13/15-
GT repeat allele heterozygosity is significantly as-
sociated with allergic subjects (43).
Microsatellites of Coding Regions. Besides trinu-
cleotide expansion diseases, characterized mostly by 
polyglutamine tracts (poly-Q), which cannot be an-
alyzed here due to space limitations, an interesting 
trinucleotide repeat has been identified in the MIC-
A gene. The exon 5 microsatellite polymorphism 
of the MIC-A gene consists of 5 alleles based on 
the number of GCT triplet repeat units (alleles A4, 
A5, A6, and A9) and the presence of an addition-
al nucleotide insertion (allele A5.1). CGT repeats 
regulate the number of Ala residues in the protein, 
and the A5.1 leads to a frameshift mutation. The 
exon encodes the membrane-binding domain of the 
protein (44). The microsatellite alleles are associ-
ated with Addison’s disease (44) and type 1 diabetes 
mellitus (45–47). Some alleles are protective against 
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juvenile idiopatic arthritis (48). Variations of CAG 
(Gln) repeats in the androgen receptor gene in phys-
iological limits, not causing insensitivity to andro-
gens, can influence certain physiological parameters. 
Shorter androgen receptor (AR) CAG is associated 
with low HDL-C and testosterone levels (49).
Intronic Microsatellites. Microsatellites within 
introns also influence a phenotype, through ways 
that are not currently understood; this is the cause 
of numerous associations of microsatellite repeat 
polymorphisms with human diseases. For exam-
ple, a GAA triplet expansion in the first intron of 
the X25 gene appears to interfere with transcrip-
tion and causes Friedreich ataxia (50). Subjects 
having more CA repeats in the first intron of the 
type 2 11β-hydroxysteroid dehydrogenase gene 
(HSD11B2) are susceptible to developing abnor-
mal glucose tolerance (51). A repeat polymorphism 
in the fourth intron of the NOS3 gene is linked to 
hypertension (52). We have detected an association 
between type 2 diabetes mellitus and microsatellite 
markers of the region 14q13 localized in the introns 
of the PSMA6 and KIAA0391 genes, rs63749745, 
rs71444202, and rs34580276(53).
Three microsatellite loci, i.e., (ATCC)n1, 
D1S1621, and (ATCC)n2, in the DISC1 gene show 
a significant association with schizophrenia. The 
microsatellites occur in intronic sequences in the 
vicinity of a critical splice junction that gives rise to 
the expression of the DISC1 isoforms (54). 
Intronic microsatellite polymorphisms deter-
mine susceptibility to certain neoplasias. For exam-
ple, polymorphisms in the CT dinucleotide repeat 
in intron 3 of the transcription factor GATA3 gene 
are associated to a certain extent with the risk of 
breast cancer, i.e., women who carry 17-CT or 18-
CT alleles of the GATA3 gene are at a lower risk of 
developing breast cancer (55). The polymorphic di-
nucleotide CA tandem repeat (ESR2_CA), located 
in intron 5 of the estrogen receptor gene 2 gene 
ESR2 (14q23.2), is associated with the risk of breast 
cancer in African women (56). Intronic D19S884 
marker A7 allele of the fibrillin 3 gene is associated 
with polycystic ovary syndrome (57). 
Intronic microsatellites repeats are implicated in 
the pathogenic mechanisms of several autoimmune 
diseases. The SLC26A4 gene, involved in the ge-
netic susceptibility of autoimmune thyroid disease, 
harbors 2 microsatellites in introns 10 and 20, and 
longer alleles of these markers appear to be associ-
ated with Hashimoto thyroiditis (58). The intronic 
rs63749745 marker of the 14q13 locus has mani-
fested a high level of association with Graves’ disease 
(59), and rs71928782, rs5807818, rs71444202, and 
rs345802276 have been found to be in association 
with juvenile idiopathic arthritis in children (60).
Polymorphisms present in the first intron of 
IFN-γ may have an important role in the regulation 
of the immune response, which could have func-
tional consequences for gene transcription. The mi-
crosatellite encoding 16 CA repeats has been shown 
to be significantly associated with the paucibacillary 
form of lepra compared with multibacillary patients 
(61). The microsatellite marker IFNGR2-MS1, lo-
cated in the 50-upstream region of the interferon 
gamma receptor 2 gene (IFNGR2), shows a signifi-
cant association with tuberculosis (62).
One allele of the D6S1276 microsatellite in in-
tron 1 of the BMP5 gene is associated with the risk of 
osteoarthritis in women; 2 alleles are protective (63). 
3'-UTR Microsatellites. Microsatellites localized 
in the 3'-untranslated regions (3'-UTRs) may affect 
the final mRNA stability, the localization, the ex-
port from the nucleus and the translation efficiency. 
The androgen receptor CAG repeat polymorphism 
(AR CAG) affects receptor transcriptional activity 
(the shorter repeats, the more sensitive AR) and is 
associated with androgenic parameters and obesity 
(49). The conserved regulatory sequences within the 
3'-UTRs and the specific elements binding to them 
enable gene expression control at the posttranscrip-
tional level, and all these processes reflect the actual 
state of the cell (64). Shorter alleles of the microsat-
ellites in the 3' flanking region of the leptin gene, 
coding for a protein hormone, mainly synthesized 
in adipocytes, which regulates the food intake and 
energy expenditure of the body, are significantly 
associated with hypertension (65). Reduced repeat 
lengths in the EGFR gene 3'-UTR polyA repeat are 
linked with osteosarcomas (66). Several alleles of the 
microsatellite (AT)n in the 3'-UTR of anticytotoxic 
T lymphocyte antigen-4 (CTLA-4) gene, namely 
104-, 106-, 110-, and 116-bp alleles, were observed 
to be predisposing to recurrent miscarriage  (67).
Remote and Locus-Specific Microsatellites. In 
some cases, the association with diseases is found 
for microsatellites localized far from the candidate 
genes. Marker D12S96 is localized 5.653 cM down-
stream the vitamin D receptor (VDR) gene. Despite 
this long distance and obscure functional relations, 
statistically significant linkage disequilibrium has 
been detected between allele 22 of locus D12S96 
and osteoporosis (68). In some cases, the associa-
tion between microsatellites and candidate genes is 
not traced at all as these are sooner the locus than 
gene markers. The 8p21-23 region microsatellites 
D8S136 and D8S520 are consistently and strong-
ly related with prostate cancer (69). The locus has 
been traced due to a frequent loss of heterozigocity 
in tumors, but not as a result of association stud-
ies. The D1S2726 microsatellite, located 30 kb from 
the KCNA3 gene, which encodes the voltage-gated 
potassium channel Kv1.3, is associated with suscep-
tibility to autoimmune pancreatitis (70).
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Conclusions
The above data clearly indicate that most mi-
crosatellites manifesting the association with hu-
man pathologies are harbored in genes encoding 
enzymes involved in pathogenesis of the patholo-
gies; in many cases, the impact of the changes in the 
microsatellite length on the gene function can be 
evaluated. Thus, further studies on microsatellite as-
sociations with diseases remain prospective, despite 
numerous whole-genome association studies. Con-
tribution of studies with individual polymorphisms 
to the understanding of genetic background of dis-
eases should not be underestimated. 
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4. DISCUSSION 
In the current study we have investigated genetic diversity of the PSMA6 (rs2277460 and 
rs1048990), PSMC6 (rs2295826 and rs2295827) and PSMA3 (rs2348071) proteasomal genes 
in 1438 unrelated subjects from LV, LT and TW populations (Publication I). The case/control 
scheme was used for association study with bronchial asthma in LV and TW populations 
(Publication III). Above listed loci and PSMB5 (rs11543947) locus were discovered on 
association with JIA subtypes (Publication II), but PSMB5 (rs11543947) and PSMC6 
(rs2295826 and rs2295827) on association with obesity in Latvians (Publication IV).  
4.1. The rs11543947 (PSMB5) gene association analysis with autoimmune and 
metabolic diseases in Latvian population 
Several loci of Chromosome 14 potentially responsible for susceptibility to autoimmune 
diseases have been identified in different human populations. A significant association was 
found between genetic variants of the PSMD9 gene and obesity-associated phenotypes in 
Italians (Gragnoli et al., 2013). Earlier It had been reported that the rs2230087 polymorphism 
of the PSMB5 gene (3’-UTR gene region) is associated with T2DM (Kim et al., 2008). In our 
study (Publication II, VI) we were interested in the rs11543947 of the same gene locating in 
exon 1 or intron 1 (PSMB5 c.70C>T or PSMB5 c.-112+300C>T, respectively) depending of 
transcript variant.  
All loci we have studied here belong to the non-coding regions of corresponding genes and 
nucleotide substitutions potentially may influence the gene expression through allele specific 
targeting of different regulatory elements. Among the allele-specific targets described in 
current study (Publication I, II) several sites showed affinity to transcription factors and 
splicing signals implicated previously in immunity and lung pathology. 
The presence of a minor allele at the rs11543947 locus creates a binding site to the PLU-
1/JARID1B nuclear protein (Fig. 4.1.1.), which is upregulated in breast cancers, belongs to 
the ARID family of DNA binding proteins and has strong transcriptional repression activity. 
(Scibetta et al., 2007). Sequence having comonnon allele at the rs11543947 site can 
potentially bind GLIF/GLIS2.01 proteins responsible for the CNS development, negative 
regulation of cell proliferation, neurogenesis ( Xu et al., 2011). 
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Figure 4.1.1. Consequences of the rs11543947 nucleotide substitutions on functional 
potential of corresponding genomic regions of the PSMB5 gene. Positive and negative DNA 
strands are indicated by capital letters P and N respectively. The transcription factors family 
and matrix names are separated by symbol of division and given according to MatInspector, 
Release 7.4 online tool at www.genomatix.de/: N: GLIF/GLIS2.01 GLI zinc finger family 
element; N: RBP2/PLU1_JARID1B.01 retinoblastoma-binding proteins with demethylase 
activity. 
 The rs11543947 heterozygous genotype manifested a modest association with obesity 
(OB) risk in total group and in children with familial OB. A rare T allele was observed more 
frequently (P < 0.05) in both these groups than in controls (Publication VI). In Latvians this 
SNP did not show any association with JIA (Publication II) and was identified as diseases 
neutral with multiple sclerosis (Kalnina et al., 2014).  
 
Figure 4.1.2. The forest plot of odds ratios (OR) and associated confidence intervals [95% 
CI] on rs11543947 locus association analysis with diseases in Latvian population. References 
on 
1
Publication II; 
2
Publication III;
 3
Kalnina et al., 2014. 
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4.2. The rs2277460 (PSMA6) gene population analysis and association with 
autoimmune and metabolic diseases in Latvian population. 
The proteasome gene, PSMA6, codes for a 246 residue protein called 𝛼1. This protein is 
structurally important in forming the outer 𝛼 rings of the 20S core proteasome. The 𝛼1 protein 
function is also likely to be modulated by posttranslational modifications including 
phosphorylation, glycosylation, and lysine acetylation (Wang et al., 2013; Choudhary et al., 
2009). The location of the PSMA6 gene occurs in a region containing microsatellites that have 
been implicated in coronary artery disease (CAD) (Alsmadi O et al., 2009), type 2 diabetes 
mellitus (T2DM) (Sjakste et al., 2007) and Grave’s disease (Sjakste et al., 2004a). 
The rs2277460 polymorphism locates in the promoter of the PSMA6 gene in distance of 
one and 110 nucleotides from the 5′-UTR and translation start respectively. Transversion C → 
A appears to be rather recent mutation which happened and was fixed in Europeans in 
historical time and appears to be functionally neutral. Alleles' and genotypes' frequencies 
observed in LV and LT are similar to reported previously for Latvia (Sjakste et al., 2007; 
Trapina et al., 2009). Rare allele A not detected previously in Asian and African HapMap 
populations was identified in Taiwanese (Publication I). In fact, our TW group represented by 
approximately 50 times more subjects than each HCB and JPT populations and potentially is 
more informative with respect to genetic diversity and rare allele, genotype and haplotype 
identification.  
Substitution to A generates binding sites to the BARBIE box proteins shown to be involved 
in signal transduction pathways during development (Arbouzova et al., 2006) and modulation 
of innate immunity (Dozmorov et al., 2009), hnRNP A1 known as alternative splicing 
repressor (Clower et al., 2010) and factor facilitating processing of specific microRNAs 
(Michlewski et al., 2010) as well as number of other splicing signals (4.2.1). The hnRNP A1 
has been shown to play a key role in many human pathologies including lung cancer and 
response to viral pathogens (Jean-Philippe et al., 2013; Guo et al., 2013). It may influence 
protein-protein interactions including those with participation of NF-kB (Jean-Philippe et al., 
2013) playing in turn a significant role in the asthma development and progression (Birrell et 
al., 2005; Edwards et al., 2009; Gagliardo et al., 2003). Additionally, it is involved in crosstalk 
with ubiquitin proteasome system at different levels of NF-kB and other regulatory proteins 
signalling pathways (Wu et al., 2013). 
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Figure 4.2.1 Consequences of the rs2277460 nucleotide substitutions on functional 
potential of corresponding genomic regions of the PSMA6 gene.  
Promoter and exon are coloured in white, 5-UTR is coloured in grey; sequences of coding 
and noncoding genes' regions are presented by capital and small letters respectively. Positive 
and negative DNA strands are indicated by capital letters P and N respectively. The 
transcription factors family and matrix names are separated by symbol of division and given 
according to MatInspector, Release 7.4 online tool at 
www.genomatix.de/:BARB/BARBIE.01. barbiturate-inducible element; P53F/P53.07. tumour 
suppressor p53; DMRT/DMRT3.01. double sex and mab-3 related TF 3. Splicing enhancers 
are indicated by solid up-directed horizontal braces; splicing silencers are indicated by 
interrupted down-directed horizontal braces; splicing enhancer and silencers motifs are 
abbreviated according to Human Splicing Finder Version 2.4 at  http://www.umd.be/HSF. 
Other abbreviations: ESR . exonic splicing regulatory sequence. Asterix (*) indicates situation 
when several splicing signals of the same type could occupy the sequence and overlap each 
other. 
The rs2277460 locus did not show any association with obesity in Latvian children. 
(Kupca et al., 2013), but has been detected as JIA susceptible. This conclusion is based on the 
results of the subtype- and sex-specific JIA association with rare allele A, heterozygous SLG, 
4-LG6 heterozygous at the rs2277460, and 4-LH6 haplotype both having the rs2277460 rare 
allele in its structure (Publication II). 
Some loci of susceptibility may be shared among many autoimmune and other immune-
mediated diseases (Lee et al., 2011; Thompson et al., 2010). Earlier the genetic pleiotropic 
effect, as frequent phenomenon in human complex traits and diseases (Sivakumaran et al., 
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2011) has been reported for asthma and obesity (Hallstrand et al., 2005; Murphy et al., 2009) 
and for asthma and juvenile rheumatoid arthritis (Lee et al., 2014; Ramirez-Bello et al., 2013). 
Similarly, rs2277460 associated with asthma in our current study (Publication III), previously 
have been found to be susceptible in Latvians with juvenile idiopathic arthritis (Trapina et al., 
2009). 
 
Figure 4.2.2. The forest plot of odds ratios (OR) and associated confidence intervals [95% 
CI] on rs2277460 locus association analysis with diseases in Latvian population. References 
on 
1
Trapina et al., 2009; 
2
Publication II; 
3
Publication III; 
4
Kupca et al., 2013. 
On other side identification of the genetic risk factors for asthma is complicated by 
potential interaction of genes, metabolic pathways, genotype with sex and environment; most 
of the reported asthma genes were not replicated across populations (Leung et al., 2014; 
Loisel et al., 2011). In Taiwanese, the rs2277460 appears to be asthma neutral and resting loci 
showed the disease susceptibility only in females (Publication III). 
4.3. The rs1048990 (PSMA6) gene population analysis and association with 
autoimmune and metabolic diseases in Latvian population 
The rs1048990 SNP located in 8 nucleotides distance upstream the PSMA6 initiation codon 
and four nucleotides upstream the Kozak consensus (Kozak et al., 1997), potentially could 
interfere splicing and initiation of translation. In fact, Ozaki et al. (2006) reported that the 
rs1048990 G allele was associated with higher expression of the PSMA6 gene in vitro and in 
vivo. Recently, Wang et al. (2013) compared levels of mRNA expression by the rs1048990 
genotypes and significant trend by G allele was also found. We showed here that both C and 
G alleles could affect sequence functional potential (Publication I, II; Fig. 4.3.1). 
Ancestral rs1048990 allele C generates presumably splicing enhancer motifs; minor allele 
G creates an exonic splicing regulatory motif, several splicing silencers and binding sites for 
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tumour suppressor p53 and mab-3 related transcription factor of DMRT family. Gene 
encoding the tumour suppressor p53 was shown to express ethnic heterogeneity and may be 
involved in ecological (climatic) adaptation (Själander et al., 1996). TFs of the DMRT family 
were shown to play significant roles during animal evolution contributing to the origin of 
novel sex-specific traits (Kopp et al., 2012) and potentially should be involved in human 
adaptation.  
 
Figure 4.3.1. Consequences of the rs1048990 nucleotide substitutions on functional 
potential of corresponding genomic regions of the PSMA6 gene. Sequence features and other 
marks are given as described in Fig. 5.1.2.1. P53F/P53.07. tumour suppressor p53; 
DMRT/DMRT3.01. double sex and mab-3 related TF 3.  
Ancestral allele C is a major allele in all human populations over the world being 
significantly less frequent in Asians than in Europeans (about 70% vs 90% in HCB and CEU 
populations respectively). Similarly, in our study (Publication I) we have observed the minor 
allele G approximately four and twice more frequent in TW compared to LV and LT 
respectively. Transversion C → G is one of the oldest mutations studied here and appears to 
happen approximately 8000–11,000 years ago in Asians. In Europeans this mutation appears 
to arise much later evolutionally or, more probably, had been introduced with human 
migrations already in historical time. Multiple case/control studies conducted during the last 
decade to search for association between the rs1048990 SNP and human diseases provide 
significant information on locus variability. Firstly, different studies applied for the same 
ethnic groups Latvians (Publication I; Trapina et al., 2009), British (Bennett et al., 2008; 
Freilinger et al., 2009), Indians (Banerjee et al., 2008, 2009) and Japanese (Hinohara et al., 
2009; Ikeda et al., 2012; Ozaki et al., 2006; Takashima et al., 2007) showed similar allele and 
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genotype frequencies suggesting that control cohorts of case/control studies could 
successfully represent corresponding population. Secondly, locus variability appears to 
express geographical- and/or ethnos-specific dynamic. The rs1048990 SNP was found to 
occur in frequencies consistent with HWE in LV and LT groups of the current study 
(Publication I) and in vast majority of populations of published studies. However, genotype 
distribution was found to deviate significantly from HWE in our TW population, South Italian 
(Barbieri et al., 2008), Saudi (Alsmadi et al., 2009) and one of Japanese control cohort (Ikeda 
et al., 2012). Three statistics applied in our study (Publication I) did not show significant 
deviation from neutral model of evolution.  
The rs1048990 locus susceptibility reported for several pathologies (Table 3) appears to 
have ethnospecific character (Wang et al., 2013). We can supplement these data by results of 
current study. Summarizing the genotyping results obtained by different teams for association 
the rs1048990 with cardiovascular diseases (Alsmadi et al.,, 2009; Banerjee et al., 2008; 
Barbieri et al., 2008; Bennett et al., 2008; Freilinger et al., 2009; Goncharov et al., 2009; 
Heckman et al., 2013; Ikeda et al., 2012), T2DM (Barbieri et al., 2008; Sjakte et al., 2007), we 
suggested a potential of this loci to influence JIA susceptibility in Latvians. However, we did 
not find any association between the rs1048990 polymorphism and JIA. Similarly, locus did 
not show any association with obesity in Latvian children (Kupca et al., 2013).  
 
 
 
Figure 4.3.2 The forest plot of odds ratios (OR) and associated confidence intervals 
[95%CI] on rs1048990 locus association analysis with diseases in Latvian population. 
References on 
1
Publication II; 
2
Publication III;
 3
Kupca et al., 2013. 
In Latvians this locus showed the asthma main effect for rare alleles and heterozygous 
genotypes. In Taiwanese the asthma risk effect was observed for the rs1048990 GG rare 
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homozygous genotypes in female group. We suggest that ethnos- and/or geographically-
specific allele and genotype distribution at the rs1048990 is an evolutionary natural 
phenomenon involved originally in the mechanisms of ethnic adaptation to the definite 
environment and may influence general morbidity of human populations. 
4.4. The rs2295826 and rs2295827 (PSMC6) gene population analysis and 
association with autoimmune and metabolic diseases in Latvian population 
 
The rs2295826 and rs2295827 loci locate in close vicinity to each other in intron 1 of the 
PSMC6 gene (PSMC6 c.86-104A>G and PSMC6 c.86-46C>T respectively) in 61 bp from 
each other, showed an r
2
 between 0.923 in Tuscans (Italy) and 1.0 (CEU) in different 
Caucasian ethnicities and a D′ of 1.0 in all ethnicities analysed until the current study, 
suggesting three AC, GT and GC the rs2295826/rs2295827 haplotypes. In both LV and LT 
populations, the rs2295826 and rs2295827 showed the same alleles' and genotypes' 
frequencies suggesting strong linkage between the loci and only AC and GT haplotypes' 
occurrence. To our surprise, we did not observed in Taiwanese the rs2295827 rare allele TT 
homozygotes. This fact suggests a disruption of linkage between the rs2295826 and 
rs2295827 loci (D =0.978; r
2
 = 0.901) and occurrence of forth rare AT haplotype in 
Taiwanese. The rs2295826 A and rs2295827 C ancestral alleles were the major in all 
populations analysed. Alleles and genotypes distributions were similar between LV and CEU 
and TW and Asian HapMap populations respectively. To our surprise, minor alleles were 
significantly more frequent in LT than in LV and CEU.  
The major allele of the rs2295826 (Fig. 4.4.1.a) generates an additional splice site acceptor 
and branch point, hnRNP A1 and several splicing enhancer and silencer motifs as well as 
sequence affinity to TFs of CREB, MYT1 and PARF families known to be involved, in 
regulation of multiple physiological processes including control of circadian clock (Male et 
al., 2012; Wang et al., 2010). Genetic variation occurred within coding and non-coding 
regions of several genes regulating circadian rhythm was shown to be ethnos specific 
(Cruciani et al., 2008; Hawkins et al., 2008) and might represent an evolutional history of 
adaptation in populations of different geographic origin.  
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a.  b.  
Figure 4.4.1. Consequences of the rs2295826 (a.) and rs2295827 (b.) nucleotide substitutions 
on functional potential of corresponding genomic regions of the PSMC6 gene. Sequence 
features and other marks are given as described in Fig. 5.1.2.1. CREB/E4BP4.01–E4BP4, 
bZIP domain, transcription repressor; MYT1/MYT1.02–MyT1 zinc finger TF involved in 
primary neurogenesis; PARF/TEF.01–thyrotrophic embryonic factor; CART/CART1.01–
Cart-1 cartilage homeoprotein 1; BRN5/BRN5.04–POU class 6 homeobox 1 (POU6F1); 
LHXF/ISL2.01–ISL LIM homeobox 2; HOXF/NANOG.01–Homeobox TF Nanog. “Pot. 
Branch Point” means potential branch point. 
The rs2295826 minor allele G generates splicing silencers mostly. Additional branch point 
is predicted for sequence encompassing the rs2295827 major allele C (Fig. 4.4.1.b). 
Sequences having the rs2295827 minor allele G can potentially bind the CART proteins 
responsible for bone and cartilage development (Furukawa et al., 2002), BRN5 and LHXF 
factors known to mediate transcriptional control of neuronal differentiation (Gill, 2003; 
Phillips and Luisi, 2000; She and Mao, 2011; Uzumcu et al., 2009) and HOXF family 
NANOG.01 factor shown to be generally involved in signal transduction pathways during 
development (Ho et al., 2012). 
Rare alleles of these loci and their risk SLGs showed JIoA subtype-specific association by 
themselves and as component of risk 4-LG5 genotype and risk 4-LH4 haplotype (Publication 
II). In our studies have found an association between rs2295826 and rs2295827 and obesity 
(Publication IV); bronchial asthma (Publication III) in Latvian population (Fig. 4.4.2.). The 
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rs2295826 and rs2295827 heterozygotes showed asthma protective effect in Taiwanese 
(Publication III)  
 
Figure 4.4.2. The forest plot of odds ratios (OR) and associated confidence intervals [95% 
CI] on rs2295826&rs2295826 locus association analysis with diseases in Latvian population. 
References on 
1
Publication II; 
2
Publication III;
 3
Publication IV. 
4.5. The rs2348071 (PSMA3) gene population analysis and association with 
autoimmune and metabolic diseases in Latvian population. 
The rs2348071 locus belongs to intron 7 of the PSMA3 gene (PSMA3 c.543+138G>A or 
c.522+138G>A depending of transcript variant, strongly discriminates Asians having a major 
ancestral allele A (about 70%) and other ethnics having a major allele G (about 70%). 
Transition A → G appears to be one of the oldest among analysed mutations which happened 
in Caucasians about 15,000 years ago and was supported by positive selection in Caucasians 
over the world. Mutation age appears to be less in Asians and might result from both the de 
novo mutation event and gene flow from other ethnics. Similar to the rs2348071, Wang et al. 
(2008) identified several loci in the PSMB1, PSMB2 and PSMB5 proteasomal genes being 
observed as minor in one ethnic group and middle/common in others and suggested that 
clinical response to proteasomal inhibitors potentially might be allele specific (hypothesis is 
discussed in Wang et al. (2008).  
The rs2348071 ancestral allele A generates binding sites for already mentioned CART 
proteins and MEF2 and HBOX factors known to mediate transcriptional control of neuronal 
differentiation (Gill et al.,  2003; Phillips et al., 2000; She et al., 2011;Uzumcu et al., 2009) 
and generates splicing signals including the hnRNP A1 and several enhancer and silencer 
motifs. Sequence having G allele appears to have a big potential in respect of splicing 
regulation as many different splicing signals might be involved in regulation. 
 69 
 
Figure 4.5.1. Consequences of the rs2348071 nucleotide substitutions on functional 
potential of corresponding genomic regions of the PSMA3 gene. Sequence features and other 
marks are given as described in Fig. 5.1.2.1. HBOX/GSH1.01–Homeobox TF Gsh-1; 
Cart/PHOX2.01–Phox2a (ARIX) and Phox2b of cartilage homeoproteins family; 
MEF2/SL1.01–member of the RSRF related to serum response factors.  
In Taiwanese the rs2348071 being in Latvian patients in HWE, significantly (P <0.001) 
deviated from equilibrium, and asthma risk effect was observed for rare alleles homozygotes 
and rare alleles. In Latvians the heterozygotes and rare alleles were found to be associated 
with BA (Publication III); for heterozygous genotypes was shown risk effect for JIA 
(Publication II). Interestingly, the rs2348071 heterozygotes were implicated previously as an 
obesity risk factor in Latvian children with a family history of obesity (Kupca, et al., 2013) 
 
Figure 4.5.2. The forest plot of odds ratios (OR) and associated confidence intervals [95% 
CI] on rs2348071 locus association analysis with diseases in Latvian population. References 
on 
1 
Publication II; 
2
Publication III;
 3
Kupca et al., 2013. 
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4.6. Comparative analysis of polymorphisms 
The non-additivity of diseases association in sex subgroups 
Several associations revealed in our study showed non-additivity between sexes. In BA 
association study (Publication III) in Latvians the rs2277460 and rs2348071 were associated 
with asthma in females, and the rs2295826 and rs2295827 were disease susceptible in males; 
in Taiwanese all asthma susceptible loci were limited to females. Rare alleles and 
heterozygous genotypes of the rs2295826 and rs2295827 showed female-specific asthma 
protective effect. Sex-specific associations with the disease have been recently reported for 
SNPs of several genes-candidates including the IFNG (Loisel 2011), IL17F (Qian, 2012), 
TSLP (Hunninghake, 2010), VDR (Raby, 2004), and KCNB1 (Seibold, 2008) genes.  
In JIA association study (Publication II) in Latvians in both the control and case groups, 
risk genotypes were more frequent in males for the rs2277460 locus and in females for the 
rs2295826 and rs2295827 loci; the rs2348071 heterozygous risk genotype was more frequent 
in females than in males in JIpA patients. 
In the current association study an interaction between sexes and familial obesity was 
revealed (Publication IV). The rs11543947 risk CT genotype and rare T allele were found 
more frequently in males with family obesity and in females without family history. The 
rs2295826 and rs2295827 heterozygous genotypes and minor alleles were associated with all 
OB subgroups in males. Sex specific differences in incidence and severity are also well 
known features for epidemiology of obesity. The sex-influenced association of obesity with 
genetic variations at the LYPLAL1 locus, which encodes a lipase/esterase expressed in adipose 
tissue was suggested (Benjamin et al., 2011). Seven new loci exhibited marked sexual 
dimorphism with a stronger effect on weight-hip ratio in women than men (Heid  et al., 2010). 
Risk/protective multi-loci genotypes 
It is important to note that strength of revealed association with the disease was much 
stronger for combination of several risk SLGs than for any individual risk SLG.  
The combination of the rs2348071 (PSMA3) and rs2295826 and/or rs2295827 (PSMC6) 
risk genotypes represents the genetic module highly associated with both JIoA and JIpA and 
JIA female phenotype and plasma proteasome level in JIoA females (Fig 4.6.1.); combination 
of the rs2348071 and rs2277460 risk genotypes (4-LG6) represents the genetic module 
presumably associated with JIpA and male phenotype (Publication II). 
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Figure 4.6.1. Plasma proteasome level in juvenile idiopathic oligoarthritis (JIoA) patients. 
Carriers of different four-locus genotypes (4-LGs), 4-LG1, 4-LG2, 4-LG3, 4-LG4, and 4-
LG5. * P < 0.05, ** P < 0.001, # P > 0.05. 
Earlier, circulating proteasomes were suggested as markers in autoimmune diseases 
(Egeger et al., 2002). Concentration of circulating proteasomes was shown to be substantially 
elevated in patients with rheumatoid (Egeger et al., 2002) and psoriatic (Henry et al., 2011) 
arthritis. The 20S proteasome has been identified as a target of the humoral autoreactive 
immune response in patients with systemic inflammatory diseases including autoimmune 
myositis (Feist et al., 1996), primary Sjӧgren’s syndrome (Feist et al., 1999), dilated 
cardiomyopathy (Voigt et al., 2010), systemic lupus erythematosus (Feist et al., 1996; Arribas 
et al., 1991; Colmegna et al., 2008), multiple sclerosis (Fissolo et al., 2008), and psoriatic 
arthritis (Colmegna et al., 2008). The proteasomal inhibitor MG132 has been reported to 
reduce the severity of arthritis and reverse the pain behaviour in the arthritic rat models 
(Ahmed et al, 2010). To our knowledge, plasma levels of factors within the UPS have not 
been yet evaluated in JIA, and in Publication II was reported data on that for the first time. 
Homozygotes on common alleles for all loci were observed more frequently in controls 
than obese patients (more than 80 % and less than 70 %, respectively). The 
rs11543947/rs2295826-rs2295827 three locus genotype heterozygous at all the loci involved 
was found about four times more frequently in OB patients than in controls and showed to be 
OB susceptible (Publication IV).  
The identified asthma risk and protective single- and multi-locus genetic variants vary 
widely among Latvian and Taiwan populations. All variants of multi locus genotypes being 
homozygous for the alleles common in Latvians showed the asthma risk effect in Taiwanese 
females (OR = 2.911 [1.327–6.387]). Multi-loci heterozygous genotypes 
rs2277460/rs2348071, rs1048990/rs2348071, rs1048990/rs2295826/rs2295827 and 
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rs2295826/rs2295827/rs2348071 showed risk effect for bronchial asthma in Latvians, were 
neutral in Taiwanese. In contrast, the rs2295826/rs2295827/rs2348071 genotype of 
AG/CT/AA configuration being neutral in Latvians, showed the protective effect in 
Taiwanese females (Publication III). 
Risk/protective haplotypes 
Other recent experimental data suggest that haplotypes are more predictive than individual 
SNPs at determining risk factors for complex diseases (Kang et al., 2011). The strong 
association with healthy phenotype was repealed in association study between JIA and genetic 
variants in the PSMA6/PSMC6/PSMA3 gene cluster, represented multi-loci haplotype C/C/G 
having no risk SLGs in its composition. 
The T/G-T haplotype represented by rare alleles of the PSMB5/PSMC6 genes studied loci 
was more frequent (P = 0.0001) in obese children when compared to controls (Publication 
IV). Haplotype diversity was higher in Latvian BA patients than in the population and did not 
differ between the cases and population in Taiwanese. The most frequent in Latvians the 
Hap1 (CCACG) showed male specific asthma protective effect. Minor Hap9 (CCGTA) was 
strongly (P < 0.0001) associated with the asthma phenotype in Latvians. 
The most important finding of our study is that CGACG haplotypes with included rare 
alleles of rs1048990 and rs2348071 loci is a strong (P < 0.0001) asthma risk factor for 
Latvians and Taiwanese patients (Publication III). 
The difference between human populations in asthma genetics is a well-known 
phenomenon described for a number of asthma susceptible loci having mainly ethnos specific 
differences in genetic diversity (Leung et al., 2014).  
The Latvian and Taiwanese populations significantly differ in genetic diversity of current 
study loci (Publication 1). This suggests involvement of these loci in the processes of 
evolutional and/or geographical adaptation to environment and a potential for allele 
substitutions to have different ethnic specific influence on the human health and population 
morbidity (Publication 1). 
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5. CONCLUSIONS 
1. Distribution of PSMA6 (rs2277460), PSMC6 (rs2295826 and rs2295827) and PSMA3 
(rs2348071) proteasomal genes variations in Latvian, Lithuanian and Taiwanese 
populations reveals that Latvian and Lithuanian populations are significantly differentiated 
by each the rs1048990 (P < 0.01), rs2295826 and rs2295827 (P < 0.05) locus. Both LV, 
LT strongly (P < 0.001) differed from Asians at the rs2277460, rs1048990 and rs2348071. 
However, at the rs2295826 and rs2295827 Asians were different only from LV (P <0.05); 
and exhibited similarities with LT.  
2. Comparison of general and sex-specific association between the PSMA6, PSMC6 and 
PSMA3 proteasomal genes variations and childhood asthma in Latvians and Taiwanese 
revealed that haplotype CGACG included rare alleles at rs1048990 (PSMA6) and 
rs2348071 (PSMA3) is associated with the diseases (P < 0.0001) in Latvians and 
Taiwanese. All loci heterozygous genotypes and haplotype CCGTA included rare alleles at 
PSMC6 SNPs and rs2348071 (PSMA3) are asthma risk factors in Latvians; rs1048990 and 
rs2348071 GG homozygotes and rs2295826 and rs2295827 heterozygotes showed asthma 
risk and protective effect in Taiwanese females respectively. Multi locus genotypes 
homozygous for alleles being common in Latvian population were identified as protective 
in Latvians.  
3. Variations at the PSMA6 (rs2277460), PSMC6 (rs2295826 and rs2295827), and PSMA3 
(rs2348071) loci contribute to JIA susceptibility; combination of the rs2348071 and 
rs2295826 and/or rs2295827 risk genotypes (4-LG5) represents the genetic module highly 
associated with both JIoA and JIpA and JIA female phenotype (P < 0.001); combination of 
the rs2348071 and rs2277460 risk genotypes (4-LG6) represents the genetic module 
presumably associated with JIpA and male phenotype; the PSMA6/PSMC6/PSMA3 
genetic variants and multiloci genetic modules could be suggested as JIA subtype- and sex-
specific risk factors. 
4. Plasma proteasome level was found to be significantly higher in females having four-locus 
risk genotypes compared to protective against JIA genotypes (P < 0.001).  
5. Heterozygous genotype at rs11543947 (PSMB5) manifested association with the disease (P 
< 0.01) in total diseases group and in patients with family history of obesity. This genotype 
was observed more frequently (P < 0.05) in males with family obesity and in females 
without family history .The heterozygotes at rs2295826 and rs2295827 (PSMC6) showed 
nominal association (P < 0.05) in OB group, in males and in patients with family history. 
The rs11543947/rs2295826/rs2295827 multi locus genotype heterozygous at all the studied 
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loci and the haplotype represented by the rare alleles were more frequent in obese children 
when compared to controls (P < 0.001 and P < 0.0001 respectively). 
6. In silico analysis reveals that that the nucleotide substitutions we have studied modify 
transcription factor binding sites and miRNAs, this can significantly modulate the 
transcription of related genes and gene network in response to the inflammation and other 
environmental stimuli and influence the diseases susceptibility. 
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